{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9e6ed5f8",
   "metadata": {},
   "source": [
    "# Clinical Trials CLassification"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "673a03cf",
   "metadata": {},
   "source": [
    "### Data Reading Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f487ae39",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "b5b8a839",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_9954/28611935.py:1: DtypeWarning: Columns (35,36,37,38,39) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>studytype</th>\n",
       "      <th>phase</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>startdate</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>numcentralcontacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Køge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 45 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                         leadsponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators       studytype   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "           overallstatus   startdate  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  numcentralcontacts                                  location_facility  \\\n",
       "0                  ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                  ?                        Zealand University Hospital   \n",
       "2                  ?             Guangdong Provincial People's Hospital   \n",
       "3                  ?  The First Affiliated Hospital of College of Me...   \n",
       "4                  ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                  ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                  ?             Stanford University School of Medicine   \n",
       "7                  ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                  ?                             Shanghai East Hospital   \n",
       "9                  ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               Køge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 45 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "496d96b9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60687, 45)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "7c70a28c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'leadsponsor',\n",
       "       'collaborators', 'studytype', 'phase', 'overallstatus', 'startdate',\n",
       "       'completiondate', 'primarycompletiondate', 'studyfirstsubmitdate',\n",
       "       'studyfirstpostdate', 'lastupdatepostdate', 'enrollment',\n",
       "       'projectedaccrual', 'eligibilitycriteria', 'designprimarypurpose',\n",
       "       'briefsummary', 'detaileddescription', 'sex', 'minimumage',\n",
       "       'maximumage', 'stdage', 'country', 'conditions', 'keywords',\n",
       "       'interventions_name', 'interventions_description', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'overallofficials_name',\n",
       "       'overallofficials_affiliation', 'oversighthasdmc',\n",
       "       'centralcontact_name', 'centralcontact_role', 'centralcontact_phone',\n",
       "       'centralcontact_phoneext', 'centralcontact_email', 'numcentralcontacts',\n",
       "       'location_facility', 'location_city', 'location_state',\n",
       "       'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4f52196e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "nctid                           object\n",
       "orgstudyid                      object\n",
       "title                           object\n",
       "organization_fullname           object\n",
       "leadsponsor                     object\n",
       "collaborators                   object\n",
       "studytype                       object\n",
       "phase                           object\n",
       "overallstatus                   object\n",
       "startdate                       object\n",
       "completiondate                  object\n",
       "primarycompletiondate           object\n",
       "studyfirstsubmitdate            object\n",
       "studyfirstpostdate              object\n",
       "lastupdatepostdate              object\n",
       "enrollment                      object\n",
       "projectedaccrual                object\n",
       "eligibilitycriteria             object\n",
       "designprimarypurpose            object\n",
       "briefsummary                    object\n",
       "detaileddescription             object\n",
       "sex                             object\n",
       "minimumage                      object\n",
       "maximumage                      object\n",
       "stdage                          object\n",
       "country                         object\n",
       "conditions                      object\n",
       "keywords                        object\n",
       "interventions_name              object\n",
       "interventions_description       object\n",
       "primary_outcomes                object\n",
       "secondary_outcomes              object\n",
       "overallofficials_name           object\n",
       "overallofficials_affiliation    object\n",
       "oversighthasdmc                 object\n",
       "centralcontact_name             object\n",
       "centralcontact_role             object\n",
       "centralcontact_phone            object\n",
       "centralcontact_phoneext         object\n",
       "centralcontact_email            object\n",
       "numcentralcontacts              object\n",
       "location_facility               object\n",
       "location_city                   object\n",
       "location_state                  object\n",
       "location_country                object\n",
       "dtype: object"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ccf5fe74",
   "metadata": {},
   "source": [
    "### Data Cleaning Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "bb93372e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0         True\n",
       "1         True\n",
       "2            ?\n",
       "3            ?\n",
       "4         True\n",
       "         ...  \n",
       "60682     True\n",
       "60683     True\n",
       "60684    False\n",
       "60685    False\n",
       "60686        ?\n",
       "Name: oversighthasdmc, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['oversighthasdmc']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "a3dae04f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-11-01\n",
       "2           2027-06\n",
       "3        2022-05-20\n",
       "4           2029-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2010-06\n",
       "60685    2020-09-18\n",
       "60686             ?\n",
       "Name: completiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['completiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "fcd8bc5b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-09-22\n",
       "2           2026-12\n",
       "3        2022-05-20\n",
       "4           2028-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2009-11\n",
       "60685    2020-09-18\n",
       "60686       2011-04\n",
       "Name: primarycompletiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primarycompletiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "570e7029",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('projectedaccrual',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "5fec18da",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                   Nivolumab 480mg and surgical resection\n",
       "1                                       Influenza Vaccines\n",
       "2        SHR-A2009 monotherapy, platinum-based dual-age...\n",
       "3                                       SIBP-02, Rituximab\n",
       "4        Venetoclax, Decitabine, Cedazuridine, Bone Mar...\n",
       "                               ...                        \n",
       "60682    Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisp...\n",
       "60683    Extracorporeal Photopheresis, Mogamulizumab, Q...\n",
       "60684                              Ispaghula husk, Placebo\n",
       "60685                                            Alphanate\n",
       "60686    obatoclax mesylate, bortezomib, laboratory bio...\n",
       "Name: interventions_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "a6668b28",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                   Tanguy Lim-Seiwert, MD\n",
       "1                                Ismail Gögenur, Professor\n",
       "2                                                      NaN\n",
       "3        Shanghai Institute Of Biological Products Co.,...\n",
       "4                                         Sanjay Mohan, MD\n",
       "                               ...                        \n",
       "60682                                           Xiuning Le\n",
       "60683                                       Pamela B Allen\n",
       "60684    Jordi Salas, MD, PhD, Luis Peña, MD, PhD, Marg...\n",
       "60685                                                  NaN\n",
       "60686                                       Joseph Tuscano\n",
       "Name: overallofficials_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overallofficials_name']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "607b00b2",
   "metadata": {},
   "source": [
    "#### Renaming Columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "21fbb0e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.rename(columns={\n",
    "    'overallstatus': 'overall_status',\n",
    "    'leadsponsor':'lead_sponsor',\n",
    "    'overallofficials_name': 'overall_officials_name',\n",
    "    'overallofficials_affiliation': 'overall_officials_affiliation',\n",
    "    'oversighthasdmc': 'oversight_has_dmc',\n",
    "    'completiondate': 'completion_date',\n",
    "    'primarycompletiondate': 'primary_completion_date',\n",
    "    'studyfirstsubmitdate': 'study_first_submit_date',\n",
    "    'studyfirstpostdate': 'study_first_post_date',\n",
    "    'lastupdatepostdate': 'last_update_post_date',\n",
    "    'eligibilitycriteria': 'eligibility_criteria',\n",
    "    'designprimarypurpose': 'design_primary_purpose',\n",
    "    'briefsummary': 'brief_summary',\n",
    "    'detaileddescription': 'detailed_description',\n",
    "    'startdate': 'start_date',\n",
    "    'studytype': 'study_type',\n",
    "    'minimumage': 'minimum_age',\n",
    "    'maximumage': 'maximum_age',\n",
    "    'numcentralcontacts': 'num_central_contacts'\n",
    "}, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "28a377d9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>study_type</th>\n",
       "      <th>phase</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>start_date</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>num_central_contacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Køge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 44 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                        lead_sponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators      study_type   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "          overall_status  start_date  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  num_central_contacts                                  location_facility  \\\n",
       "0                    ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                    ?                        Zealand University Hospital   \n",
       "2                    ?             Guangdong Provincial People's Hospital   \n",
       "3                    ?  The First Affiliated Hospital of College of Me...   \n",
       "4                    ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                    ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                    ?             Stanford University School of Medicine   \n",
       "7                    ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                    ?                             Shanghai East Hospital   \n",
       "9                    ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               Køge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 44 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "a8e54541",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'lead_sponsor',\n",
       "       'collaborators', 'study_type', 'phase', 'overall_status', 'start_date',\n",
       "       'completion_date', 'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'centralcontact_name', 'centralcontact_role',\n",
       "       'centralcontact_phone', 'centralcontact_phoneext',\n",
       "       'centralcontact_email', 'num_central_contacts', 'location_facility',\n",
       "       'location_city', 'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "512cc5dc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of duplicate rows with same title and phase: 186\n"
     ]
    }
   ],
   "source": [
    "duplicate_count = df.duplicated(subset=['title', 'phase']).sum()\n",
    "print(f\"Number of duplicate rows with same title and phase: {duplicate_count}\")\n",
    "\n",
    "# duplicate_rows.to_csv('duplicate_titles.csv', index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "4e72af34",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dataframe shape after removing duplicates: (60501, 44)\n"
     ]
    }
   ],
   "source": [
    "df = df.drop_duplicates(subset=['title', 'phase'], keep='first')\n",
    "print(f\"Dataframe shape after removing duplicates: {df.shape}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "792e627c",
   "metadata": {},
   "source": [
    "Dropping unnecessary columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "a8ad7392",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['nctid', 'orgstudyid','title','centralcontact_name','centralcontact_role','centralcontact_phone','centralcontact_phoneext','centralcontact_email','num_central_contacts'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "5e1df37e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['organization_fullname', 'lead_sponsor', 'collaborators', 'study_type',\n",
       "       'phase', 'overall_status', 'start_date', 'completion_date',\n",
       "       'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'location_facility', 'location_city',\n",
       "       'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9bdc7ca0",
   "metadata": {},
   "source": [
    "checking if the location of the organization and the location of the facility are the same to see correlation "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "a48244b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>is_same</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Prism Pharma Co., Ltd.</td>\n",
       "      <td>Emory University / Winship Cancer Institute, U...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "      <td>Universitaetsklinikum Halle</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "      <td>National Naval Medical Center, Warren Grant Ma...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>University Hospital, Basel, Switzerland</td>\n",
       "      <td>Carsten T. Viehl, MD, Urban Laffer, MD, Markus...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "      <td>Brigham and Women's Hospital, Dana Farber Canc...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Aarhus University Hospital</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Cure&amp;Sure Biotech Co., LTD</td>\n",
       "      <td>Cancer Insititute and Hospital,Chinese Academy...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>GOG Foundation</td>\n",
       "      <td>CCOP - Western Regional, Arizona, CCOP - Chris...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Shenzhen Yangli Pharmaceutical Technology Co.,...</td>\n",
       "      <td>The 1st Affiliated Hospital of Henan Universit...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sunshine Guojian Pharmaceutical (Shanghai) Co....</td>\n",
       "      <td>The 307 Hospital of People's Liberation Army, ...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                organization_fullname  \\\n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                         Zealand University Hospital   \n",
       "2        Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3           Shanghai Institute Of Biological Products   \n",
       "4                     Vanderbilt-Ingram Cancer Center   \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6              Stanford University School of Medicine   \n",
       "7                     National Cancer Institute (NCI)   \n",
       "8                       Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                    AEterna Zentaris   \n",
       "10                             Prism Pharma Co., Ltd.   \n",
       "11         Martin-Luther-Universität Halle-Wittenberg   \n",
       "12    University of Texas Southwestern Medical Center   \n",
       "13               Beijing Tsinghua Chang Gung Hospital   \n",
       "14  National Institutes of Health Clinical Center ...   \n",
       "15            University Hospital, Basel, Switzerland   \n",
       "16              St. Jude Children's Research Hospital   \n",
       "17          Emory University Winship Cancer Institute   \n",
       "18                       Dana-Farber Cancer Institute   \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...   \n",
       "20                  Sunnybrook Health Sciences Centre   \n",
       "21                         Aarhus University Hospital   \n",
       "22                 University Health Network, Toronto   \n",
       "23                         Cure&Sure Biotech Co., LTD   \n",
       "24                                     GOG Foundation   \n",
       "25                        M.D. Anderson Cancer Center   \n",
       "26  Emory University Winship Cancer Institute, The...   \n",
       "27  Shenzhen Yangli Pharmaceutical Technology Co.,...   \n",
       "28                                  Dong-A University   \n",
       "29  Sunshine Guojian Pharmaceutical (Shanghai) Co....   \n",
       "\n",
       "                                    location_facility is_same  \n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...    True  \n",
       "1                         Zealand University Hospital    True  \n",
       "2              Guangdong Provincial People's Hospital   False  \n",
       "3   The First Affiliated Hospital of College of Me...   False  \n",
       "4          Vanderbilt University/Ingram Cancer Center   False  \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...    True  \n",
       "6              Stanford University School of Medicine    True  \n",
       "7   Rebecca and John Moores UCSD Cancer Center, Jo...   False  \n",
       "8                              Shanghai East Hospital   False  \n",
       "9   AOI Pharmaceuticals Investigative Site, AOI Ph...   False  \n",
       "10  Emory University / Winship Cancer Institute, U...   False  \n",
       "11                        Universitaetsklinikum Halle   False  \n",
       "12    University of Texas Southwestern Medical Center    True  \n",
       "13               Beijing Tsinghua Chang Gung Hospital    True  \n",
       "14  National Naval Medical Center, Warren Grant Ma...   False  \n",
       "15  Carsten T. Viehl, MD, Urban Laffer, MD, Markus...   False  \n",
       "16              St. Jude Children's Research Hospital    True  \n",
       "17          Emory University Winship Cancer Institute    True  \n",
       "18  Brigham and Women's Hospital, Dana Farber Canc...   False  \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...    True  \n",
       "20                  Sunnybrook Health Sciences Centre    True  \n",
       "21                                                NaN     NaN  \n",
       "22                    Princess Margaret Cancer Centre   False  \n",
       "23  Cancer Insititute and Hospital,Chinese Academy...   False  \n",
       "24  CCOP - Western Regional, Arizona, CCOP - Chris...   False  \n",
       "25                        M.D. Anderson Cancer Center    True  \n",
       "26  Emory University Winship Cancer Institute, The...    True  \n",
       "27  The 1st Affiliated Hospital of Henan Universit...   False  \n",
       "28                                  Dong-A University    True  \n",
       "29  The 307 Hospital of People's Liberation Army, ...   False  "
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from rapidfuzz import fuzz\n",
    "import re\n",
    "import pandas as pd\n",
    "\n",
    "# Cleaning function\n",
    "def clean_text(text):\n",
    "    if not isinstance(text, str):\n",
    "        return \"\"\n",
    "    text = text.lower()\n",
    "    text = re.sub(r'[^a-z0-9\\s]', '', text)  # remove punctuation\n",
    "    text = re.sub(r'\\s+', ' ', text).strip()  # normalize spaces\n",
    "    return text\n",
    "\n",
    "\n",
    "def fuzzy_match_and_replace(row, threshold=85):\n",
    "    org = row['organization_fullname']\n",
    "    loc = row['location_facility']\n",
    "    \n",
    "    if pd.isna(org) or pd.isna(loc):\n",
    "        return row  # skip if any is NaN\n",
    "\n",
    "    org_clean = clean_text(org)\n",
    "    loc_clean = clean_text(loc)\n",
    "    \n",
    "    score = fuzz.token_set_ratio(org_clean, loc_clean)\n",
    "    \n",
    "    if score >= threshold:\n",
    "        # Choose the longer original string (not cleaned)\n",
    "        unified_name = org if len(org) >= len(loc) else loc\n",
    "        row['organization_fullname'] = unified_name\n",
    "        row['location_facility'] = unified_name\n",
    "        row['is_same'] = True\n",
    "    else:\n",
    "        row['is_same'] = False\n",
    "\n",
    "    return row\n",
    "\n",
    "# Apply to the whole DataFrame\n",
    "df = df.apply(fuzzy_match_and_replace, axis=1)\n",
    "\n",
    "# View subset\n",
    "subset = df[['organization_fullname', 'location_facility', 'is_same']]\n",
    "subset.head(30)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "9f1d03fc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "is_same\n",
       "False    34611\n",
       "True     22636\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['is_same'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "0c18d87e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "collaborators                    37279\n",
       "keywords                         21735\n",
       "detailed_description             19041\n",
       "secondary_outcomes               10606\n",
       "overall_officials_affiliation    10358\n",
       "overall_officials_name           10235\n",
       "interventions_description         8944\n",
       "location_city                     3254\n",
       "location_state                    3254\n",
       "location_facility                 3254\n",
       "location_country                  3254\n",
       "is_same                           3254\n",
       "country                           3254\n",
       "primary_outcomes                  2680\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "31ebca20",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_status\n",
       "COMPLETED                  22111\n",
       "TERMINATED                 17935\n",
       "RECRUITING                  7898\n",
       "UNKNOWN                     6175\n",
       "ACTIVE_NOT_RECRUITING       4293\n",
       "NOT_YET_RECRUITING          1995\n",
       "ENROLLING_BY_INVITATION       94\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_status'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "7126ada5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'collaborators', 'completion_date', 'conditions',\n",
       "       'country', 'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d5842b44",
   "metadata": {},
   "source": [
    "Checking what influence does collaborators have on completed/terminated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "eae71127",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "When 'collaborators' is NULL:\n",
      "overall_status\n",
      "COMPLETED     12657\n",
      "TERMINATED    11701\n",
      "Name: count, dtype: int64\n",
      "Total: 24358\n",
      "\n",
      "When 'collaborators' is NOT NULL:\n",
      "overall_status\n",
      "COMPLETED     9454\n",
      "TERMINATED    6234\n",
      "Name: count, dtype: int64\n",
      "Total: 15688\n"
     ]
    }
   ],
   "source": [
    "# Case 1: collaborators is NULL and status is COMPLETED or TERMINATED\n",
    "null_mask = df['collaborators'].isnull()\n",
    "null_and_status = df[null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NULL:\")\n",
    "print(null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {null_and_status.shape[0]}\\n\")\n",
    "\n",
    "# Case 2: collaborators is NOT NULL and status is COMPLETED or TERMINATED\n",
    "not_null_mask = df['collaborators'].notnull()\n",
    "not_null_and_status = df[not_null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NOT NULL:\")\n",
    "print(not_null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {not_null_and_status.shape[0]}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "79e74313",
   "metadata": {},
   "source": [
    "The general data distribution shows no such trend as having an influence on the overall status as compeleted/terminated, so we can drop it"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "07441ab7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('collaborators', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fa3b11a3",
   "metadata": {},
   "source": [
    "Checking for data types and their conversion (dates). Some fields have missing days, so I am manually setting day as 15\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "9dd4bf9d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60501, 35)"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "ed026f27",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ，SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injection，100mg/10ml; Injection，100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>?</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\n• To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase Ⅰ/Ⅱ, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-∞]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillation；SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>?</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\n• This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...         2027-06   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...         2029-03   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...         2009-07   \n",
       "7   RATIONALE: The timing of breast cancer surgery...         2004-10   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...         2011-10   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...         2017-09   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...         2008-10   \n",
       "15  The study is a feasibility and validation stud...         2009-01   \n",
       "16  This study is a phase I study designed to eval...         2031-01   \n",
       "17  This is an open-label (doctors and patients kn...         2015-11   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...         2024-10   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...         2019-11   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...               ?   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...         2013-09   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...         2024-03   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...         2009-02   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...         2019-03   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...               ?   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...         2013-09   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...         2026-12   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...         2027-02   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...         2014-07   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...         2013-08   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\n• To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase Ⅰ/Ⅱ, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\n• This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ，SHR-A2009 will be admin...   \n",
       "3          Injection，100mg/10ml; Injection，100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillation；SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2                  2026-12  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4                  2028-03  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6                  2009-02  In this phase I study the endpoint is the dete...   \n",
       "7                        ?                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9                  2010-12       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11                 2017-09  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14                 2008-04  Dose-limiting toxicities and maximum tolerated...   \n",
       "15                 2009-01  To assess the extent of upstaging due to the S...   \n",
       "16                 2030-01  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17                 2015-11  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23                 2016-11  blood count; blood count; blood count; blood c...   \n",
       "24                 2007-01                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28                 2013-02  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-∞]; Cmax   \n",
       "30                 2023-12                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32                 2008-11                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37                 2019-03  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                       ?                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42                 2013-07  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43                 2026-09                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45                 2026-08  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47                 2014-07  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49                 2013-08  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex  start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL  2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL  2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL  2024-11-29   \n",
       "3                                                 NaN     ALL  2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL  2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL  2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL     2006-05   \n",
       "7                                                 NaN  FEMALE     1999-01   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL  2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL     2005-08   \n",
       "10                     Preliminary Efficacy Endpoints     ALL     2012-07   \n",
       "11  number of participants with adverse events as ...     ALL     2014-09   \n",
       "12                                                NaN     ALL     2013-05   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL  2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL     2001-03   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL     2000-05   \n",
       "16                                                NaN     ALL     2025-05   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL     2008-02   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL  2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL  2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL  2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL  2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL  2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL     2012-03   \n",
       "24                                                NaN  FEMALE     1999-11   \n",
       "25                                                NaN     ALL  2023-05-23   \n",
       "26                                                NaN     ALL  2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE  2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL     2011-03   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL  2018-12-18   \n",
       "30                                                NaN  FEMALE     2021-03   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL  2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL     2006-08   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL  2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL  2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL  2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL  2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL     2015-09   \n",
       "38                          Progression Free Survival     ALL     2015-05   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL  2003-10-27   \n",
       "40                                                NaN     ALL     2002-06   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL  2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL     2010-04   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL  2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL  2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL  2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL  2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL     2006-05   \n",
       "48  overall response rate; 1-year progression free...     ALL  2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL     2010-03   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "9388472b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# Your date columns\n",
    "date_cols = [\n",
    "    'completion_date',\n",
    "    'last_update_post_date',\n",
    "    'primary_completion_date',\n",
    "    'start_date',\n",
    "    'study_first_post_date',\n",
    "    'study_first_submit_date'\n",
    "]\n",
    "\n",
    "# Function to insert day=15 if day is missing\n",
    "def fill_day_15(date_str):\n",
    "    if pd.isna(date_str):\n",
    "        return np.nan\n",
    "    date_str = str(date_str).strip()\n",
    "    \n",
    "    # Check if format is like \"Jan 2023\" or \"2023-01\"\n",
    "    if re.fullmatch(r'[A-Za-z]{3,9}\\s+\\d{4}', date_str):  # e.g., \"March 2021\"\n",
    "        return f'15 {date_str}'\n",
    "    elif re.fullmatch(r'\\d{4}-\\d{2}', date_str):  # e.g., \"2023-01\"\n",
    "        return f'{date_str}-15'\n",
    "    return date_str  # return unchanged if full date is already present\n",
    "\n",
    "# Apply transformation and convert to datetime\n",
    "for col in date_cols:\n",
    "    df[col] = df[col].apply(fill_day_15)  # Fill in day if needed\n",
    "    df[col] = pd.to_datetime(df[col], errors='coerce')  # Convert to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "2d671049",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06-15</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ，SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injection，100mg/10ml; Injection，100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03-15</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03-15</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10-15</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10-15</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12-15</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01-15</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01-15</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05-15</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10-15</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11-15</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01-15</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\n• To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase Ⅰ/Ⅱ, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02-15</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-∞]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03-15</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12-15</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11-15</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillation；SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07-15</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09-15</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02-15</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08-15</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\n• This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...      2027-06-15   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...      2029-03-15   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...      2009-07-15   \n",
       "7   RATIONALE: The timing of breast cancer surgery...      2004-10-15   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...      2011-10-15   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...      2017-09-15   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...      2008-10-15   \n",
       "15  The study is a feasibility and validation stud...      2009-01-15   \n",
       "16  This study is a phase I study designed to eval...      2031-01-15   \n",
       "17  This is an open-label (doctors and patients kn...      2015-11-15   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...      2024-10-15   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...      2019-11-15   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...             NaT   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...      2013-09-15   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...      2024-03-15   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...      2009-02-15   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...      2019-03-15   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...             NaT   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...      2013-09-15   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...      2026-12-15   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...      2027-02-15   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...      2014-07-15   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...      2013-08-15   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\n• To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase Ⅰ/Ⅱ, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\n• This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ，SHR-A2009 will be admin...   \n",
       "3          Injection，100mg/10ml; Injection，100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillation；SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2               2026-12-15  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4               2028-03-15  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6               2009-02-15  In this phase I study the endpoint is the dete...   \n",
       "7                      NaT                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9               2010-12-15       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11              2017-09-15  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14              2008-04-15  Dose-limiting toxicities and maximum tolerated...   \n",
       "15              2009-01-15  To assess the extent of upstaging due to the S...   \n",
       "16              2030-01-15  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17              2015-11-15  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23              2016-11-15  blood count; blood count; blood count; blood c...   \n",
       "24              2007-01-15                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28              2013-02-15  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-∞]; Cmax   \n",
       "30              2023-12-15                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32              2008-11-15                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37              2019-03-15  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                     NaT                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42              2013-07-15  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43              2026-09-15                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45              2026-08-15  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47              2014-07-15  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49              2013-08-15  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL 2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL 2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL 2024-11-29   \n",
       "3                                                 NaN     ALL 2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL 2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL 2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL 2006-05-15   \n",
       "7                                                 NaN  FEMALE 1999-01-15   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL 2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL 2005-08-15   \n",
       "10                     Preliminary Efficacy Endpoints     ALL 2012-07-15   \n",
       "11  number of participants with adverse events as ...     ALL 2014-09-15   \n",
       "12                                                NaN     ALL 2013-05-15   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL 2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL 2001-03-15   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL 2000-05-15   \n",
       "16                                                NaN     ALL 2025-05-15   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL 2008-02-15   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL 2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL 2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL 2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL 2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL 2012-03-15   \n",
       "24                                                NaN  FEMALE 1999-11-15   \n",
       "25                                                NaN     ALL 2023-05-23   \n",
       "26                                                NaN     ALL 2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE 2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL 2011-03-15   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL 2018-12-18   \n",
       "30                                                NaN  FEMALE 2021-03-15   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL 2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL 2006-08-15   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL 2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL 2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL 2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL 2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL 2015-09-15   \n",
       "38                          Progression Free Survival     ALL 2015-05-15   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL 2003-10-27   \n",
       "40                                                NaN     ALL 2002-06-15   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL 2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL 2010-04-15   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL 2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL 2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL 2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL 2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL 2006-05-15   \n",
       "48  overall response rate; 1-year progression free...     ALL 2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL 2010-03-15   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1016c95e",
   "metadata": {},
   "source": [
    "Remove all the rows that have Nan values in their date columns "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "7f976375",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(55590, 35)"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Replace '?' with NaN in a temporary view of the date columns\n",
    "df_temp = df[date_cols].replace('?', pd.NA)\n",
    "\n",
    "# Identify rows that have NaN or '?'\n",
    "rows_with_nan_or_question = df_temp.isna().any(axis=1)\n",
    "\n",
    "# Remove those rows from the original dataframe\n",
    "df = df[~rows_with_nan_or_question].reset_index(drop=True)\n",
    "df.shape\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "19aee9b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "615da2d3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20465\n",
       "detailed_description             17688\n",
       "overall_officials_affiliation     9647\n",
       "overall_officials_name            9577\n",
       "secondary_outcomes                8314\n",
       "interventions_description         5318\n",
       "location_city                     2833\n",
       "location_state                    2833\n",
       "location_facility                 2833\n",
       "location_country                  2833\n",
       "is_same                           2833\n",
       "country                           2833\n",
       "primary_outcomes                   995\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "9435ec7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>This is an open-label, single arm, phase 2 stu...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>In this single-center, open-label, nonrandomiz...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...</td>\n",
       "      <td>29</td>\n",
       "      <td>A humanized monoclonal immunoglobulin; A DNA m...</td>\n",
       "      <td>Camrelizumab(SHR-1210), Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2020-12-31</td>\n",
       "      <td>Overall response rate; Complete remission (CR)...</td>\n",
       "      <td>Progress-free survival (PFS); Overall survival...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-20</td>\n",
       "      <td>2020-04-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>Time to progression (physical examination and ...</td>\n",
       "      <td>2008-06-15</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patients with primary...</td>\n",
       "      <td>105</td>\n",
       "      <td>4 cycles of Carboplatin AUC 5 every 3 weeks. 1...</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Progression-free Survival. Progression is Defi...</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2003-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2005-09-12</td>\n",
       "      <td>2005-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>Our study aims at assessment of response, surv...</td>\n",
       "      <td>2022-09-01</td>\n",
       "      <td>Advanced Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Ovarian cancer is the most lethal gynecologic ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Female patients diagn...</td>\n",
       "      <td>40</td>\n",
       "      <td>The chemotherapy regimen will be Paclitaxel (1...</td>\n",
       "      <td>Bevacizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-08-31</td>\n",
       "      <td>progression free survival</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2018-09-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2018-08-02</td>\n",
       "      <td>2018-07-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>Endometrial cancer (EC) is the 8th most common...</td>\n",
       "      <td>2014-04-15</td>\n",
       "      <td>Recurrent Endometrial Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Patients receive weekly Ixabepilone 32 mg/m2 (...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Histologically confi...</td>\n",
       "      <td>24</td>\n",
       "      <td>Ixabepilone 40 mg/m2 Lapatinib 250 mg</td>\n",
       "      <td>Lapatinib and ixempra</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-04-15</td>\n",
       "      <td>Determine the Maximum Tolerated Dosage (MTD) o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2011-10-19</td>\n",
       "      <td>2011-09-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55435</th>\n",
       "      <td>The investigators plan to to study an extended...</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Bipolar Disorder, Mania</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Clonidine has been reported to be effective in...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* meet SCID criteria fo...</td>\n",
       "      <td>5</td>\n",
       "      <td>Subjects will received 0.2 mg extended-release...</td>\n",
       "      <td>extended-release clonidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Score on a Mania Rating Scale</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-01-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2017-02-28</td>\n",
       "      <td>2012-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55457</th>\n",
       "      <td>The purpose of this study is to assess the eff...</td>\n",
       "      <td>2011-09-15</td>\n",
       "      <td>Allergic Rhinitis Due to Dust Mite</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>After the screening period, the patients will ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Male or female outpat...</td>\n",
       "      <td>471</td>\n",
       "      <td>300 IR, once a day, for one year.; once a day,...</td>\n",
       "      <td>Dpte and Dfar Allergen Extracts, placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2011-01-15</td>\n",
       "      <td>Efficacy Assessment</td>\n",
       "      <td>Efficacy Assessment at the end of the treatmen...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2009-10-15</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>2010-09-10</td>\n",
       "      <td>2010-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55479</th>\n",
       "      <td>The purpose of this study is to provide an inv...</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Hypercholesterolemia, Familial, Lipid Metaboli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Homozygous familial h...</td>\n",
       "      <td>49</td>\n",
       "      <td>Ezetimibe (MK0653) 10 mg once daily for 3 years.</td>\n",
       "      <td>Comparator: ezetimibe</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Incidence of clinical and laboratory adverse e...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-07-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-09-28</td>\n",
       "      <td>2004-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55550</th>\n",
       "      <td>This study will assess the efficacy of a singl...</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Staphylococcus Aureus, Bacteremia, Mediastinitis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant is schedu...</td>\n",
       "      <td>8031</td>\n",
       "      <td>0.5-mL single injection of V710 (60 µg); 0.5-m...</td>\n",
       "      <td>V710, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Number of Participants With Staphylococcus Aur...</td>\n",
       "      <td>Number of Participants With Invasive Staphyloc...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2007-08-21</td>\n",
       "      <td>2007-08-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55570</th>\n",
       "      <td>In this study, we propose to employ a randomiz...</td>\n",
       "      <td>2016-09-11</td>\n",
       "      <td>Post-traumatic Stress Disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women between...</td>\n",
       "      <td>10</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, one dose, one ti...</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, Pomaglumetad Met...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2016-02-11</td>\n",
       "      <td>To Evaluate the Effect of 160mg and 40mg of Po...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2014-09-09</td>\n",
       "      <td>2014-09-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2833 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           brief_summary completion_date  \\\n",
       "20     The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "86     This is an open-label, single arm, phase 2 stu...      2022-12-31   \n",
       "120    Time to progression (physical examination and ...      2008-06-15   \n",
       "148    Our study aims at assessment of response, surv...      2022-09-01   \n",
       "163    Endometrial cancer (EC) is the 8th most common...      2014-04-15   \n",
       "...                                                  ...             ...   \n",
       "55435  The investigators plan to to study an extended...      2013-01-15   \n",
       "55457  The purpose of this study is to assess the eff...      2011-09-15   \n",
       "55479  The purpose of this study is to provide an inv...      2005-05-15   \n",
       "55550  This study will assess the efficacy of a singl...      2011-08-15   \n",
       "55570  In this study, we propose to employ a randomiz...      2016-09-11   \n",
       "\n",
       "                                              conditions country  \\\n",
       "20                    Non-Muscle Invasive Bladder Cancer     NaN   \n",
       "86                                Acute Myeloid Leukemia     NaN   \n",
       "120                                       Ovarian Cancer     NaN   \n",
       "148                              Advanced Ovarian Cancer     NaN   \n",
       "163                         Recurrent Endometrial Cancer     NaN   \n",
       "...                                                  ...     ...   \n",
       "55435                            Bipolar Disorder, Mania     NaN   \n",
       "55457                 Allergic Rhinitis Due to Dust Mite     NaN   \n",
       "55479  Hypercholesterolemia, Familial, Lipid Metaboli...     NaN   \n",
       "55550   Staphylococcus Aureus, Bacteremia, Mediastinitis     NaN   \n",
       "55570                     Post-traumatic Stress Disorder     NaN   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "20                 TREATMENT   \n",
       "86                 TREATMENT   \n",
       "120                TREATMENT   \n",
       "148                TREATMENT   \n",
       "163                TREATMENT   \n",
       "...                      ...   \n",
       "55435              TREATMENT   \n",
       "55457              TREATMENT   \n",
       "55479              TREATMENT   \n",
       "55550             PREVENTION   \n",
       "55570              TREATMENT   \n",
       "\n",
       "                                    detailed_description  \\\n",
       "20                                                   NaN   \n",
       "86     In this single-center, open-label, nonrandomiz...   \n",
       "120                                                  NaN   \n",
       "148    Ovarian cancer is the most lethal gynecologic ...   \n",
       "163    Patients receive weekly Ixabepilone 32 mg/m2 (...   \n",
       "...                                                  ...   \n",
       "55435  Clonidine has been reported to be effective in...   \n",
       "55457  After the screening period, the patients will ...   \n",
       "55479                                                NaN   \n",
       "55550                                                NaN   \n",
       "55570                                                NaN   \n",
       "\n",
       "                                    eligibility_criteria enrollment  \\\n",
       "20     Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "86     Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...         29   \n",
       "120    Inclusion Criteria:\\n\\n* patients with primary...        105   \n",
       "148    Inclusion Criteria:\\n\\n* Female patients diagn...         40   \n",
       "163    Inclusion Criteria:\\n\\n1. Histologically confi...         24   \n",
       "...                                                  ...        ...   \n",
       "55435  Inclusion Criteria:\\n\\n* meet SCID criteria fo...          5   \n",
       "55457  Inclusion Criteria:\\n\\n* Male or female outpat...        471   \n",
       "55479  Inclusion Criteria:\\n\\n* Homozygous familial h...         49   \n",
       "55550  Inclusion Criteria:\\n\\n* Participant is schedu...       8031   \n",
       "55570  Inclusion Criteria:\\n\\n* Men and women between...         10   \n",
       "\n",
       "                               interventions_description  \\\n",
       "20                                         Chemoablation   \n",
       "86     A humanized monoclonal immunoglobulin; A DNA m...   \n",
       "120    4 cycles of Carboplatin AUC 5 every 3 weeks. 1...   \n",
       "148    The chemotherapy regimen will be Paclitaxel (1...   \n",
       "163                Ixabepilone 40 mg/m2 Lapatinib 250 mg   \n",
       "...                                                  ...   \n",
       "55435  Subjects will received 0.2 mg extended-release...   \n",
       "55457  300 IR, once a day, for one year.; once a day,...   \n",
       "55479   Ezetimibe (MK0653) 10 mg once daily for 3 years.   \n",
       "55550  0.5-mL single injection of V710 (60 µg); 0.5-m...   \n",
       "55570  Pomaglumetad Methionil 160mg, one dose, one ti...   \n",
       "\n",
       "                                      interventions_name  ...           phase  \\\n",
       "20                                           Mitomycin c  ...          PHASE4   \n",
       "86                    Camrelizumab(SHR-1210), Decitabine  ...          PHASE2   \n",
       "120                                           Paclitaxel  ...          PHASE2   \n",
       "148                                          Bevacizumab  ...          PHASE2   \n",
       "163                                Lapatinib and ixempra  ...          PHASE1   \n",
       "...                                                  ...  ...             ...   \n",
       "55435                         extended-release clonidine  ...          PHASE4   \n",
       "55457           Dpte and Dfar Allergen Extracts, placebo  ...          PHASE3   \n",
       "55479                              Comparator: ezetimibe  ...          PHASE3   \n",
       "55550                                      V710, Placebo  ...  PHASE2, PHASE3   \n",
       "55570  Pomaglumetad Methionil 160mg, Pomaglumetad Met...  ...          PHASE1   \n",
       "\n",
       "      primary_completion_date  \\\n",
       "20                 2029-02-01   \n",
       "86                 2020-12-31   \n",
       "120                2008-04-15   \n",
       "148                2022-08-31   \n",
       "163                2013-04-15   \n",
       "...                       ...   \n",
       "55435              2013-01-15   \n",
       "55457              2011-01-15   \n",
       "55479              2005-05-15   \n",
       "55550              2011-08-15   \n",
       "55570              2016-02-11   \n",
       "\n",
       "                                        primary_outcomes  \\\n",
       "20                     Two-year Recurrence Free Survival   \n",
       "86     Overall response rate; Complete remission (CR)...   \n",
       "120    Progression-free Survival. Progression is Defi...   \n",
       "148                            progression free survival   \n",
       "163    Determine the Maximum Tolerated Dosage (MTD) o...   \n",
       "...                                                  ...   \n",
       "55435                      Score on a Mania Rating Scale   \n",
       "55457                                Efficacy Assessment   \n",
       "55479  Incidence of clinical and laboratory adverse e...   \n",
       "55550  Number of Participants With Staphylococcus Aur...   \n",
       "55570  To Evaluate the Effect of 160mg and 40mg of Po...   \n",
       "\n",
       "                                      secondary_outcomes     sex start_date  \\\n",
       "20     Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "86     Progress-free survival (PFS); Overall survival...     ALL 2020-04-25   \n",
       "120                                             Toxicity  FEMALE 2003-07-15   \n",
       "148                                                  NaN  FEMALE 2018-09-01   \n",
       "163                                                  NaN  FEMALE 2011-03-15   \n",
       "...                                                  ...     ...        ...   \n",
       "55435                                                NaN     ALL 2012-01-15   \n",
       "55457  Efficacy Assessment at the end of the treatmen...     ALL 2009-10-15   \n",
       "55479                                                NaN     ALL 2002-07-15   \n",
       "55550  Number of Participants With Invasive Staphyloc...     ALL 2007-12-15   \n",
       "55570                                                NaN     ALL 2014-09-15   \n",
       "\n",
       "                          stdage study_first_post_date  \\\n",
       "20            ADULT, OLDER_ADULT            2025-01-17   \n",
       "86            ADULT, OLDER_ADULT            2020-04-20   \n",
       "120           ADULT, OLDER_ADULT            2005-09-12   \n",
       "148           ADULT, OLDER_ADULT            2018-08-02   \n",
       "163           ADULT, OLDER_ADULT            2011-10-19   \n",
       "...                          ...                   ...   \n",
       "55435                      ADULT            2017-02-28   \n",
       "55457                      CHILD            2010-09-10   \n",
       "55479  CHILD, ADULT, OLDER_ADULT            2004-09-28   \n",
       "55550         ADULT, OLDER_ADULT            2007-08-21   \n",
       "55570                      ADULT            2014-09-09   \n",
       "\n",
       "      study_first_submit_date      study_type  \n",
       "20                 2025-01-14  INTERVENTIONAL  \n",
       "86                 2020-04-14  INTERVENTIONAL  \n",
       "120                2005-09-09  INTERVENTIONAL  \n",
       "148                2018-07-17  INTERVENTIONAL  \n",
       "163                2011-09-28  INTERVENTIONAL  \n",
       "...                       ...             ...  \n",
       "55435              2012-11-06  INTERVENTIONAL  \n",
       "55457              2010-09-09  INTERVENTIONAL  \n",
       "55479              2004-09-23  INTERVENTIONAL  \n",
       "55550              2007-08-17  INTERVENTIONAL  \n",
       "55570              2014-09-03  INTERVENTIONAL  \n",
       "\n",
       "[2833 rows x 35 columns]"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['is_same'].isna()]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6858cda0",
   "metadata": {},
   "source": [
    "Dropping data for which primary outcomes are null"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "b99bb206",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        Safety as Measured by Number of Participants W...\n",
       "1        Safety - Adverse reactions are classified acco...\n",
       "2        Progression-free survival (PFS) assessed by BI...\n",
       "3                              Overall Response Rate (ORR)\n",
       "4        Composite complete response (CR) rate (CR/comp...\n",
       "                               ...                        \n",
       "55585    Number of Participants With Treatment Emergent...\n",
       "55586    Best Objective Response Rate (ORR) Within 6 Mo...\n",
       "55587    Frequency of dose-limiting toxicities (DLT's) ...\n",
       "55588    Remission of the metabolic syndrome following ...\n",
       "55589    Percentage of Participants Who Achieved Comple...\n",
       "Name: primary_outcomes, Length: 55590, dtype: object"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primary_outcomes']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "8d818180",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['primary_outcomes'].isna() | (df['primary_outcomes'].str.strip() == ''))]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "cf8d7403",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['conditions'].isna())]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "1b8a09d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20392\n",
       "detailed_description             17572\n",
       "overall_officials_affiliation     9553\n",
       "overall_officials_name            9484\n",
       "secondary_outcomes                7321\n",
       "interventions_description         4405\n",
       "location_city                     2775\n",
       "location_state                    2775\n",
       "location_facility                 2775\n",
       "location_country                  2775\n",
       "is_same                           2775\n",
       "country                           2775\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "ec08e85a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(54594, 35)"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "05481d11",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                 Johns Hopkins University\n",
       "1                              Zealand University Hospital\n",
       "2                                                      NaN\n",
       "3                           SINOPHARM, Zhejiang University\n",
       "4               Vanderbilt University/Ingram Cancer Center\n",
       "                               ...                        \n",
       "55585                                               AbbVie\n",
       "55586                          M.D. Anderson Cancer Center\n",
       "55587    Emory University Hospital/Winship Cancer Insti...\n",
       "55588    Hospital Universitari San Joan de Reus (Tarrag...\n",
       "55589                                                  NaN\n",
       "Name: overall_officials_affiliation, Length: 54594, dtype: object"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_officials_affiliation']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "0354b4d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20392\n",
       "detailed_description             17572\n",
       "overall_officials_affiliation     9553\n",
       "overall_officials_name            9484\n",
       "secondary_outcomes                7321\n",
       "interventions_description         4405\n",
       "location_city                     2775\n",
       "location_state                    2775\n",
       "location_facility                 2775\n",
       "location_country                  2775\n",
       "is_same                           2775\n",
       "country                           2775\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "cab79b6c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(54594, 35)"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "cbd8cd7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.int64(0)"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.duplicated().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "f8c94fce",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['is_same'] = df['is_same'].astype(bool)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "6d37e175",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ For is_same == True:\n",
      "overall_status\n",
      "COMPLETED     32.098149\n",
      "TERMINATED    25.468912\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "❌ For is_same == False:\n",
      "overall_status\n",
      "COMPLETED     35.909522\n",
      "TERMINATED    33.889816\n",
      "Name: proportion, dtype: float64\n"
     ]
    }
   ],
   "source": [
    "# Filter True and False separately\n",
    "true_group = df[df['is_same'] == True]['overall_status'].value_counts(normalize=True) * 100\n",
    "false_group = df[df['is_same'] == False]['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "# Display counts with percentages\n",
    "print(\"✅ For is_same == True:\")\n",
    "print(true_group[['COMPLETED', 'TERMINATED']])\n",
    "\n",
    "print(\"\\n❌ For is_same == False:\")\n",
    "print(false_group[['COMPLETED', 'TERMINATED']])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "51692465",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Counts:\n",
      "is_same\n",
      "False    30549\n",
      "True     24045\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "counts = df['is_same'].astype(bool).value_counts()\n",
    "print(\"Counts:\")\n",
    "print(counts)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "beffaec2",
   "metadata": {},
   "source": [
    "Dropping rows that have empty location_facility"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "302d0353",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.dropna(subset=['location_facility'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "50d49749",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(51819, 35)"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "fca1e46e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "f680c8a9",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['keywords','detailed_description'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "01c61533",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_officials_affiliation    8461\n",
       "overall_officials_name           8395\n",
       "secondary_outcomes               6886\n",
       "interventions_description        4117\n",
       "brief_summary                       0\n",
       "design_primary_purpose              0\n",
       "completion_date                     0\n",
       "country                             0\n",
       "conditions                          0\n",
       "is_same                             0\n",
       "last_update_post_date               0\n",
       "lead_sponsor                        0\n",
       "location_city                       0\n",
       "location_country                    0\n",
       "eligibility_criteria                0\n",
       "enrollment                          0\n",
       "interventions_name                  0\n",
       "maximum_age                         0\n",
       "location_state                      0\n",
       "location_facility                   0\n",
       "organization_fullname               0\n",
       "overall_status                      0\n",
       "oversight_has_dmc                   0\n",
       "phase                               0\n",
       "minimum_age                         0\n",
       "primary_completion_date             0\n",
       "primary_outcomes                    0\n",
       "sex                                 0\n",
       "start_date                          0\n",
       "stdage                              0\n",
       "study_first_post_date               0\n",
       "study_first_submit_date             0\n",
       "study_type                          0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "42441328",
   "metadata": {},
   "source": [
    "Checking that if officials are from the same university, then what is the ratio of it beign completed/terminated "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "0e75c7f7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>overall_officials_affiliation</th>\n",
       "      <th>overall_officials_name</th>\n",
       "      <th>organization_fullname</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>Tanguy Lim-Seiwert, MD</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Ismail Gögenur, Professor</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>SINOPHARM, Zhejiang University</td>\n",
       "      <td>Shanghai Institute Of Biological Products Co.,...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan, MD</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Chao Family Comprehensive Cancer Center</td>\n",
       "      <td>Farshid Dayyani, MD, PhD</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Nelson N Teng</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Online Collaborative Oncology Group</td>\n",
       "      <td>Craig Henderson, MD</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Jorge Cortes, MD</td>\n",
       "      <td>Prism Pharma Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "      <td>Carsten Mueller-Tidow, Prof.</td>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>UT Southwestern Medical Center</td>\n",
       "      <td>Arthur E. Frankel, MD</td>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>Donghong Chen, Dr.</td>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCI - Medical Oncology Branch</td>\n",
       "      <td>Shivaani Kummar, MD</td>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>aktuell: Spitalzentrum Biel-Bienne, Kantonsspi...</td>\n",
       "      <td>Carsten T. Viehl, MD, Markus Zuber, MD</td>\n",
       "      <td>University Hospital, Basel, Switzerland</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>Rebecca Epperly, MD</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Emory University</td>\n",
       "      <td>Christopher Flowers, MD</td>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "      <td>Elahe Salehi, DNP, ANP-BC</td>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Department of Respiratory Medicine, Juntendo U...</td>\n",
       "      <td>Ryo Ko, MD, PhD</td>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>Simron Singh</td>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>Robert C. Grant, MD</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cancer Insititute and Hospital,Chinese Academy...</td>\n",
       "      <td>Jianqiang Cai, meidical, Lei Yu, medical</td>\n",
       "      <td>Cure&amp;Sure Biotech Co., LTD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Clinton Yam, MD</td>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Vassiliki Papadimitrakopoulou, M.D.</td>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Fudan University Affiliated Cancer Hospital</td>\n",
       "      <td>Jian Zhang</td>\n",
       "      <td>Shenzhen Yangli Pharmaceutical Technology Co.,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>Ki-Hoon Song, M.D., Ph.D.</td>\n",
       "      <td>Dong-A University</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Sunshine Guojian Pharmaceutical (Shanghai) Co....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The First Affiliated Hospital of Sun Yat-sen U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>Bristol Myers Squibb</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adnexus, A Bristol-Myers Squibb R&amp;D Company</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>920th Hospital of Joint Logistics Support Forc...</td>\n",
       "      <td>Wang Sanbin, Doctor</td>\n",
       "      <td>920th Hospital of Joint Logistics Support Forc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Janssen Research &amp; Development, LLC</td>\n",
       "      <td>Janssen Research &amp; Development, LLC Clinical T...</td>\n",
       "      <td>Janssen Research &amp; Development, LLC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Dartmouth-Hitchcock Medical Center</td>\n",
       "      <td>Kenneth Meehan, MD</td>\n",
       "      <td>Dartmouth-Hitchcock Medical Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Fudan University</td>\n",
       "      <td>Dingwei Ye, MD</td>\n",
       "      <td>Fudan University Shanghai Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Forma Therapeutics, Inc.</td>\n",
       "      <td>Patrick Kelly, MD</td>\n",
       "      <td>Novo Nordisk A/S</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>University of Texas Health Science Center San ...</td>\n",
       "      <td>Andrew Brenner, MD</td>\n",
       "      <td>Dana-Farber Cancer Institute, University of Te...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Princess Margaret Hospital, Canada</td>\n",
       "      <td>Lillian L. Siu, MD, FRCPC</td>\n",
       "      <td>Canadian Cancer Trials Group</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Aeglea Biotherapeutics, Inc.</td>\n",
       "      <td>Josie Gayton</td>\n",
       "      <td>Aeglea Biotherapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>Kenzie A Cameron, PhD</td>\n",
       "      <td>Northwestern University</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>University Hospital Cologne</td>\n",
       "      <td>Jürgen Wolf, MD</td>\n",
       "      <td>University Hospital Cologne</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Qingdao Central Hospital, Qingdao Cancer Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Shuttle Pharmaceuticals, Inc.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Nouscom SRL</td>\n",
       "      <td>Sven Gogov, MD</td>\n",
       "      <td>Nouscom SRL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Divisione di Ematologia dell'Università di Tor...</td>\n",
       "      <td>Mario Boccadoro, MD</td>\n",
       "      <td>Fondazione EMN Italy Onlus</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Beijing Tongren Hospital</td>\n",
       "      <td>Jing-wen Wang, M.D.</td>\n",
       "      <td>Beijing Tongren Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Wake Forest University Health Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>University of Kentucky</td>\n",
       "      <td>Zhonglin Hao, MD</td>\n",
       "      <td>University of Kentucky</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>Srikala Sridhar, M.D.</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Oncotartis, Inc.</td>\n",
       "      <td>Eric Rowinsky, MD</td>\n",
       "      <td>Oncotartis, Inc.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>University of British Columbia</td>\n",
       "      <td>Kristin L Campbell, PhD</td>\n",
       "      <td>University of British Columbia Breast Cancer R...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        overall_officials_affiliation  \\\n",
       "0                            Johns Hopkins University   \n",
       "1                         Zealand University Hospital   \n",
       "2                                                 NaN   \n",
       "3                      SINOPHARM, Zhejiang University   \n",
       "4          Vanderbilt University/Ingram Cancer Center   \n",
       "5             Chao Family Comprehensive Cancer Center   \n",
       "6                                 Stanford University   \n",
       "7                                                 NaN   \n",
       "8                 Online Collaborative Oncology Group   \n",
       "9                         M.D. Anderson Cancer Center   \n",
       "10         Martin-Luther-Universität Halle-Wittenberg   \n",
       "11                     UT Southwestern Medical Center   \n",
       "12               Beijing Tsinghua Chang Gung Hospital   \n",
       "13                      NCI - Medical Oncology Branch   \n",
       "14  aktuell: Spitalzentrum Biel-Bienne, Kantonsspi...   \n",
       "15              St. Jude Children's Research Hospital   \n",
       "16                                   Emory University   \n",
       "17                       Dana-Farber Cancer Institute   \n",
       "18  Department of Respiratory Medicine, Juntendo U...   \n",
       "19                  Sunnybrook Health Sciences Centre   \n",
       "21                    Princess Margaret Cancer Centre   \n",
       "22  Cancer Insititute and Hospital,Chinese Academy...   \n",
       "23                        M.D. Anderson Cancer Center   \n",
       "24                        M.D. Anderson Cancer Center   \n",
       "25        Fudan University Affiliated Cancer Hospital   \n",
       "26                                  Dong-A University   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                               Bristol-Myers Squibb   \n",
       "30                                                NaN   \n",
       "31  920th Hospital of Joint Logistics Support Forc...   \n",
       "32                Janssen Research & Development, LLC   \n",
       "33                 Dartmouth-Hitchcock Medical Center   \n",
       "34                                   Fudan University   \n",
       "35                           Forma Therapeutics, Inc.   \n",
       "36  University of Texas Health Science Center San ...   \n",
       "37                 Princess Margaret Hospital, Canada   \n",
       "38                       Aeglea Biotherapeutics, Inc.   \n",
       "39                            Northwestern University   \n",
       "40                        University Hospital Cologne   \n",
       "41                                                NaN   \n",
       "42                                                NaN   \n",
       "43                                        Nouscom SRL   \n",
       "44  Divisione di Ematologia dell'Università di Tor...   \n",
       "45                           Beijing Tongren Hospital   \n",
       "46                                                NaN   \n",
       "47                             University of Kentucky   \n",
       "48                    Princess Margaret Cancer Centre   \n",
       "49                                   Oncotartis, Inc.   \n",
       "50                     University of British Columbia   \n",
       "\n",
       "                               overall_officials_name  \\\n",
       "0                              Tanguy Lim-Seiwert, MD   \n",
       "1                           Ismail Gögenur, Professor   \n",
       "2                                                 NaN   \n",
       "3   Shanghai Institute Of Biological Products Co.,...   \n",
       "4                                    Sanjay Mohan, MD   \n",
       "5                            Farshid Dayyani, MD, PhD   \n",
       "6                                       Nelson N Teng   \n",
       "7                                                 NaN   \n",
       "8                                 Craig Henderson, MD   \n",
       "9                                    Jorge Cortes, MD   \n",
       "10                       Carsten Mueller-Tidow, Prof.   \n",
       "11                              Arthur E. Frankel, MD   \n",
       "12                                 Donghong Chen, Dr.   \n",
       "13                                Shivaani Kummar, MD   \n",
       "14             Carsten T. Viehl, MD, Markus Zuber, MD   \n",
       "15                                Rebecca Epperly, MD   \n",
       "16                            Christopher Flowers, MD   \n",
       "17                          Elahe Salehi, DNP, ANP-BC   \n",
       "18                                    Ryo Ko, MD, PhD   \n",
       "19                                       Simron Singh   \n",
       "21                                Robert C. Grant, MD   \n",
       "22           Jianqiang Cai, meidical, Lei Yu, medical   \n",
       "23                                    Clinton Yam, MD   \n",
       "24                Vassiliki Papadimitrakopoulou, M.D.   \n",
       "25                                         Jian Zhang   \n",
       "26                          Ki-Hoon Song, M.D., Ph.D.   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                               Bristol Myers Squibb   \n",
       "30                                                NaN   \n",
       "31                                Wang Sanbin, Doctor   \n",
       "32  Janssen Research & Development, LLC Clinical T...   \n",
       "33                                 Kenneth Meehan, MD   \n",
       "34                                     Dingwei Ye, MD   \n",
       "35                                  Patrick Kelly, MD   \n",
       "36                                 Andrew Brenner, MD   \n",
       "37                          Lillian L. Siu, MD, FRCPC   \n",
       "38                                       Josie Gayton   \n",
       "39                              Kenzie A Cameron, PhD   \n",
       "40                                    Jürgen Wolf, MD   \n",
       "41                                                NaN   \n",
       "42                                                NaN   \n",
       "43                                     Sven Gogov, MD   \n",
       "44                                Mario Boccadoro, MD   \n",
       "45                                Jing-wen Wang, M.D.   \n",
       "46                                                NaN   \n",
       "47                                   Zhonglin Hao, MD   \n",
       "48                              Srikala Sridhar, M.D.   \n",
       "49                                  Eric Rowinsky, MD   \n",
       "50                            Kristin L Campbell, PhD   \n",
       "\n",
       "                                organization_fullname  \n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...  \n",
       "1                         Zealand University Hospital  \n",
       "2        Suzhou Suncadia Biopharmaceuticals Co., Ltd.  \n",
       "3           Shanghai Institute Of Biological Products  \n",
       "4                     Vanderbilt-Ingram Cancer Center  \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...  \n",
       "6              Stanford University School of Medicine  \n",
       "7                       Qilu Pharmaceutical Co., Ltd.  \n",
       "8                                    AEterna Zentaris  \n",
       "9                              Prism Pharma Co., Ltd.  \n",
       "10         Martin-Luther-Universität Halle-Wittenberg  \n",
       "11    University of Texas Southwestern Medical Center  \n",
       "12               Beijing Tsinghua Chang Gung Hospital  \n",
       "13  National Institutes of Health Clinical Center ...  \n",
       "14            University Hospital, Basel, Switzerland  \n",
       "15              St. Jude Children's Research Hospital  \n",
       "16          Emory University Winship Cancer Institute  \n",
       "17                       Dana-Farber Cancer Institute  \n",
       "18  Juntendo Urayasu Hospital, St. Marianna Univer...  \n",
       "19                  Sunnybrook Health Sciences Centre  \n",
       "21                 University Health Network, Toronto  \n",
       "22                         Cure&Sure Biotech Co., LTD  \n",
       "23                        M.D. Anderson Cancer Center  \n",
       "24  Emory University Winship Cancer Institute, The...  \n",
       "25  Shenzhen Yangli Pharmaceutical Technology Co.,...  \n",
       "26                                  Dong-A University  \n",
       "27  Sunshine Guojian Pharmaceutical (Shanghai) Co....  \n",
       "28  The First Affiliated Hospital of Sun Yat-sen U...  \n",
       "29                               Bristol-Myers Squibb  \n",
       "30        Adnexus, A Bristol-Myers Squibb R&D Company  \n",
       "31  920th Hospital of Joint Logistics Support Forc...  \n",
       "32                Janssen Research & Development, LLC  \n",
       "33                 Dartmouth-Hitchcock Medical Center  \n",
       "34            Fudan University Shanghai Cancer Center  \n",
       "35                                   Novo Nordisk A/S  \n",
       "36  Dana-Farber Cancer Institute, University of Te...  \n",
       "37                       Canadian Cancer Trials Group  \n",
       "38                             Aeglea Biotherapeutics  \n",
       "39                            Northwestern University  \n",
       "40                        University Hospital Cologne  \n",
       "41  Qingdao Central Hospital, Qingdao Cancer Hospital  \n",
       "42                      Shuttle Pharmaceuticals, Inc.  \n",
       "43                                        Nouscom SRL  \n",
       "44                         Fondazione EMN Italy Onlus  \n",
       "45                           Beijing Tongren Hospital  \n",
       "46             Wake Forest University Health Sciences  \n",
       "47                             University of Kentucky  \n",
       "48                 University Health Network, Toronto  \n",
       "49                                   Oncotartis, Inc.  \n",
       "50  University of British Columbia Breast Cancer R...  "
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['overall_officials_affiliation', 'overall_officials_name','organization_fullname']].head(50)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "b1a266e9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_officials_name\n",
       "Clinical Trials              722\n",
       "Pfizer CT.gov Call Center    627\n",
       "Novartis Pharmaceuticals     609\n",
       "Bristol-Myers Squibb         470\n",
       "Medical Director             436\n",
       "                            ... \n",
       "Jeremy S Connors, MD           1\n",
       "James K Mangan, MD, PhD        1\n",
       "Sarah Taylor, MD               1\n",
       "Yanhua Ding                    1\n",
       "Afshin Dowlati                 1\n",
       "Name: count, Length: 27974, dtype: int64"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_officials_name'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "2b359701",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Matching rows (fuzzy): 28325 out of 51819 (54.66%)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "def is_similar(a, b, threshold=85):\n",
    "    a_clean = clean_text(a)\n",
    "    b_clean = clean_text(b)\n",
    "    return fuzz.token_set_ratio(a_clean, b_clean) >= threshold\n",
    "\n",
    "# Apply the fuzzy match row-wise\n",
    "df['affiliation_matches_org'] = df.apply(\n",
    "    lambda row: is_similar(row['overall_officials_affiliation'], row['organization_fullname']), axis=1\n",
    ")\n",
    "\n",
    "# Get percentage\n",
    "total = df.shape[0]\n",
    "matches = df['affiliation_matches_org'].sum()\n",
    "percentage = (matches / total) * 100\n",
    "\n",
    "print(f\"Matching rows (fuzzy): {matches} out of {total} ({percentage:.2f}%)\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "30b83574",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[df['overall_status'].isin(['COMPLETED', 'TERMINATED', 'RECRUITING'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "a74edf72",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Status distribution for MATCHED rows:\n",
      "overall_status\n",
      "COMPLETED     43.91\n",
      "TERMINATED    39.05\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "Status distribution for UNMATCHED rows:\n",
      "overall_status\n",
      "COMPLETED     41.91\n",
      "TERMINATED    36.84\n",
      "Name: proportion, dtype: float64\n"
     ]
    }
   ],
   "source": [
    "# Filter matched and unmatched rows\n",
    "matched = df[df['affiliation_matches_org'] == True]\n",
    "unmatched = df[df['affiliation_matches_org'] == False]\n",
    "\n",
    "# Get counts for COMPLETED and TERMINATED in matched\n",
    "matched_status_counts = matched['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "# Get counts for COMPLETED and TERMINATED in unmatched\n",
    "unmatched_status_counts = unmatched['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "print(\"Status distribution for MATCHED rows:\")\n",
    "print(matched_status_counts[['COMPLETED', 'TERMINATED']].fillna(0).round(2))\n",
    "\n",
    "print(\"\\nStatus distribution for UNMATCHED rows:\")\n",
    "print(unmatched_status_counts[['COMPLETED', 'TERMINATED']].fillna(0).round(2))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "38400b59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'is_same',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "1004c190",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.rename(columns={'is_same':'organization_match'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d9b69e10",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "89aeb3f7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['eligibility_criteria'] = df['eligibility_criteria'].str.replace(r'^.*?\\n\\n', '', regex=True)\n",
    "df['eligibility_criteria'] = df['eligibility_criteria'].str.replace('/', '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "be68e6f0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Cohort 1: Subjects must have histologically co...\n",
       "1     * Patients must be mentally capable of underst...\n",
       "2     1. Age 18 to 75 years old (inclusive), Female ...\n",
       "3     * 18-75 years old, male or female;\\n* Patients...\n",
       "4     * Age \\>= 18 years at the time of signing the ...\n",
       "6     3.1.1 Age Patients must be \\>= 18 years old at...\n",
       "8     1. In the opinion of the treating physician, t...\n",
       "9     1. Patients 18 years or older\\n2. Part I: Pati...\n",
       "11    * Diagnosis of 1 of the following:\\n\\n  * Hist...\n",
       "12    * Written informed consent provided.\\n* Unrese...\n",
       "13    * Histologically confirmed malignancy that is ...\n",
       "14    * Colon cancer at any stage diagnosed histolog...\n",
       "16    * Tissue diagnosis of a previously untreated, ...\n",
       "17    * Men and women with a diagnosis of metastatic...\n",
       "19    * Adults (males or females), aged 18 years or ...\n",
       "23    1. Female or male patients 18 years of age or ...\n",
       "24    1. Male or female patients with one of the fol...\n",
       "25    1. voluntary participation in clinical trials ...\n",
       "26    * patient's request for alternative treatment ...\n",
       "29    Inclusion Criteria:\\n\\n1. All subjects must ha...\n",
       "30    * Histologically proven advanced solid maligna...\n",
       "31    1. Male or female, aged 2-75 years;\\n2. A defi...\n",
       "32    * Participant must have documented multiple my...\n",
       "33    1. Age less than or equal to 75 years\\n2. The ...\n",
       "35    * Single agent (SA) Dose Escalation: Histologi...\n",
       "36    * At least 18 years of age\\n* Ability to under...\n",
       "37    * Histologically or cytologically confirmed ma...\n",
       "38    1. Patient is able and willing to provide writ...\n",
       "39    * Patients aged 50-75 years of age (in month 1...\n",
       "41    Participant must have histologically or cytolo...\n",
       "42    * Written informed consent form signed and dat...\n",
       "44    * Age \\> 65 year old and not a candidate for s...\n",
       "46    * Newly diagnosed or recurrent patients with l...\n",
       "48    * Histologically confirmed squamous cell carci...\n",
       "50    * newly diagnosed with stage I-IIIA breast can...\n",
       "51    * This trial will include subjects with stage ...\n",
       "52    * Patients have an established, pathologically...\n",
       "53    1. Histologically or cytologically confirmed a...\n",
       "54    Signed informed consent\\n\\n* Age ≥ 18 years\\n*...\n",
       "55    * Histologically confirmed metastatic ER+ ando...\n",
       "57    1. Histologically confirmed unresectable stage...\n",
       "58    1) Women with newly diagnosed or recurrent CIN...\n",
       "59    * Age 18 years or older\\n* HIV-1 infection\\n* ...\n",
       "60    Phase I\\n\\nPatients must meet the following cr...\n",
       "61    * Signs of a bleeding in the stomach\\n* One en...\n",
       "62    * Histologically confirmed CD30+ classical Hod...\n",
       "65    1. A healthy adult whose age is over 19 years ...\n",
       "67    * Hodgkin Lymphoma, intermediate or advanced s...\n",
       "69    1. Histologically confirmed Primary Central Ne...\n",
       "70    * Histologically confirmed endometrial adenoca...\n",
       "Name: eligibility_criteria, dtype: object"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['eligibility_criteria'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "4feb08ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['enrollment'] = df['enrollment'].astype(str).str.replace('?', '0').astype(int)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "abeb4988",
   "metadata": {},
   "source": [
    "Checking for correlation between people enrolled and the status of the trial"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "4768dbb7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_9954/1339257951.py:8: FutureWarning: A value is trying to be set on a copy of a DataFrame or Series through chained assignment using an inplace method.\n",
      "The behavior will change in pandas 3.0. This inplace method will never work because the intermediate object on which we are setting values always behaves as a copy.\n",
      "\n",
      "For example, when doing 'df[col].method(value, inplace=True)', try using 'df.method({col: value}, inplace=True)' or df[col] = df[col].method(value) instead, to perform the operation inplace on the original object.\n",
      "\n",
      "\n",
      "  df['enrollment'].fillna(0, inplace=True)\n",
      "/tmp/ipykernel_9954/1339257951.py:23: FutureWarning: DataFrameGroupBy.apply operated on the grouping columns. This behavior is deprecated, and in a future version of pandas the grouping columns will be excluded from the operation. Either pass `include_groups=False` to exclude the groupings or explicitly select the grouping columns after groupby to silence this warning.\n",
      "  filtered_df = filtered_df.groupby('overall_status', group_keys=False).apply(remove_outliers_iqr)\n",
      "/tmp/ipykernel_9954/1339257951.py:27: FutureWarning: \n",
      "\n",
      "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `x` variable to `hue` and set `legend=False` for the same effect.\n",
      "\n",
      "  sns.boxplot(data=filtered_df, x='overall_status', y='enrollment', palette='Set2')\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Summary statistics:\n",
      "                  count       mean        std  min   25%   50%   75%    max\n",
      "overall_status                                                             \n",
      "COMPLETED       15796.0  56.081350  48.430779  0.0  21.0  40.0  74.0  229.0\n",
      "TERMINATED      13821.0  25.894725  28.528671  0.0   6.0  15.0  35.0  132.0\n",
      "\n",
      "T-test Results: t-statistic = 66.288, p-value = 0.00000\n",
      "\n",
      "✅ There is a **statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "from scipy.stats import ttest_ind\n",
    "\n",
    "# Convert to numeric and handle missing\n",
    "df['enrollment'] = pd.to_numeric(df['enrollment'], errors='coerce')\n",
    "df['enrollment'].fillna(0, inplace=True)\n",
    "\n",
    "# Filter for only relevant statuses\n",
    "filtered_df = df[df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "\n",
    "# Remove outliers using IQR method for each group\n",
    "def remove_outliers_iqr(group):\n",
    "    Q1 = group['enrollment'].quantile(0.25)\n",
    "    Q3 = group['enrollment'].quantile(0.75)\n",
    "    IQR = Q3 - Q1\n",
    "    lower_bound = Q1 - 1.5 * IQR\n",
    "    upper_bound = Q3 + 1.5 * IQR\n",
    "    return group[(group['enrollment'] >= lower_bound) & (group['enrollment'] <= upper_bound)]\n",
    "\n",
    "# Apply outlier removal\n",
    "filtered_df = filtered_df.groupby('overall_status', group_keys=False).apply(remove_outliers_iqr)\n",
    "\n",
    "# Boxplot after removing outliers\n",
    "plt.figure(figsize=(8, 5))\n",
    "sns.boxplot(data=filtered_df, x='overall_status', y='enrollment', palette='Set2')\n",
    "plt.title('Enrollment Distribution by Trial Status (Outliers Removed)')\n",
    "plt.ylabel('Number of People Enrolled')\n",
    "plt.xlabel('Trial Status')\n",
    "plt.tight_layout()\n",
    "plt.show()\n",
    "\n",
    "# Summary statistics\n",
    "summary = filtered_df.groupby('overall_status')['enrollment'].describe()\n",
    "print(\"\\nSummary statistics:\")\n",
    "print(summary)\n",
    "\n",
    "# T-test: Compare mean enrollments\n",
    "completed = filtered_df[filtered_df['overall_status'] == 'COMPLETED']['enrollment']\n",
    "terminated = filtered_df[filtered_df['overall_status'] == 'TERMINATED']['enrollment']\n",
    "\n",
    "t_stat, p_value = ttest_ind(completed, terminated, equal_var=False)\n",
    "print(f\"\\nT-test Results: t-statistic = {t_stat:.3f}, p-value = {p_value:.5f}\")\n",
    "\n",
    "# Verdict\n",
    "if p_value < 0.05:\n",
    "    print(\"\\n✅ There is a **statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\")\n",
    "else:\n",
    "    print(\"\\n❌ There is **no statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f53ad4b1",
   "metadata": {},
   "source": [
    "Quite a positive relation between the number of people enrolled for the trial and its overall status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "9e7298ec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'organization_match',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "842f5dcd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_officials_affiliation    6117\n",
       "overall_officials_name           6061\n",
       "secondary_outcomes               5881\n",
       "interventions_description        3735\n",
       "completion_date                     0\n",
       "brief_summary                       0\n",
       "eligibility_criteria                0\n",
       "conditions                          0\n",
       "design_primary_purpose              0\n",
       "country                             0\n",
       "last_update_post_date               0\n",
       "lead_sponsor                        0\n",
       "location_city                       0\n",
       "location_country                    0\n",
       "location_facility                   0\n",
       "enrollment                          0\n",
       "interventions_name                  0\n",
       "organization_match                  0\n",
       "minimum_age                         0\n",
       "maximum_age                         0\n",
       "location_state                      0\n",
       "organization_fullname               0\n",
       "oversight_has_dmc                   0\n",
       "phase                               0\n",
       "primary_completion_date             0\n",
       "overall_status                      0\n",
       "primary_outcomes                    0\n",
       "sex                                 0\n",
       "start_date                          0\n",
       "stdage                              0\n",
       "study_first_post_date               0\n",
       "study_first_submit_date             0\n",
       "study_type                          0\n",
       "affiliation_matches_org             0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "78649d1e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'organization_match',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "91d2e17f",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['overall_officials_affiliation', 'overall_officials_name'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "075ad9b6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     One dose of Nivolumab 480mg given four weeks p...\n",
       "1     Intratumoral application of an unattenuated in...\n",
       "2     SHR-A2009 monotherapy ，SHR-A2009 will be admin...\n",
       "3            Injection，100mg/10ml; Injection，100mg/10ml\n",
       "4     Given by mouth; Given by mouth; Given by mouth...\n",
       "6     Dosage: 1.25mg/kg intravenous with dose escala...\n",
       "8     Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...\n",
       "9     PRI-724; PRI-724 in combination with dasatinib...\n",
       "11    Intravenously via a 3 cc plastic syringe as a ...\n",
       "12    Tislelizumab: 200mg, IV, day 1 of each 21-day ...\n",
       "13                                                  NaN\n",
       "14    After careful mobilization of the affected col...\n",
       "16    Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...\n",
       "17    Cap attached to coolant lines connected to a r...\n",
       "19    Avelumab will be administered intravenously as...\n",
       "23               Given by IV (vein); Given by IV (vein)\n",
       "24         150 mg by mouth daily; Tablet by mouth daily\n",
       "25                            TFX06 tablet taken orally\n",
       "26    AFL was performed using a 2940-nm Er:YAG ablat...\n",
       "29                                                  NaN\n",
       "30                     IV solution, weekly or bi-weekly\n",
       "31    UCAR-T Cellswill be administered by vein. The ...\n",
       "32    Participants will receive velcade 1.3 mg/m\\^2,...\n",
       "33    Fludarabine: 30 mg/m2 daily for 5 days; Busulf...\n",
       "35    FT-1101 will be supplied as 5 mg, 20 mg or 100...\n",
       "36                                    10mg/kg; 670mg/m2\n",
       "37                                                  NaN\n",
       "38                     Administered IV; Administered IV\n",
       "39    Physicians at these clinics will participate i...\n",
       "41    Osimertinib, 80mg, oral daily; bevacizumab (av...\n",
       "42    Ropidoxuridine is administered daily, 5 days a...\n",
       "44    Induction therapy:\\n\\n9 courses with weekly VE...\n",
       "46    15 mCi 11C-choline will be administered intrav...\n",
       "48    Avelumab is a fully human monoclonal antibody ...\n",
       "50    An acute bout of exercise performed 24 hours p...\n",
       "51                        Correlative studies; Given IV\n",
       "52    Venetoclax administered orally once daily on d...\n",
       "53    25 mg/m\\^2 administered by intravenous (IV) ro...\n",
       "54    Azacitidine; Donor lymphocytes in patients wit...\n",
       "55    Palbociclib at a dose of 125 mg should be take...\n",
       "57    Part I Safety Run in:\\n\\nCohort 1.1: RO6874281...\n",
       "58    Arm I-II: Patients receive one of two differen...\n",
       "59    Lopinavir/ritonavir 200/50mg plus Emtricitabin...\n",
       "60    A166 is an Antibody Drug Conjugate (ADC) targe...\n",
       "61                                                  NaN\n",
       "62        25mg/m2; 10mg/m2; 6mg/m2; 375mg/m2; 1.2 mg/kg\n",
       "65    Memantine Tab. 10mg\\* 2T/day, QD, PO; Memantin...\n",
       "67    50mg/m2 day 1 + 15; 375mg/m2 day 1 + 15; day 1...\n",
       "69    375mg/m2 intravenous infusion d1, every 3 week...\n",
       "70                                             Given IV\n",
       "Name: interventions_description, dtype: object"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_description'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "3b578f12",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41761, 32)"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3d6456b7",
   "metadata": {},
   "source": [
    "Adding a new feature of the days in which the trial is completed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "38d977cd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>start_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>2019-07-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>2021-02-26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2027-06-15</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2024-11-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>2019-07-25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2029-03-15</td>\n",
       "      <td>2028-03-15</td>\n",
       "      <td>2024-01-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>2006-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2011-10-15</td>\n",
       "      <td>2010-12-15</td>\n",
       "      <td>2005-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>2012-07-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>2013-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>2023-03-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2008-10-15</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>2001-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>2000-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>2008-02-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>2021-10-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>2017-11-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>2023-05-23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2006-11-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>2023-04-17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>2013-02-15</td>\n",
       "      <td>2011-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>2016-02-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>2008-11-15</td>\n",
       "      <td>2006-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2022-12-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>2014-12-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>2016-09-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>2015-09-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>2015-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>2003-10-27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>2017-12-21</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>2013-07-15</td>\n",
       "      <td>2010-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>2021-07-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>2027-02-15</td>\n",
       "      <td>2026-08-15</td>\n",
       "      <td>2024-09-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>2006-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>2010-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2018-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>2016-05-25</td>\n",
       "      <td>2016-05-25</td>\n",
       "      <td>2016-01-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>2019-04-01</td>\n",
       "      <td>2018-01-04</td>\n",
       "      <td>2014-10-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>2026-07-15</td>\n",
       "      <td>2026-07-15</td>\n",
       "      <td>2024-06-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>2009-09-15</td>\n",
       "      <td>2009-09-15</td>\n",
       "      <td>2007-01-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2022-11-22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>2023-03-31</td>\n",
       "      <td>2020-03-13</td>\n",
       "      <td>2017-06-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>2022-07-14</td>\n",
       "      <td>2022-07-14</td>\n",
       "      <td>2019-06-24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>2004-04-27</td>\n",
       "      <td>2004-04-27</td>\n",
       "      <td>1998-06-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>2012-07-15</td>\n",
       "      <td>2012-02-15</td>\n",
       "      <td>2007-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>2022-01-12</td>\n",
       "      <td>2022-01-12</td>\n",
       "      <td>2018-07-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>2005-10-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>2022-06-02</td>\n",
       "      <td>2016-12-15</td>\n",
       "      <td>2015-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2018-05-21</td>\n",
       "      <td>2018-04-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>2016-02-15</td>\n",
       "      <td>2014-04-15</td>\n",
       "      <td>2010-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>2022-11-15</td>\n",
       "      <td>2022-10-15</td>\n",
       "      <td>2020-01-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2005-05-15</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   completion_date primary_completion_date start_date\n",
       "0       2023-10-17              2023-10-17 2019-07-08\n",
       "1       2021-11-01              2021-09-22 2021-02-26\n",
       "2       2027-06-15              2026-12-15 2024-11-29\n",
       "3       2022-05-20              2022-05-20 2019-07-25\n",
       "4       2029-03-15              2028-03-15 2024-01-29\n",
       "6       2009-07-15              2009-02-15 2006-05-15\n",
       "8       2011-10-15              2010-12-15 2005-08-15\n",
       "9       2016-12-30              2016-12-30 2012-07-15\n",
       "11      2017-07-27              2017-07-27 2013-05-15\n",
       "12      2024-04-30              2024-02-29 2023-03-12\n",
       "13      2008-10-15              2008-04-15 2001-03-15\n",
       "14      2009-01-15              2009-01-15 2000-05-15\n",
       "16      2015-11-15              2015-11-15 2008-02-15\n",
       "17      2028-06-01              2026-06-01 2021-10-07\n",
       "19      2023-07-06              2021-07-26 2017-11-15\n",
       "23      2026-12-31              2026-12-31 2023-05-23\n",
       "24      2018-06-04              2018-06-04 2006-11-03\n",
       "25      2025-04-30              2024-12-30 2023-04-17\n",
       "26      2013-09-15              2013-02-15 2011-03-15\n",
       "29      2020-06-12              2019-07-29 2016-02-09\n",
       "30      2009-02-15              2008-11-15 2006-08-15\n",
       "31      2025-12-31              2024-12-31 2022-12-05\n",
       "32      2024-08-07              2017-11-21 2014-12-09\n",
       "33      2022-02-11              2019-06-07 2016-09-06\n",
       "35      2019-03-15              2019-03-15 2015-09-15\n",
       "36      2019-12-04              2019-01-04 2015-05-15\n",
       "37      2009-02-10              2008-09-29 2003-10-27\n",
       "38      2021-01-01              2021-01-01 2017-12-21\n",
       "39      2013-09-15              2013-07-15 2010-04-15\n",
       "41      2024-12-31              2024-07-31 2021-07-01\n",
       "42      2027-02-15              2026-08-15 2024-09-02\n",
       "44      2014-07-15              2014-07-15 2006-05-15\n",
       "46      2013-08-15              2013-08-15 2010-03-15\n",
       "48      2024-12-31              2024-12-31 2018-08-15\n",
       "50      2016-05-25              2016-05-25 2016-01-15\n",
       "51      2019-04-01              2018-01-04 2014-10-15\n",
       "52      2026-07-15              2026-07-15 2024-06-03\n",
       "53      2009-09-15              2009-09-15 2007-01-15\n",
       "54      2026-12-15              2026-12-15 2022-11-22\n",
       "55      2023-03-31              2020-03-13 2017-06-15\n",
       "57      2022-07-14              2022-07-14 2019-06-24\n",
       "58      2004-04-27              2004-04-27 1998-06-19\n",
       "59      2012-07-15              2012-02-15 2007-04-15\n",
       "60      2022-01-12              2022-01-12 2018-07-16\n",
       "61      2007-12-15              2007-12-15 2005-10-15\n",
       "62      2022-06-02              2016-12-15 2015-03-15\n",
       "65      2018-06-04              2018-05-21 2018-04-16\n",
       "67      2016-02-15              2014-04-15 2010-04-15\n",
       "69      2022-11-15              2022-10-15 2020-01-01\n",
       "70      2009-07-15              2009-07-15 2005-05-15"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "date_cols = [\n",
    "    'completion_date',\n",
    "    'primary_completion_date',\n",
    "    'start_date',\n",
    "]\n",
    "\n",
    "df[date_cols].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "a5530c1c",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['study_first_submit_date', 'study_first_post_date','last_update_post_date'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "01912ba1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Ensure the date columns are in datetime format\n",
    "df['start_date'] = pd.to_datetime(df['start_date'], errors='coerce')\n",
    "df['completion_date'] = pd.to_datetime(df['completion_date'], errors='coerce')\n",
    "df['primary_completion_date'] = pd.to_datetime(df['primary_completion_date'], errors='coerce')\n",
    "\n",
    "# Create new columns with duration in days\n",
    "df['total_study_duration_days'] = (df['completion_date'] - df['start_date']).dt.days\n",
    "df['primary_outcome_duration_days'] = (df['primary_completion_date'] - df['start_date']).dt.days\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "d365d1e5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "start_date                       datetime64[ns]\n",
       "completion_date                  datetime64[ns]\n",
       "primary_completion_date          datetime64[ns]\n",
       "total_study_duration_days                 int64\n",
       "primary_outcome_duration_days             int64\n",
       "dtype: object"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['start_date', 'completion_date', 'primary_completion_date',\n",
    "    'total_study_duration_days', 'primary_outcome_duration_days']].dtypes\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "b09428db",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['start_date', 'completion_date','primary_completion_date'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "b7aa9cf6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'conditions', 'country', 'design_primary_purpose',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'organization_match', 'lead_sponsor',\n",
       "       'location_city', 'location_country', 'location_facility',\n",
       "       'location_state', 'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'stdage', 'study_type',\n",
       "       'affiliation_matches_org', 'total_study_duration_days',\n",
       "       'primary_outcome_duration_days'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "42a56e87",
   "metadata": {},
   "source": [
    "Checking for trend in lead sponsors and its relation with 'COMPLETED'/'TERMINATED'/'RECRUITING'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "7fa457ef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AHS Cancer Control Alberta: 55.77% COMPLETED\n",
      "AIDS Malignancy Consortium: 75.00% COMPLETED\n",
      "AIO-Studien-gGmbH: 63.41% COMPLETED\n",
      "ARCAGY/ GINECO GROUP: 62.50% COMPLETED\n",
      "AVEO Pharmaceuticals, Inc.: 68.18% COMPLETED\n",
      "AbbVie: 36.92% COMPLETED\n",
      "AbbVie (prior sponsor, Abbott): 80.95% COMPLETED\n",
      "Abbott: 18.75% COMPLETED\n",
      "Abramson Cancer Center at Penn Medicine: 57.89% COMPLETED\n",
      "Academic and Community Cancer Research United: 52.38% COMPLETED\n",
      "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): 50.00% COMPLETED\n",
      "Acrotech Biopharma Inc.: 88.89% COMPLETED\n",
      "Actelion: 3.57% COMPLETED\n",
      "Akeso: 39.39% COMPLETED\n",
      "Albert Einstein College of Medicine: 48.15% COMPLETED\n",
      "Alcon Research: 0.00% COMPLETED\n",
      "Alexion Pharmaceuticals, Inc.: 3.57% COMPLETED\n",
      "Allergan: 0.00% COMPLETED\n",
      "Alliance for Clinical Trials in Oncology: 85.15% COMPLETED\n",
      "Amgen: 46.52% COMPLETED\n",
      "Amsterdam UMC, location VUmc: 33.33% COMPLETED\n",
      "Arbeitsgemeinschaft medikamentoese Tumortherapie: 72.00% COMPLETED\n",
      "Asan Medical Center: 72.00% COMPLETED\n",
      "Ascentage Pharma Group Inc.: 12.50% COMPLETED\n",
      "Assistance Publique - Hôpitaux de Paris: 28.36% COMPLETED\n",
      "Assistance Publique Hopitaux De Marseille: 33.33% COMPLETED\n",
      "Astellas Pharma Global Development, Inc.: 45.65% COMPLETED\n",
      "Astellas Pharma Inc: 61.82% COMPLETED\n",
      "Astex Pharmaceuticals, Inc.: 70.00% COMPLETED\n",
      "AstraZeneca: 50.00% COMPLETED\n",
      "Barbara Ann Karmanos Cancer Institute: 68.12% COMPLETED\n",
      "Bausch Health Americas, Inc.: 40.00% COMPLETED\n",
      "Baxalta now part of Shire: 6.25% COMPLETED\n",
      "Bayer: 53.23% COMPLETED\n",
      "Baylor College of Medicine: 35.48% COMPLETED\n",
      "BeiGene: 59.68% COMPLETED\n",
      "Beth Israel Deaconess Medical Center: 48.21% COMPLETED\n",
      "Betta Pharmaceuticals Co., Ltd.: 62.50% COMPLETED\n",
      "Biocad: 43.75% COMPLETED\n",
      "Biogen: 22.67% COMPLETED\n",
      "Boehringer Ingelheim: 46.41% COMPLETED\n",
      "Boston Medical Center: 27.27% COMPLETED\n",
      "Boston Scientific Corporation: 21.74% COMPLETED\n",
      "Brigham and Women's Hospital: 5.41% COMPLETED\n",
      "Bristol-Myers Squibb: 65.95% COMPLETED\n",
      "British Columbia Cancer Agency: 64.00% COMPLETED\n",
      "Brown University: 33.33% COMPLETED\n",
      "Burzynski Research Institute: 41.38% COMPLETED\n",
      "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: 9.09% COMPLETED\n",
      "Calithera Biosciences, Inc: 50.00% COMPLETED\n",
      "Cambridge University Hospitals NHS Foundation Trust: 47.06% COMPLETED\n",
      "Canadian Cancer Trials Group: 55.00% COMPLETED\n",
      "Cancer Institute and Hospital, Chinese Academy of Medical Sciences: 7.27% COMPLETED\n",
      "Cancer Research UK: 48.65% COMPLETED\n",
      "Cancer Trials Ireland: 60.87% COMPLETED\n",
      "Case Comprehensive Cancer Center: 71.01% COMPLETED\n",
      "Cedars-Sinai Medical Center: 31.58% COMPLETED\n",
      "Celgene: 67.79% COMPLETED\n",
      "Celgene Corporation: 73.68% COMPLETED\n",
      "Celldex Therapeutics: 59.09% COMPLETED\n",
      "Centre Francois Baclesse: 36.84% COMPLETED\n",
      "Centre Hospitalier Universitaire de Besancon: 35.29% COMPLETED\n",
      "Centre Hospitalier Universitaire de Saint Etienne: 22.73% COMPLETED\n",
      "Centre Leon Berard: 56.00% COMPLETED\n",
      "Centre Oscar Lambret: 62.86% COMPLETED\n",
      "Centre hospitalier de l'Université de Montréal (CHUM): 30.00% COMPLETED\n",
      "Cephalon: 47.06% COMPLETED\n",
      "Charite University, Berlin, Germany: 29.63% COMPLETED\n",
      "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: 38.46% COMPLETED\n",
      "Children's Hospital Medical Center, Cincinnati: 21.88% COMPLETED\n",
      "Children's Hospital of Philadelphia: 17.39% COMPLETED\n",
      "Children's Oncology Group: 87.34% COMPLETED\n",
      "Chinese Academy of Medical Sciences: 67.86% COMPLETED\n",
      "Chinese PLA General Hospital: 20.51% COMPLETED\n",
      "Chinese University of Hong Kong: 60.61% COMPLETED\n",
      "Chongqing Precision Biotech Co., Ltd: 3.70% COMPLETED\n",
      "City of Hope Medical Center: 48.68% COMPLETED\n",
      "Cliniques universitaires Saint-Luc- Université Catholique de Louvain: 35.00% COMPLETED\n",
      "Columbia University: 33.68% COMPLETED\n",
      "Daiichi Sankyo: 43.06% COMPLETED\n",
      "Daiichi Sankyo Co., Ltd.: 84.21% COMPLETED\n",
      "Dana-Farber Cancer Institute: 67.50% COMPLETED\n",
      "Dartmouth-Hitchcock Medical Center: 53.66% COMPLETED\n",
      "DePuy International: 0.00% COMPLETED\n",
      "Debiopharm International SA: 35.29% COMPLETED\n",
      "Duke University: 47.31% COMPLETED\n",
      "ECOG-ACRIN Cancer Research Group: 27.78% COMPLETED\n",
      "EMD Serono: 38.24% COMPLETED\n",
      "EMD Serono Research & Development Institute, Inc.: 32.43% COMPLETED\n",
      "ETOP IBCSG Partners Foundation: 65.71% COMPLETED\n",
      "Eastern Cooperative Oncology Group: 76.92% COMPLETED\n",
      "Eisai Inc.: 68.04% COMPLETED\n",
      "Eli Lilly and Company: 66.58% COMPLETED\n",
      "Emory University: 34.13% COMPLETED\n",
      "Erasmus Medical Center: 18.52% COMPLETED\n",
      "European Institute of Oncology: 29.41% COMPLETED\n",
      "European Organisation for Research and Treatment of Cancer - EORTC: 60.34% COMPLETED\n",
      "Exelixis: 40.00% COMPLETED\n",
      "Federation Francophone de Cancerologie Digestive: 72.41% COMPLETED\n",
      "Ferring Pharmaceuticals: 63.27% COMPLETED\n",
      "First Affiliated Hospital of Zhejiang University: 4.55% COMPLETED\n",
      "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: 73.53% COMPLETED\n",
      "Fondazione Italiana Linfomi - ETS: 62.16% COMPLETED\n",
      "Fox Chase Cancer Center: 38.60% COMPLETED\n",
      "Fred Hutchinson Cancer Center: 57.72% COMPLETED\n",
      "French Innovative Leukemia Organisation: 65.22% COMPLETED\n",
      "Fuda Cancer Hospital, Guangzhou: 100.00% COMPLETED\n",
      "Fudan University: 23.87% COMPLETED\n",
      "Galapagos NV: 0.00% COMPLETED\n",
      "Genentech, Inc.: 72.58% COMPLETED\n",
      "Genmab: 23.33% COMPLETED\n",
      "Genzyme, a Sanofi Company: 61.73% COMPLETED\n",
      "Georgetown University: 34.78% COMPLETED\n",
      "German Breast Group: 80.00% COMPLETED\n",
      "German CLL Study Group: 81.82% COMPLETED\n",
      "Gilead Sciences: 23.57% COMPLETED\n",
      "GlaxoSmithKline: 37.61% COMPLETED\n",
      "Goethe University: 81.82% COMPLETED\n",
      "Groupe Francophone des Myelodysplasies: 66.67% COMPLETED\n",
      "Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea: 87.50% COMPLETED\n",
      "Gruppo Italiano Malattie EMatologiche dell'Adulto: 72.97% COMPLETED\n",
      "Gruppo Oncologico del Nord-Ovest: 33.33% COMPLETED\n",
      "Guangdong Provincial People's Hospital: 42.86% COMPLETED\n",
      "Gustave Roussy, Cancer Campus, Grand Paris: 51.52% COMPLETED\n",
      "Gynecologic Oncology Group: 90.00% COMPLETED\n",
      "H. Lee Moffitt Cancer Center and Research Institute: 54.67% COMPLETED\n",
      "H. Lundbeck A/S: 0.00% COMPLETED\n",
      "Hackensack Meridian Health: 33.33% COMPLETED\n",
      "Hannover Medical School: 29.41% COMPLETED\n",
      "Heidelberg University: 70.00% COMPLETED\n",
      "Hellenic Oncology Research Group: 59.09% COMPLETED\n",
      "Henan Cancer Hospital: 15.22% COMPLETED\n",
      "Herlev Hospital: 64.71% COMPLETED\n",
      "Hoffmann-La Roche: 68.56% COMPLETED\n",
      "Hoosier Cancer Research Network: 45.00% COMPLETED\n",
      "Hospices Civils de Lyon: 51.72% COMPLETED\n",
      "Hunan Province Tumor Hospital: 20.00% COMPLETED\n",
      "Hutchison Medipharma Limited: 54.55% COMPLETED\n",
      "Hutchmed: 56.25% COMPLETED\n",
      "IRCCS San Raffaele: 50.00% COMPLETED\n",
      "Icahn School of Medicine at Mount Sinai: 14.00% COMPLETED\n",
      "ImmunityBio, Inc.: 27.59% COMPLETED\n",
      "Imperial College London: 28.57% COMPLETED\n",
      "Incyte Corporation: 42.11% COMPLETED\n",
      "Indiana University: 26.67% COMPLETED\n",
      "Indiana University School of Medicine: 55.00% COMPLETED\n",
      "Inge Marie Svane: 70.59% COMPLETED\n",
      "Innovent Biologics (Suzhou) Co. Ltd.: 48.94% COMPLETED\n",
      "Insel Gruppe AG, University Hospital Bern: 26.67% COMPLETED\n",
      "Institut Bergonié: 52.00% COMPLETED\n",
      "Institut Claudius Regaud: 48.39% COMPLETED\n",
      "Institut Curie: 55.88% COMPLETED\n",
      "Institut de Recherches Internationales Servier: 50.00% COMPLETED\n",
      "Institut du Cancer de Montpellier - Val d'Aurelle: 67.86% COMPLETED\n",
      "Institute of Cancer Research, United Kingdom: 27.27% COMPLETED\n",
      "Institute of Hematology & Blood Diseases Hospital, China: 13.95% COMPLETED\n",
      "Intergroupe Francophone de Cancerologie Thoracique: 75.00% COMPLETED\n",
      "Ipsen: 37.74% COMPLETED\n",
      "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori: 45.16% COMPLETED\n",
      "Janssen Pharmaceutical K.K.: 57.14% COMPLETED\n",
      "Janssen Research & Development, LLC: 40.51% COMPLETED\n",
      "Jazz Pharmaceuticals: 44.00% COMPLETED\n",
      "Jiangsu HengRui Medicine Co., Ltd.: 55.06% COMPLETED\n",
      "Johns Hopkins University: 13.51% COMPLETED\n",
      "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: 39.39% COMPLETED\n",
      "Jonsson Comprehensive Cancer Center: 57.41% COMPLETED\n",
      "Jules Bordet Institute: 64.52% COMPLETED\n",
      "Karolinska University Hospital: 37.50% COMPLETED\n",
      "Karyopharm Therapeutics Inc: 27.27% COMPLETED\n",
      "Kite, A Gilead Company: 33.33% COMPLETED\n",
      "Kyowa Kirin Co., Ltd.: 51.52% COMPLETED\n",
      "Leiden University Medical Center: 26.32% COMPLETED\n",
      "London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's: 21.43% COMPLETED\n",
      "Loyola University: 21.05% COMPLETED\n",
      "Ludwig Institute for Cancer Research: 75.00% COMPLETED\n",
      "Lund University Hospital: 66.67% COMPLETED\n",
      "Lymphoma Study Association: 82.35% COMPLETED\n",
      "M.D. Anderson Cancer Center: 54.10% COMPLETED\n",
      "Maastricht Radiation Oncology: 68.75% COMPLETED\n",
      "MacroGenics: 52.38% COMPLETED\n",
      "Mallinckrodt: 0.00% COMPLETED\n",
      "Mario Negri Institute for Pharmacological Research: 30.77% COMPLETED\n",
      "Masonic Cancer Center, University of Minnesota: 48.00% COMPLETED\n",
      "Massachusetts General Hospital: 45.76% COMPLETED\n",
      "Mayo Clinic: 47.97% COMPLETED\n",
      "McGill University Health Centre/Research Institute of the McGill University Health Centre: 23.53% COMPLETED\n",
      "McMaster University: 25.00% COMPLETED\n",
      "MedImmune LLC: 59.18% COMPLETED\n",
      "MedSIR: 57.69% COMPLETED\n",
      "Medical College of Wisconsin: 40.32% COMPLETED\n",
      "Medical University of South Carolina: 36.73% COMPLETED\n",
      "Medical University of Vienna: 37.84% COMPLETED\n",
      "Memorial Sloan Kettering Cancer Center: 64.53% COMPLETED\n",
      "Merck KGaA, Darmstadt, Germany: 55.77% COMPLETED\n",
      "Merck Sharp & Dohme LLC: 35.29% COMPLETED\n",
      "Millennium Pharmaceuticals, Inc.: 80.00% COMPLETED\n",
      "Milton S. Hershey Medical Center: 16.67% COMPLETED\n",
      "Mirati Therapeutics Inc.: 38.46% COMPLETED\n",
      "Montefiore Medical Center: 11.11% COMPLETED\n",
      "Morphotek: 58.82% COMPLETED\n",
      "NCIC Clinical Trials Group: 92.75% COMPLETED\n",
      "NRG Oncology: 10.00% COMPLETED\n",
      "NSABP Foundation Inc: 75.76% COMPLETED\n",
      "NYU Langone Health: 33.67% COMPLETED\n",
      "Nanfang Hospital, Southern Medical University: 40.00% COMPLETED\n",
      "Nantes University Hospital: 36.96% COMPLETED\n",
      "National Cancer Center, Korea: 57.58% COMPLETED\n",
      "National Cancer Centre, Singapore: 36.67% COMPLETED\n",
      "National Cancer Institute (NCI): 63.92% COMPLETED\n",
      "National Cancer Institute, Naples: 50.00% COMPLETED\n",
      "National Health Research Institutes, Taiwan: 55.00% COMPLETED\n",
      "National Heart, Lung, and Blood Institute (NHLBI): 66.04% COMPLETED\n",
      "National Institute of Allergy and Infectious Diseases (NIAID): 3.09% COMPLETED\n",
      "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 11.76% COMPLETED\n",
      "National Institute of Mental Health (NIMH): 5.26% COMPLETED\n",
      "National Institutes of Health Clinical Center (CC): 61.76% COMPLETED\n",
      "National Taiwan University Hospital: 35.90% COMPLETED\n",
      "National University Hospital, Singapore: 30.00% COMPLETED\n",
      "Nationwide Children's Hospital: 5.00% COMPLETED\n",
      "Nektar Therapeutics: 58.82% COMPLETED\n",
      "New Mexico Cancer Research Alliance: 37.04% COMPLETED\n",
      "New York Medical College: 47.06% COMPLETED\n",
      "New York State Psychiatric Institute: 3.03% COMPLETED\n",
      "NewLink Genetics Corporation: 51.85% COMPLETED\n",
      "Northwell Health: 23.53% COMPLETED\n",
      "Northwestern University: 35.88% COMPLETED\n",
      "Novartis: 26.92% COMPLETED\n",
      "Novartis Pharmaceuticals: 52.08% COMPLETED\n",
      "Novo Nordisk A/S: 15.56% COMPLETED\n",
      "OHSU Knight Cancer Institute: 40.00% COMPLETED\n",
      "Ohio State University Comprehensive Cancer Center: 75.00% COMPLETED\n",
      "OncoMed Pharmaceuticals, Inc.: 75.00% COMPLETED\n",
      "Ontario Clinical Oncology Group (OCOG): 81.82% COMPLETED\n",
      "Oslo University Hospital: 32.43% COMPLETED\n",
      "Otsuka Pharmaceutical Development & Commercialization, Inc.: 15.38% COMPLETED\n",
      "Ottawa Hospital Research Institute: 64.71% COMPLETED\n",
      "PETHEMA Foundation: 73.08% COMPLETED\n",
      "PTC Therapeutics: 12.50% COMPLETED\n",
      "Pediatric Brain Tumor Consortium: 42.86% COMPLETED\n",
      "Peking Union Medical College Hospital: 30.16% COMPLETED\n",
      "Peking University: 27.59% COMPLETED\n",
      "Peking University Cancer Hospital & Institute: 28.57% COMPLETED\n",
      "Peking University People's Hospital: 16.67% COMPLETED\n",
      "Peter MacCallum Cancer Centre, Australia: 58.06% COMPLETED\n",
      "Pfizer: 35.44% COMPLETED\n",
      "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.: 11.11% COMPLETED\n",
      "PharmaMar: 60.71% COMPLETED\n",
      "Pharmacyclics LLC.: 87.10% COMPLETED\n",
      "Philogen S.p.A.: 33.33% COMPLETED\n",
      "Providence Health & Services: 40.00% COMPLETED\n",
      "Puma Biotechnology, Inc.: 86.36% COMPLETED\n",
      "Queen's University: 0.00% COMPLETED\n",
      "R-Pharm: 73.68% COMPLETED\n",
      "Radboud University Medical Center: 64.71% COMPLETED\n",
      "Radiation Therapy Oncology Group: 94.44% COMPLETED\n",
      "Regeneron Pharmaceuticals: 11.54% COMPLETED\n",
      "RemeGen Co., Ltd.: 18.18% COMPLETED\n",
      "RenJi Hospital: 16.67% COMPLETED\n",
      "Rennes University Hospital: 36.36% COMPLETED\n",
      "Rigshospitalet, Denmark: 58.33% COMPLETED\n",
      "Roswell Park Cancer Institute: 52.24% COMPLETED\n",
      "Royal Marsden NHS Foundation Trust: 34.78% COMPLETED\n",
      "Ruijin Hospital: 9.09% COMPLETED\n",
      "Rush University Medical Center: 5.56% COMPLETED\n",
      "Rutgers, The State University of New Jersey: 30.51% COMPLETED\n",
      "SCRI Development Innovations, LLC: 86.07% COMPLETED\n",
      "SOLTI Breast Cancer Research Group: 41.18% COMPLETED\n",
      "SWOG Cancer Research Network: 71.35% COMPLETED\n",
      "Samsung Medical Center: 70.59% COMPLETED\n",
      "Sanofi: 51.96% COMPLETED\n",
      "Seagen Inc.: 53.16% COMPLETED\n",
      "Second Affiliated Hospital, School of Medicine, Zhejiang University: 3.70% COMPLETED\n",
      "Seoul National University Hospital: 54.67% COMPLETED\n",
      "Shandong Cancer Hospital and Institute: 23.81% COMPLETED\n",
      "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine: 25.00% COMPLETED\n",
      "Shanghai Henlius Biotech: 29.41% COMPLETED\n",
      "Shanghai Jiao Tong University School of Medicine: 39.47% COMPLETED\n",
      "Shanghai Junshi Bioscience Co., Ltd.: 42.86% COMPLETED\n",
      "Shanghai Pulmonary Hospital, Shanghai, China: 5.88% COMPLETED\n",
      "Sheba Medical Center: 41.67% COMPLETED\n",
      "Shire: 2.78% COMPLETED\n",
      "Sichuan Baili Pharmaceutical Co., Ltd.: 0.00% COMPLETED\n",
      "Sichuan University: 12.50% COMPLETED\n",
      "Sidney Kimmel Cancer Center at Thomas Jefferson University: 78.95% COMPLETED\n",
      "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 55.60% COMPLETED\n",
      "Singapore General Hospital: 55.00% COMPLETED\n",
      "Spanish Breast Cancer Research Group: 82.76% COMPLETED\n",
      "Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD): 82.61% COMPLETED\n",
      "Spectrum Pharmaceuticals, Inc: 44.19% COMPLETED\n",
      "St. Jude Children's Research Hospital: 60.19% COMPLETED\n",
      "St. Petersburg State Pavlov Medical University: 35.29% COMPLETED\n",
      "Stanford University: 46.62% COMPLETED\n",
      "Stemline Therapeutics, Inc.: 43.75% COMPLETED\n",
      "Sumitomo Pharma America, Inc.: 33.33% COMPLETED\n",
      "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: 11.76% COMPLETED\n",
      "Sun Yat-sen University: 26.77% COMPLETED\n",
      "Sunnybrook Health Sciences Centre: 37.50% COMPLETED\n",
      "Suzhou Suncadia Biopharmaceuticals Co., Ltd.: 0.00% COMPLETED\n",
      "Suzhou Zelgen Biopharmaceuticals Co.,Ltd: 35.29% COMPLETED\n",
      "Swiss Group for Clinical Cancer Research: 67.44% COMPLETED\n",
      "Syndax Pharmaceuticals: 64.71% COMPLETED\n",
      "TG Therapeutics, Inc.: 45.83% COMPLETED\n",
      "Taiho Oncology, Inc.: 33.33% COMPLETED\n",
      "Taiho Pharmaceutical Co., Ltd.: 70.59% COMPLETED\n",
      "Takeda: 31.00% COMPLETED\n",
      "Technische Universität Dresden: 43.48% COMPLETED\n",
      "Teva Branded Pharmaceutical Products R&D, Inc.: 25.00% COMPLETED\n",
      "The Cleveland Clinic: 33.33% COMPLETED\n",
      "The First Affiliated Hospital of Soochow University: 12.77% COMPLETED\n",
      "The First Affiliated Hospital of Xiamen University: 0.00% COMPLETED\n",
      "The First Affiliated Hospital with Nanjing Medical University: 10.87% COMPLETED\n",
      "The Hospital for Sick Children: 25.00% COMPLETED\n",
      "The Lymphoma Academic Research Organisation: 67.57% COMPLETED\n",
      "The Methodist Hospital Research Institute: 36.36% COMPLETED\n",
      "The Netherlands Cancer Institute: 46.67% COMPLETED\n",
      "The University of Texas Health Science Center at San Antonio: 58.33% COMPLETED\n",
      "The University of Texas Health Science Center, Houston: 17.39% COMPLETED\n",
      "The University of Texas Medical Branch, Galveston: 13.64% COMPLETED\n",
      "Therapeutic Advances in Childhood Leukemia Consortium: 37.50% COMPLETED\n",
      "Thomas Jefferson University: 29.17% COMPLETED\n",
      "Tianjin Medical University Cancer Institute and Hospital: 17.39% COMPLETED\n",
      "Traws Pharma, Inc.: 75.00% COMPLETED\n",
      "Tufts Medical Center: 24.00% COMPLETED\n",
      "UCB Pharma: 11.76% COMPLETED\n",
      "UMC Utrecht: 32.14% COMPLETED\n",
      "UNC Lineberger Comprehensive Cancer Center: 58.25% COMPLETED\n",
      "UNICANCER: 68.67% COMPLETED\n",
      "US Oncology Research: 87.50% COMPLETED\n",
      "Universitair Ziekenhuis Brussel: 50.00% COMPLETED\n",
      "Universitaire Ziekenhuizen KU Leuven: 36.67% COMPLETED\n",
      "University College, London: 55.93% COMPLETED\n",
      "University Health Network, Toronto: 59.38% COMPLETED\n",
      "University Hospital Heidelberg: 47.37% COMPLETED\n",
      "University Hospital Muenster: 40.00% COMPLETED\n",
      "University Hospital Tuebingen: 55.56% COMPLETED\n",
      "University Hospital, Basel, Switzerland: 26.47% COMPLETED\n",
      "University Hospital, Bordeaux: 62.50% COMPLETED\n",
      "University Hospital, Ghent: 54.17% COMPLETED\n",
      "University Hospital, Grenoble: 11.11% COMPLETED\n",
      "University Hospital, Lille: 36.84% COMPLETED\n",
      "University Hospital, Limoges: 47.06% COMPLETED\n",
      "University Hospital, Strasbourg, France: 13.64% COMPLETED\n",
      "University Hospital, Toulouse: 36.84% COMPLETED\n",
      "University Medical Center Groningen: 55.56% COMPLETED\n",
      "University of Aarhus: 30.00% COMPLETED\n",
      "University of Alabama at Birmingham: 49.07% COMPLETED\n",
      "University of Alberta: 28.95% COMPLETED\n",
      "University of Arizona: 54.35% COMPLETED\n",
      "University of Arkansas: 52.73% COMPLETED\n",
      "University of Birmingham: 56.25% COMPLETED\n",
      "University of British Columbia: 25.00% COMPLETED\n",
      "University of Calgary: 5.26% COMPLETED\n",
      "University of California, Davis: 47.27% COMPLETED\n",
      "University of California, Irvine: 44.83% COMPLETED\n",
      "University of California, Los Angeles: 15.15% COMPLETED\n",
      "University of California, San Diego: 28.95% COMPLETED\n",
      "University of California, San Francisco: 43.56% COMPLETED\n",
      "University of Chicago: 44.51% COMPLETED\n",
      "University of Cincinnati: 17.65% COMPLETED\n",
      "University of Cologne: 66.67% COMPLETED\n",
      "University of Colorado, Denver: 50.65% COMPLETED\n",
      "University of Erlangen-Nürnberg Medical School: 20.00% COMPLETED\n",
      "University of Florida: 26.09% COMPLETED\n",
      "University of Illinois at Chicago: 13.79% COMPLETED\n",
      "University of Iowa: 30.00% COMPLETED\n",
      "University of Kansas Medical Center: 41.18% COMPLETED\n",
      "University of Louisville: 39.13% COMPLETED\n",
      "University of Maryland, Baltimore: 13.46% COMPLETED\n",
      "University of Medicine and Dentistry of New Jersey: 18.18% COMPLETED\n",
      "University of Miami: 33.78% COMPLETED\n",
      "University of Michigan: 18.60% COMPLETED\n",
      "University of Michigan Rogel Cancer Center: 55.37% COMPLETED\n",
      "University of Minnesota: 21.74% COMPLETED\n",
      "University of Nebraska: 44.12% COMPLETED\n",
      "University of North Carolina, Chapel Hill: 5.71% COMPLETED\n",
      "University of Oklahoma: 34.29% COMPLETED\n",
      "University of Oxford: 43.75% COMPLETED\n",
      "University of Pennsylvania: 37.21% COMPLETED\n",
      "University of Pittsburgh: 54.72% COMPLETED\n",
      "University of Rochester: 46.43% COMPLETED\n",
      "University of Sao Paulo: 18.75% COMPLETED\n",
      "University of Southern California: 35.62% COMPLETED\n",
      "University of Texas Southwestern Medical Center: 30.84% COMPLETED\n",
      "University of Ulm: 62.07% COMPLETED\n",
      "University of Utah: 29.41% COMPLETED\n",
      "University of Virginia: 21.21% COMPLETED\n",
      "University of Washington: 42.47% COMPLETED\n",
      "University of Wisconsin, Madison: 41.38% COMPLETED\n",
      "University of Zurich: 31.03% COMPLETED\n",
      "Universitätsklinikum Hamburg-Eppendorf: 40.00% COMPLETED\n",
      "VA Office of Research and Development: 17.31% COMPLETED\n",
      "Vanderbilt University: 17.86% COMPLETED\n",
      "Vanderbilt University Medical Center: 9.09% COMPLETED\n",
      "Vanderbilt-Ingram Cancer Center: 49.37% COMPLETED\n",
      "Vejle Hospital: 81.48% COMPLETED\n",
      "ViiV Healthcare: 5.56% COMPLETED\n",
      "Virginia Commonwealth University: 30.65% COMPLETED\n",
      "Wake Forest University Health Sciences: 45.39% COMPLETED\n",
      "Washington University School of Medicine: 39.86% COMPLETED\n",
      "Weill Medical College of Cornell University: 38.69% COMPLETED\n",
      "West China Hospital: 17.24% COMPLETED\n",
      "Western Regional Medical Center: 6.25% COMPLETED\n",
      "Wuhan Union Hospital, China: 0.00% COMPLETED\n",
      "Wyeth is now a wholly owned subsidiary of Pfizer: 20.83% COMPLETED\n",
      "Xencor, Inc.: 47.06% COMPLETED\n",
      "Yale University: 35.54% COMPLETED\n",
      "Yonsei University: 51.11% COMPLETED\n",
      "Zhejiang Cancer Hospital: 27.66% COMPLETED\n",
      "Zhejiang University: 26.47% COMPLETED\n"
     ]
    }
   ],
   "source": [
    "# Count number of trials per sponsor\n",
    "sponsor_counts = df['lead_sponsor'].value_counts()\n",
    "\n",
    "# Keep sponsors with more than 15 trials\n",
    "top_sponsors = sponsor_counts[sponsor_counts > 15].index\n",
    "\n",
    "# Filter DataFrame for top sponsors only\n",
    "top_df = df[df['lead_sponsor'].isin(top_sponsors)]\n",
    "\n",
    "# Group by sponsor and trial status\n",
    "status_counts = top_df.groupby(['lead_sponsor', 'overall_status']).size().unstack(fill_value=0)\n",
    "\n",
    "# Compute total trials\n",
    "total_trials = status_counts.sum(axis=1)\n",
    "\n",
    "# Compute percentage for COMPLETED only\n",
    "completed_percent = (status_counts['COMPLETED'] / total_trials) * 100\n",
    "\n",
    "# Convert to dictionary\n",
    "completed_percent_dict = completed_percent.to_dict()\n",
    "\n",
    "# Optional: Print\n",
    "for sponsor, pct in completed_percent_dict.items():\n",
    "    print(f\"{sponsor}: {pct:.2f}% COMPLETED\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0cbfd625",
   "metadata": {},
   "source": [
    "I selected the lead sponsors with over 50 trials and detected a trend of some lead sponsors as stronger"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2c3f3ed5",
   "metadata": {},
   "source": [
    "Comparing the lead sponsors in the recruiting subset and comparison with other"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "7221de60",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Sponsors in both Recruiting & Top Sponsors (>10 trials):\n",
      "['AHS Cancer Control Alberta', 'AIDS Malignancy Consortium', 'AIO-Studien-gGmbH', 'ARCAGY/ GINECO GROUP', 'AVEO Pharmaceuticals, Inc.', 'AbbVie', 'Abramson Cancer Center at Penn Medicine', 'Academic and Community Cancer Research United', 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', 'Acrotech Biopharma Inc.', 'Akeso', 'Albert Einstein College of Medicine', 'Alliance for Clinical Trials in Oncology', 'Amgen', 'Amsterdam UMC, location VUmc', 'Arbeitsgemeinschaft medikamentoese Tumortherapie', 'Asan Medical Center', 'Ascentage Pharma Group Inc.', 'Assistance Publique - Hôpitaux de Paris', 'Assistance Publique Hopitaux De Marseille', 'Astellas Pharma Global Development, Inc.', 'AstraZeneca', 'Barbara Ann Karmanos Cancer Institute', 'Bayer', 'Baylor College of Medicine', 'BeiGene', 'Beth Israel Deaconess Medical Center', 'Betta Pharmaceuticals Co., Ltd.', 'Biocad', 'Boehringer Ingelheim', \"Brigham and Women's Hospital\", 'Bristol-Myers Squibb', 'British Columbia Cancer Agency', 'Brown University', 'CSPC ZhongQi Pharmaceutical Technology Co., Ltd.', 'Cambridge University Hospitals NHS Foundation Trust', 'Canadian Cancer Trials Group', 'Cancer Institute and Hospital, Chinese Academy of Medical Sciences', 'Cancer Research UK', 'Cancer Trials Ireland', 'Case Comprehensive Cancer Center', 'Cedars-Sinai Medical Center', 'Celgene', 'Centre Francois Baclesse', 'Centre Hospitalier Universitaire de Besancon', 'Centre Leon Berard', 'Centre Oscar Lambret', \"Centre hospitalier de l'Université de Montréal (CHUM)\", 'Charite University, Berlin, Germany', 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.', \"Children's Hospital Medical Center, Cincinnati\", \"Children's Hospital of Philadelphia\", \"Children's Oncology Group\", 'Chinese Academy of Medical Sciences', 'Chinese PLA General Hospital', 'Chinese University of Hong Kong', 'Chongqing Precision Biotech Co., Ltd', 'City of Hope Medical Center', 'Columbia University', 'Daiichi Sankyo', 'Dana-Farber Cancer Institute', 'Dartmouth-Hitchcock Medical Center', 'Debiopharm International SA', 'Duke University', 'ECOG-ACRIN Cancer Research Group', 'EMD Serono Research & Development Institute, Inc.', 'ETOP IBCSG Partners Foundation', 'Eastern Cooperative Oncology Group', 'Eisai Inc.', 'Eli Lilly and Company', 'Emory University', 'Erasmus Medical Center', 'European Institute of Oncology', 'European Organisation for Research and Treatment of Cancer - EORTC', 'Exelixis', 'Federation Francophone de Cancerologie Digestive', 'Ferring Pharmaceuticals', 'First Affiliated Hospital of Zhejiang University', 'Fondazione IRCCS Istituto Nazionale dei Tumori, Milano', 'Fondazione Italiana Linfomi - ETS', 'Fox Chase Cancer Center', 'Fred Hutchinson Cancer Center', 'French Innovative Leukemia Organisation', 'Fudan University', 'Galapagos NV', 'Genentech, Inc.', 'Genmab', 'Georgetown University', 'German Breast Group', 'German CLL Study Group', 'Gilead Sciences', 'GlaxoSmithKline', 'Goethe University', 'Groupe Francophone des Myelodysplasies', 'Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea', \"Gruppo Italiano Malattie EMatologiche dell'Adulto\", 'Gruppo Oncologico del Nord-Ovest', \"Guangdong Provincial People's Hospital\", 'Gustave Roussy, Cancer Campus, Grand Paris', 'H. Lee Moffitt Cancer Center and Research Institute', 'Hackensack Meridian Health', 'Heidelberg University', 'Henan Cancer Hospital', 'Hoffmann-La Roche', 'Hospices Civils de Lyon', 'Hunan Province Tumor Hospital', 'Hutchison Medipharma Limited', 'Hutchmed', 'IRCCS San Raffaele', 'Icahn School of Medicine at Mount Sinai', 'ImmunityBio, Inc.', 'Imperial College London', 'Incyte Corporation', 'Indiana University', 'Inge Marie Svane', 'Innovent Biologics (Suzhou) Co. Ltd.', 'Insel Gruppe AG, University Hospital Bern', 'Institut Bergonié', 'Institut Claudius Regaud', 'Institut Curie', 'Institut de Recherches Internationales Servier', \"Institut du Cancer de Montpellier - Val d'Aurelle\", 'Institute of Cancer Research, United Kingdom', 'Institute of Hematology & Blood Diseases Hospital, China', 'Intergroupe Francophone de Cancerologie Thoracique', 'Ipsen', 'Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori', 'Janssen Research & Development, LLC', 'Jazz Pharmaceuticals', 'Jiangsu HengRui Medicine Co., Ltd.', 'Johns Hopkins University', 'Jonsson Comprehensive Cancer Center', 'Jules Bordet Institute', 'Karolinska University Hospital', 'Karyopharm Therapeutics Inc', 'Kite, A Gilead Company', 'Kyowa Kirin Co., Ltd.', 'Leiden University Medical Center', \"London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's\", 'Loyola University', 'Lund University Hospital', 'M.D. Anderson Cancer Center', 'MacroGenics', 'Mario Negri Institute for Pharmacological Research', 'Masonic Cancer Center, University of Minnesota', 'Massachusetts General Hospital', 'Mayo Clinic', 'McGill University Health Centre/Research Institute of the McGill University Health Centre', 'McMaster University', 'MedSIR', 'Medical College of Wisconsin', 'Medical University of South Carolina', 'Medical University of Vienna', 'Memorial Sloan Kettering Cancer Center', 'Merck Sharp & Dohme LLC', 'Milton S. Hershey Medical Center', 'Mirati Therapeutics Inc.', 'Montefiore Medical Center', 'NRG Oncology', 'NSABP Foundation Inc', 'NYU Langone Health', 'Nanfang Hospital, Southern Medical University', 'Nantes University Hospital', 'National Cancer Center, Korea', 'National Cancer Centre, Singapore', 'National Cancer Institute (NCI)', 'National Cancer Institute, Naples', 'National Health Research Institutes, Taiwan', 'National Heart, Lung, and Blood Institute (NHLBI)', 'National Institute of Allergy and Infectious Diseases (NIAID)', 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'National Taiwan University Hospital', 'National University Hospital, Singapore', \"Nationwide Children's Hospital\", 'New York Medical College', 'Northwell Health', 'Northwestern University', 'Novartis Pharmaceuticals', 'OHSU Knight Cancer Institute', 'Ohio State University Comprehensive Cancer Center', 'Ontario Clinical Oncology Group (OCOG)', 'Oslo University Hospital', 'Ottawa Hospital Research Institute', 'PETHEMA Foundation', 'Pediatric Brain Tumor Consortium', 'Peking Union Medical College Hospital', 'Peking University', 'Peking University Cancer Hospital & Institute', \"Peking University People's Hospital\", 'Peter MacCallum Cancer Centre, Australia', 'Pfizer', 'PharmaMar', 'Philogen S.p.A.', 'Providence Health & Services', 'Puma Biotechnology, Inc.', 'Radboud University Medical Center', 'Regeneron Pharmaceuticals', 'RemeGen Co., Ltd.', 'RenJi Hospital', 'Rigshospitalet, Denmark', 'Roswell Park Cancer Institute', 'Royal Marsden NHS Foundation Trust', 'Ruijin Hospital', 'Rush University Medical Center', 'Rutgers, The State University of New Jersey', 'SCRI Development Innovations, LLC', 'SOLTI Breast Cancer Research Group', 'SWOG Cancer Research Network', 'Samsung Medical Center', 'Sanofi', 'Seagen Inc.', 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'Seoul National University Hospital', 'Shandong Cancer Hospital and Institute', 'Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine', 'Shanghai Henlius Biotech', 'Shanghai Jiao Tong University School of Medicine', 'Shanghai Junshi Bioscience Co., Ltd.', 'Shanghai Pulmonary Hospital, Shanghai, China', 'Sheba Medical Center', 'Sichuan Baili Pharmaceutical Co., Ltd.', 'Sichuan University', 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'Singapore General Hospital', 'Spanish Breast Cancer Research Group', 'Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)', 'Spectrum Pharmaceuticals, Inc', \"St. Jude Children's Research Hospital\", 'St. Petersburg State Pavlov Medical University', 'Stanford University', 'Stemline Therapeutics, Inc.', 'Sumitomo Pharma America, Inc.', 'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University', 'Sun Yat-sen University', 'Sunnybrook Health Sciences Centre', 'Suzhou Suncadia Biopharmaceuticals Co., Ltd.', 'Suzhou Zelgen Biopharmaceuticals Co.,Ltd', 'Swiss Group for Clinical Cancer Research', 'Syndax Pharmaceuticals', 'Taiho Oncology, Inc.', 'Taiho Pharmaceutical Co., Ltd.', 'Takeda', 'Technische Universität Dresden', 'The Cleveland Clinic', 'The First Affiliated Hospital of Soochow University', 'The First Affiliated Hospital of Xiamen University', 'The First Affiliated Hospital with Nanjing Medical University', 'The Lymphoma Academic Research Organisation', 'The Methodist Hospital Research Institute', 'The Netherlands Cancer Institute', 'The University of Texas Health Science Center at San Antonio', 'The University of Texas Health Science Center, Houston', 'Therapeutic Advances in Childhood Leukemia Consortium', 'Thomas Jefferson University', 'Tianjin Medical University Cancer Institute and Hospital', 'Traws Pharma, Inc.', 'UMC Utrecht', 'UNC Lineberger Comprehensive Cancer Center', 'UNICANCER', 'Universitair Ziekenhuis Brussel', 'Universitaire Ziekenhuizen KU Leuven', 'University College, London', 'University Health Network, Toronto', 'University Hospital Heidelberg', 'University Hospital Muenster', 'University Hospital Tuebingen', 'University Hospital, Basel, Switzerland', 'University Hospital, Bordeaux', 'University Hospital, Ghent', 'University Hospital, Grenoble', 'University Hospital, Lille', 'University Hospital, Strasbourg, France', 'University Hospital, Toulouse', 'University Medical Center Groningen', 'University of Aarhus', 'University of Alabama at Birmingham', 'University of Alberta', 'University of Arizona', 'University of Arkansas', 'University of Birmingham', 'University of British Columbia', 'University of California, Davis', 'University of California, Irvine', 'University of California, San Diego', 'University of California, San Francisco', 'University of Chicago', 'University of Cincinnati', 'University of Cologne', 'University of Colorado, Denver', 'University of Erlangen-Nürnberg Medical School', 'University of Florida', 'University of Illinois at Chicago', 'University of Iowa', 'University of Kansas Medical Center', 'University of Louisville', 'University of Maryland, Baltimore', 'University of Miami', 'University of Michigan', 'University of Michigan Rogel Cancer Center', 'University of Nebraska', 'University of Oklahoma', 'University of Oxford', 'University of Pennsylvania', 'University of Rochester', 'University of Sao Paulo', 'University of Southern California', 'University of Texas Southwestern Medical Center', 'University of Ulm', 'University of Utah', 'University of Virginia', 'University of Washington', 'University of Wisconsin, Madison', 'University of Zurich', 'Universitätsklinikum Hamburg-Eppendorf', 'VA Office of Research and Development', 'Vanderbilt University', 'Vanderbilt University Medical Center', 'Vanderbilt-Ingram Cancer Center', 'Vejle Hospital', 'Virginia Commonwealth University', 'Wake Forest University Health Sciences', 'Washington University School of Medicine', 'Weill Medical College of Cornell University', 'West China Hospital', 'Wuhan Union Hospital, China', 'Xencor, Inc.', 'Yale University', 'Yonsei University', 'Zhejiang Cancer Hospital', 'Zhejiang University']\n",
      "\n",
      "❌ Sponsors in Recruiting but NOT in Top Sponsors:\n",
      "['1Globe Health Institute LLC', '3D Medicines (Sichuan) Co., Ltd.', '4th Military Clinical Hospital with Polyclinic, Poland', '7 Hills Pharma, LLC', '858 Therapeutics, Inc.', \"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China\", 'A&G Pharmaceutical Inc.', 'A.J.M. van den Eertwegh', 'A2 Biotherapeutics Inc.', 'A2A Pharmaceuticals Inc.', 'AB Science', 'ABSCINT NV/SA', 'ABX advanced biochemical compounds GmbH', 'AC Camargo Cancer Center', 'ADC Therapeutics S.A.', 'AGO Research GmbH', 'AGO Study Group', 'AIM ImmunoTech Inc.', 'AIPING ZHOU', 'ALX Oncology Inc.', 'AO GENERIUM', 'AUM Biosciences Pte Ltd', 'AUSL Romagna Rimini', 'Aadi Bioscience, Inc.', 'Aalborg University Hospital', 'Aarhus University Hospital', 'Aaron Logan, MD', 'Aaron Wolfson', 'AbClon', 'Abbisko Therapeutics Co, Ltd', 'Abdera Therapeutics Inc.', 'Abdullah Khan', 'AbelZeta, Inc.', 'Abnoba Gmbh', 'Accent Therapeutics', 'Accutar Biotechnology Inc', 'Acepodia Biotech, Inc.', 'Acerand Therapeutics (Shanghai) Limited', 'Acousia Therapeutics GmbH', 'Acrivon Therapeutics', 'Actinium Pharmaceuticals', 'Actuate Therapeutics Inc.', 'Adaptimmune', 'Adcentrx Therapeutics', 'Adicet Therapeutics', 'Adlai Nortye Biopharma Co., Ltd.', 'Adriana Rossi', 'Adrienne G. Waks', 'AdvanCell Isotopes Pty Limited', 'Advanced BioDesign', 'Advenchen Laboratories Nanjing Ltd.', 'Advenchen Pharmaceuticals, LLC.', 'AdventHealth', 'Affiliated Cancer Hospital & Institute of Guangzhou Medical University', 'Affiliated Cancer Hospital of Shantou University Medical College', 'Affiliated Hospital of Jiangnan University', 'Affiliated Hospital of Nantong University', 'Affiliated Hospital to Academy of Military Medical Sciences', 'Affimed GmbH', 'Affini-T Therapeutics, Inc.', 'AffyImmune Therapeutics, Inc.', 'Agios Pharmaceuticals, Inc.', 'AgonOx, Inc.', 'Ahon Pharmaceutical Co., Ltd.', 'Aibin Liang，MD，Ph.D.', 'Ain Shams University', 'Air Force Military Medical University, China', 'Aivita Biomedical, Inc.', 'Akouos, Inc.', 'Al-Azhar University', 'Alain Algazi', 'Albany Medical College', 'Alentis Therapeutics AG', 'Alessa Therapeutics Inc.', 'Alessandro Santin', 'Alethia Biotherapeutics', 'Alexander B Olawaiye, MD', 'Alice Chung', 'Alice Mims', 'Aline Fusco Fares, MD', 'All India Institute of Medical Sciences, Jodhpur', 'All India Institute of Medical Sciences, New Delhi', 'Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)', 'Alliance Foundation Trials, LLC.', \"Allison O'Neill, MD\", 'Allist Pharmaceuticals, Inc.', 'Allogene Therapeutics', 'Alterome Therapeutics, Inc.', 'Alvaro Alencar, MD', 'Ambrx, Inc.', 'American College of Radiology', 'American Society of Clinical Oncology', 'Amphia Hospital', 'Amunix, a Sanofi Company', 'Ana C Garrido-Castro, MD', 'Anbogen Therapeutics, Inc.', 'Andalusian Network for Design and Translation of Advanced Therapies', 'Andarix Pharmaceuticals', 'Anders Rosendal Korshøj', 'Andrei Iagaru', 'Andrew E. Place, MD', 'Andrew J. Armstrong, MD', 'Andrew Yee, MD', 'Angelica Lindén Hirschberg', 'Angiex, Inc.', 'Anhui Provincial Cancer Hospital', 'Anhui Provincial Hospital', 'Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.', 'Ankyra Therapeutics, Inc', \"Ann & Robert H Lurie Children's Hospital of Chicago\", 'Ann-Sofie Backman', 'Anna Raciborska', 'Anne Noonan', 'Antengene (Hangzhou) Biologics Co., Ltd.', 'Antengene Biologics Limited', 'Antengene Corporation', 'Antonio Giordano, MD', 'Antonio M Jimenez Jimenez', 'Antonio Pérez Martínez', 'Anwaar Saeed', 'Anwita Biosciences', 'Apollo Therapeutics Ltd', 'Apollomics Inc.', 'April Salama, M.D.', 'Aptose Biosciences Inc.', 'Aragon Pharmaceuticals, Inc.', 'Arbele Pty Ltd', 'Arcellx, Inc.', 'Arcus Biosciences, Inc.', 'Arjun Mittra', 'Army Medical Center of PLA', 'ArriVent BioPharma, Inc.', 'Arsenal Biosciences, Inc.', 'Artios Pharma Ltd', 'Artiva Biotherapeutics, Inc.', 'Arvinas Inc.', 'Ascendis Pharma Oncology Division A/S', 'Ascension South East Michigan', 'Ascentawits Pharmaceuticals, Ltd', 'Aseel Alsouqi', 'Asher Biotherapeutics, Inc.', 'Ashish Manne', 'Ashish Shah', 'Ashutosh Kumar Tewari', 'Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas', 'Assaf-Harofeh Medical Center', 'Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie', 'Associazione Italiana Ematologia Oncologia Pediatrica', 'Associazione Qol-one', 'Atara Biotherapeutics', 'Athenex, Inc.', 'Atish Choudhury, MD', 'AtlasMedx, Incorporated', 'Atossa Therapeutics, Inc.', 'Augusta University', 'Aulos Bioscience, Inc.', 'Aura Biosciences', 'Aurigene Discovery Technologies Limited', 'Austin I Kim', 'Australasian Gastro-Intestinal Trials Group', 'Australasian Leukaemia and Lymphoma Group', 'Australia New Zealand Gynaecological Oncology Group', \"Australian & New Zealand Children's Haematology/Oncology Group\", 'Australian and New Zealand Urogenital and Prostate Cancer Trials Group', 'Autolus Limited', 'Avacta Life Sciences Ltd', 'AvenCell Europe GmbH', 'Avenzo Therapeutics, Inc.', 'Aveta Biomics, Inc.', 'Avistone Biotechnology Co., Ltd.', 'Axter Therapeutics (Beijing) Co., Ltd', 'Azienda Ospedaliera di Padova', 'Azienda Ospedaliero-Universitaria Careggi', 'Azienda Ospedaliero-Universitaria di Modena', 'Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia', 'BPGbio', 'Bambino Gesù Hospital and Research Institute', 'Banaras Hindu University', 'Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh', 'Bantam Pharmaceuticals', 'Baohui Han', 'Baptist Health South Florida', 'Barbara Burtness', 'Barretos Cancer Hospital', 'Baruch Brenner', 'Baylor Breast Care Center', 'Baylor Research Institute', 'Bayside Health', 'BeBetter Med Inc', 'Beat AML, LLC', 'Beihua Kong', 'Beijing 302 Hospital', 'Beijing Biostar Pharmaceuticals Co., Ltd.', 'Beijing Chest Hospital, Capital Medical University', 'Beijing Friendship Hospital', 'Beijing GoBroad Hospital', 'Beijing Hospital', 'Beijing Immunochina Medical Science & Technology Co., Ltd.', 'Beijing InnoCare Pharma Tech Co., Ltd.', 'Beijing Konruns Pharmaceutical Co., Ltd.', 'Beijing Mabworks Biotech Co., Ltd.', 'Beijing Neurosurgical Institute', 'Beijing Pearl Biotechnology Limited Liability Company', 'Beijing Sanbo Brain Hospital', 'Beijing Scitech-Mq Pharmaceuticals Limited', 'Beijing Tiantan Hospital', 'Beijing Tongren Hospital', 'Beijing Tsinghua Chang Gung Hospital', 'Beijing Yongtai Ruike Biotechnology Company Ltd', 'Belarusian Research Center for Pediatric Oncology, Hematology and Immunology', 'Benedetto Falsini', 'Beni-Suef University', 'Benjamin T Diamond, MD', 'BerGenBio ASA', 'Beta Pharma (Suzhou) Co., Ltd.', 'BeyondBio Inc.', 'Bicara Therapeutics', 'BicycleTx Limited', 'Bilal G. Rahim', 'Binhui Biopharmaceutical Co., Ltd.', 'Binkui Li', 'Bio-Thera Solutions', 'BioAtla, Inc.', 'BioEclipse Therapeutics', 'BioInvent International AB', 'BioNTech SE', 'BioNova Pharmaceuticals (Shanghai) LTD.', 'BioSight Ltd.', 'BioSyngen Pte Ltd', 'Biocity Biopharmaceutics Co., Ltd.', 'Biomea Fusion Inc.', 'Bioray Laboratories', 'Biostar Pharma, Inc.', 'Biotheryx, Inc.', 'Biotheus Inc.', 'Biozeus Biopharmaceutical S.A.', 'Bivision Pharmaceuticals, Inc.', 'Biyun Wang, MD', 'Black Diamond Therapeutics, Inc.', \"Blokhin's Russian Cancer Research Center\", 'BlossomHill Therapeutics', 'Blue Earth Diagnostics', 'Blue Earth Therapeutics Ltd', 'BlueSky Immunotherapies GmbH', 'Bold Therapeutics, Inc.', 'Borstkanker Onderzoek Groep', 'Boston University', 'Boundless Bio', 'Bradley A. McGregor, MD', 'Brandon Huffman, MD', 'Breast Cancer Trials, Australia and New Zealand', 'BriaCell Therapeutics Corporation', 'Brian Anderson, MD', 'Brian Henick, MD', 'Brian Jonas', 'BridGene Biosciences Inc.', 'Bridge Biotherapeutics, Inc.', 'British University In Egypt', 'Bruno Bockorny', 'Buzzard Pharmaceuticals', 'Byondis B.V.', 'C. Babis Andreadis', 'C4 Therapeutics, Inc.', 'CARsgen Therapeutics Co., Ltd.', 'CAS Lamvac Biotech Co., Ltd.', 'CCTU', 'CEBIOTEX', 'CG Oncology, Inc.', 'CHU de Quebec-Universite Laval', 'CJ Bioscience, Inc.', 'CNAO National Center of Oncological Hadrontherapy', 'CNBG-Virogin Biotech (Shanghai) Ltd.', 'CRISPR Therapeutics', 'CRISPR Therapeutics AG', 'CStone Pharmaceuticals', 'Caigang Liu', 'Cairo University', 'California Pacific Medical Center Research Institute', 'Can-Fite BioPharma', 'Canadian Myeloma Research Group', 'CanariaBio Inc.', 'Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center', 'Cancer Hospital of Guangxi Medical University', 'Cancer Research Antwerp', 'Cantargia AB', 'Cantex Pharmaceuticals', 'Canwell Biotech Limited', 'Capital Medical University', 'CarThera', 'Cardiff Oncology', 'Carey Anders, M.D.', 'Caribou Biosciences, Inc.', 'Carina Biotech Limited', 'Carl Allen', 'Carl Ola Landgren, MD, PhD', 'Carlo Contreras', 'Carna Biosciences, Inc.', 'Cartesian Therapeutics', 'CatalYm GmbH', 'Catapult Therapeutics', 'Catharina Ziekenhuis Eindhoven', 'Catherine Bollard', 'Catherine Spina', 'Cecilia Soderberg-Naucler', 'Celcuity Inc', 'CellCentric Ltd.', 'CellSight Technologies, Inc.', 'Cellectar Biosciences, Inc.', 'Cellectis S.A.', 'Cellvax Therapeutics Inc', 'Celon Pharma SA', 'Celyad Oncology SA', 'Center for International Blood and Marrow Transplant Research', 'Central Hospital, Nancy, France', 'Centre Antoine Lacassagne', 'Centre Georges Francois Leclerc', 'Centre Hospitalier Universitaire Dijon', 'Centre Hospitalier Universitaire Vaudois', 'Centre Hospitalier Universitaire de Nice', 'Centre de recherche du Centre hospitalier universitaire de Sherbrooke', 'Centro di Riferimento Oncologico - Aviano', 'Century Therapeutics, Inc.', 'Chad R. Tracy', 'Chang Gung Memorial Hospital', 'Changchun Deng, MD', 'Changchun GeneScience Pharmaceutical Co., Ltd.', 'Changhai Hospital', 'Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.', \"Changzhou No.2 People's Hospital\", 'Changzhou Qianhong Bio-pharma Co., Ltd.', 'Charles University, Czech Republic', 'Chen Suning', 'Chen Xiaoping', 'Chengdu CoenBiotech Co., Ltd', 'Chengdu Zenitar Biomedical Technology Co., Ltd', 'Chi Kong Li', 'Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.', \"Children's Cancer Group, China\", \"Children's Hospital Los Angeles\", \"Children's Hospital of Soochow University\", \"Children's National Research Institute\", 'Chimeric Therapeutics', 'Chimerix', 'China Medical University Hospital', 'China Medical University, China', 'Chinese Anti-Cancer Association', 'Chipscreen Biosciences, Ltd.', 'Chirag G. Patil', 'Cho Pharma Inc.', 'Chongqing Peg-Bio Biopharm Co., Ltd.', 'Chongqing University Cancer Hospital', 'Chordia Therapeutics, Inc.', 'Christian Hinrichs', 'Christian Schmidt, MD', 'Christine Ryan', 'Christopher Strouse', 'Christopher Wilke', 'Chuangzhen Chen', 'Chulalongkorn University', 'Chungnam National University Hospital', 'Chunguang yang (101937)', 'Chunji Gao', 'Chunyan Sun, MD', 'Cinnagen', 'Circle Pharma', 'City Clinical Oncology Hospital No 1', \"Ciusss de L'Est de l'Île de Montréal\", 'CivaTech Oncology', 'Clarity Pharmaceuticals Ltd', 'Claudia Guerrieri', 'Clinical Hub for Interventional Research (CHOIR)', 'Cogent Biosciences, Inc.', 'Coherus Biosciences, Inc.', 'Colette Shen', 'Colin D. Weekes, M.D., PhD', 'Collin Blakely', 'Colorado State University', 'Compass Therapeutics', 'Compugen Ltd', 'Consorzio Oncotech', 'Constellation Pharmaceuticals', 'Context Therapeutics Inc.', 'Convergent Therapeutics', \"Cook Children's Health Care System\", 'Coordinación de Investigación en Salud, Mexico', 'Copernicus Memorial Hospital', 'Corvus Pharmaceuticals, Inc.', 'Criterium, Inc.', 'Crossignal Therapeutics, Inc.', 'Crystal Mackall, MD', 'CrystalGenomics, Inc.', 'Cullinan Therapeutics Inc.', 'Curasight', 'Curis, Inc.', 'Curium US LLC', 'Curocell Inc.', 'Curon Biopharmaceutical (Shanghai) Co.,Ltd', 'Cybrexa Therapeutics', 'Cyclacel Pharmaceuticals, Inc.', 'CytoAgents, Inc.', 'CytoCares Inc', 'CytosinLab Therapeutics Co., Ltd.', 'Cytosite Biopharma Inc.', \"D'Or Institute for Research and Education\", 'DEKA Biosciences', 'Dai, Guanghai', 'Dalarna County Council, Sweden', 'Dallas VA Medical Center', 'Damanhour University', 'Dan Zandberg', 'Daping Hospital and the Research Institute of Surgery of the Third Military Medical University', 'Darell Bigner', 'David Baskin MD', 'David Bond, MD', 'David Palma', 'David S Shulman, MD', 'David Wald', 'Day One Biopharmaceuticals, Inc.', 'Deciphera Pharmaceuticals, LLC', 'Delta-Fly Pharma, Inc.', 'DermBiont, Inc.', 'DeuterOncology', 'DexTech Medical AB', 'Di Deng', 'Di Wu', 'Dickran Kazandjian, MD', 'Dipenkumar Modi', 'Disc Medicine, Inc', 'Divaya Bhutani', 'Diwakar Davar', 'Dizal Pharmaceuticals', 'Doma Biopharmaceutical（Suzhou）Co., Ltd.', 'Dominik Paul Modest', 'Donald Basel', 'Donald Mabbott', 'Dong Wang', 'Dongkook Pharmaceutical Co., Ltd.', 'Douglas Tremblay', 'Dr Jean Yannis PERENTES', 'Dr Rajendra A. Badwe', 'Dr. Jean-Sebastien Delisle, MD, PhD', 'Dr. Melody Smith, MD, MS', 'Dren Bio', 'DualityBio Inc.', 'Duk-Woo Park, MD', 'Dustin Deming', 'Dwight Owen', 'EP Plus Group Sdn Bhd', 'ERLINDA M GORDON', 'ETH Zurich', 'Eastern Hepatobiliary Surgery Hospital', 'Eben Rosenthal', 'Edgewood Oncology Inc.', 'Edwin Posadas, MD', 'Eikon Therapeutics', 'Eileen Connolly', 'Electra Therapeutics Inc.', 'Elevation Oncology', 'Elisabethinen Hospital', 'Elizabeth Buchbinder, MD', 'Ellen Kim, MD', 'Ellipses Pharma', 'Elpiscience Biopharma, Ltd.', 'Elvira Umyarova', 'Endeavor Health', 'Endocyte', 'Enliven Therapeutics', 'Ente Ospedaliero Ospedali Galliera', 'Enterome', 'EpicentRx, Inc.', 'Epigenetix, Inc.', 'EpimAb Biotherapeutics (Suzhou)Co., Ltd.', 'Epizyme, Inc.', 'Epkin', 'Epsilogen Ltd', 'Erasca, Inc.', 'Eric Stephen Winer, MD', 'Esperas Pharma Inc.', 'Essen Biotech', 'Estrella Biopharma, Inc.', 'Etan Orgel', 'EtiraRx Australia Pty Ltd', 'Etnova Therapeutics Corp.', 'Eucure (Beijing) Biopharma Co., Ltd', 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)', 'Eunseong Medical Foundation Good GANG-AN HOSPITAL', 'Eureka Therapeutics Inc.', 'Eurofarma Laboratorios S.A.', 'Eutilex', 'Eva Marie Erfurth, MD, PhD', 'Evaxion Biotech A/S', 'Eve Rodler', 'Ever Supreme Bio Technology Co., Ltd.', 'Evopoint Biosciences Inc.', 'Excyte Biopharma Ltd', 'ExpreS2ion Biotechnologies', 'Eye & ENT Hospital of Fudan University', 'Ezra Cohen', 'FBD Biologics Limited', 'Faeth Therapeutics', 'Falo, Louis, MD', 'FamiCordTx', 'Faron Pharmaceuticals Ltd', 'Fate Therapeutics', 'Federal Research Institute of Pediatric Hematology, Oncology and Immunology', 'Feixue Song', 'Feng Tian', 'Fifth Affiliated Hospital, Sun Yat-Sen University', 'Filipa Lynce, MD', 'Finn, Olivera, PhD', \"First Affiliated Hospital Xi'an Jiaotong University\", 'First Affiliated Hospital of Chengdu Medical College', 'First Affiliated Hospital of Chongqing Medical University', 'First Affiliated Hospital of Guangxi Medical University', 'First Affiliated Hospital of Ningbo University', 'First Affiliated Hospital of Wannan Medical College', 'First Affiliated Hospital of Wenzhou Medical University', 'First Affiliated Hospital, Sun Yat-Sen University', \"First People's Hospital of Hangzhou\", 'Five Eleven Pharma, Inc.', 'Flamingo Therapeutics NV', 'Flemming Forsberg', 'FluidAI Medical', 'Foghorn Therapeutics Inc.', 'Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta', 'Fondazione IRCCS Policlinico San Matteo di Pavia', 'Fondazione Matilde Tettamanti Menotti De Marchi Onlus', 'Fondazione Oncotech', 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'Fondazione Ricerca Traslazionale', 'Formycon AG', 'Forward Pharmaceuticals Co., Ltd.', 'Fourth Affiliated Hospital of Guangxi Medical University', 'Francesco De Cobelli', 'Franziska Wachter', 'Frontier Medicines Corporation', 'Fujian Cancer Hospital', 'Fujian Medical University Union Hospital', 'Fujian Provincial Hospital', 'Fujifilm Pharmaceuticals U.S.A., Inc.', 'Fujun Zhang', 'Fulgent Pharma LLC.', 'Fuling Zhou', 'Full-Life Technologies GmbH', 'Fundacio Clinic Barcelona', 'Fundacion Oncosur', \"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau\", 'Fundación GECP', 'Fundación IVI', 'Fundación de investigación HM', 'Fundación para el Progreso de la Oncología en Cantabria', 'Fusion Pharmaceuticals Inc.', 'Future University in Egypt', 'FutureChem', 'Fuzhou General Hospital', 'G1 Therapeutics, Inc.', 'GCP-Service International West GmbH', 'GE Healthcare', 'GELLC (Grupo Español de Leucemia Linfocítica Crónica)', 'GERCOR - Multidisciplinary Oncology Cooperative Group', 'GI Cell, Inc.', 'GI Innovation, Inc.', 'GOG Foundation', 'GONGCHU Biotechnology Co., Ltd', 'GPCR Therapeutics, Inc.', 'GT Medical Technologies, Inc.', 'GV20 Therapeutics', 'GWT-TUD GmbH', 'Gadjah Mada University', 'Galician Research Group on Digestive Tumors', 'Gangnam Severance Hospital', 'Geisinger Clinic', 'Geistlich Pharma AG', 'GeneMedicine Co., Ltd.', 'GeneQuantum Healthcare (Suzhou) Co., Ltd.', 'Genelux Corporation', 'Genenta Science', 'General Oncology, Inc.', 'Genfit', 'Genfleet Therapeutics (Shanghai) Inc.', 'Genor Biopharma Co., Ltd.', 'Genprex, Inc.', 'Genrix (Shanghai) Biopharmaceutical Co., Ltd.', 'GeoVax, Inc.', 'George Washington University', 'Georgiamune Inc', 'German Cancer Research Center', 'German Oncology Center, Cyprus', 'German Society for Pediatric Oncology and Hematology GPOH gGmbH', 'Giselle Sholler', 'Glenn Bauman', 'Glenn J. Hanna', 'Global Coalition for Adaptive Research', 'Global Neurosciences Institute', 'GluBio Therapeutics Inc.', 'Gracell Biotechnologies Ltd.', 'Great Novel Therapeutics Biotech & Medicals Corporation', 'Great Ormond Street Hospital for Children NHS Foundation Trust', 'Greenwich LifeSciences, Inc.', 'Greg Durm, MD', 'Gregory Daniels', 'Grifols Therapeutics LLC', 'Grit Biotechnology', 'Groupe Francais De Pneumo-Cancerologie', 'Groupe Hospitalier Diaconesses Croix Saint-Simon', 'Groupe Oncologie Radiotherapie Tete et Cou', 'Grupo Espanol Multidisciplinario del Cancer Digestivo', 'Grupo Espanol de Investigacion en Sarcomas', 'Grupo Espanol de Tumores Neuroendocrinos', 'Grupo Español de Tratamiento de Tumores de Cabeza y Cuello', 'Gruppo Oncologico Italiano di Ricerca Clinica', \"Guang'anmen Hospital of China Academy of Chinese Medical Sciences\", 'Guangdong Association of Clinical Trials', 'Guangdong Ruishun Biotech Co., Ltd', 'Guangxi Medical University', 'Guangzhou Bio-gene Technology Co., Ltd', 'Guangzhou Excelmab Inc.', 'Guangzhou Institute of Respiratory Disease', 'Guangzhou Lupeng Pharmaceutical Company LTD.', 'Guangzhou University of Traditional Chinese Medicine', \"Guangzhou Women and Children's Medical Center\", 'Guerbet', 'Gulam Manji', 'Guo Xufeng', 'Gustav Stalhammar', 'Gut-Brain-Axis Therapeutics Inc.', 'Gynaecologisch Oncologisch Centrum Zuid', 'HRYZ Biotech Co.', 'HTA Co., Ltd.', 'HUYABIO International, LLC.', 'Hadassah Medical Organization', 'Haihe Biopharma Co., Ltd.', 'Halda Therapeutics OpCo, Inc.', 'Han weidong', 'Hangzhou Converd Co., Ltd.', 'Hangzhou GluBio Pharmaceutical Co., Ltd.', 'Hangzhou Hanx Biopharmaceuticals, Ltd.', 'Hangzhou Sumgen Biotech Co., Ltd.', 'Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.', 'Hanny Al-Samkari, MD', 'Hansoh BioMedical R&D Company', 'Hao Zeng', 'Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)', 'Harry H Yoon', 'Haukeland University Hospital', 'He Huang', 'HealthPartners Institute', 'Healthgen Biotechnology Corp.', 'Healx Limited', 'Hebei Medical University Fourth Hospital', 'Hebei Senlang Biotechnology Inc., Ltd.', 'Hecheng Li M.D., Ph.D', 'Hee Young Ju', 'Hefei TG ImmunoPharma Co., Ltd.', 'Heidelberg Pharma AG', 'Heinrich-Heine University, Duesseldorf', 'Hellenic Society of Hematology', 'Helsinki University Central Hospital', 'Helwan University', 'Hematology department of the 920th hospital', 'Hemerion Therapeutics', 'Hemogenyx Pharmaceuticals LLC', \"Henan Provincial People's Hospital\", 'Henrik Lindman', 'Henry Ford Health System', 'Herbert Lyerly', 'Heron Neutron Medical Corp.', 'Herui Yao', 'Hi-Q Marine Biotech International, Ltd.', 'HiFiBiO Therapeutics', 'HiberCell, Inc.', 'Hideho Okada, MD, PhD', 'Highlight Therapeutics', 'Hinova Pharmaceuticals Inc.', 'Hiroshima University Hospital', 'Hirva Mamdani', 'HitGen Inc.', 'Ho Joon Im', 'Ho Sup Lee', 'Hoag Memorial Hospital Presbyterian', 'Hokkaido University Hospital', \"Hong Kong Children's Hospital\", 'Hongmeng Yu', 'HonorHealth Research Institute', 'Hope Rugo, MD', 'Hopital Foch', 'Hospital Civil de Guadalajara', 'Hospital Israelita Albert Einstein', 'Hospital JP Garrahan', 'Hospital Municipal São José', 'Hospital Regional de Alta Especialidad del Bajio', 'Hospital San Carlos, Madrid', 'Hospital Universitario Doctor Peset', 'Hospital Universitario Dr. Jose E. Gonzalez', 'Hospital Universitario de Fuenlabrada', 'Hospital do Coracao', 'Hospital of Stomatology, Wuhan University', 'Howard S. Hochster, MD', 'Hrain Biotechnology Co., Ltd.', 'Hua Li', 'Hua Zhang', 'Huabo Biopharm Co., Ltd.', \"Huai'an First People's Hospital\", 'Huashan Hospital', 'Huazhong University of Science and Technology', 'Hubei Cancer Hospital', 'Huda Salman', 'Hui Zeng', 'Huihan Wang', 'Huihua Xiong', 'Huijing Wu', 'Huiqiang Huang', 'Hull University Teaching Hospitals NHS Trust', 'Hummingbird Bioscience', 'Hunan Cancer Hospital', 'Hôpital Franco-Britannique-Fondation Cognacq-Jay', 'I-Mab Biopharma US Limited', 'IDEAYA Biosciences', 'IDP Discovery Pharma S.L.', 'IDRx, Inc.', 'IFOM ETS - The AIRC Institute of Molecular Oncology', 'IO Biotech', 'IRCCS Azienda Ospedaliero-Universitaria di Bologna', 'ITM Solucin GmbH', 'Iacopo Sardi', 'Iambic Therapeutics, Inc', 'Ibrahim Halil Sahin', 'Ichnos Sciences SA', 'Ikena Oncology', 'Iksuda Therapeutics Ltd.', 'Il-Yang Pharm. Co., Ltd.', 'ImmPACT Bio', 'ImmVira Pharma Co. Ltd', 'ImmVirx Pty Ltd', 'Immatics Biotechnologies GmbH', 'Immatics US, Inc.', 'Immune Cell, Inc.', 'Immune Oncology Research Institute', 'Immune System Key Ltd', 'ImmuneOnco Biopharmaceuticals (Shanghai) Inc.', 'Immuneering Corporation', 'Immunitas Therapeutics', 'ImmunoGenesis', 'ImmunoVaccine Technologies, Inc. (IMV Inc.)', 'Immunocore Ltd', 'Immunolight, LLC', 'Impact Biotech Ltd', 'Imugene Limited', 'Imunon', 'InSightec', 'InSilico Medicine Hong Kong Limited', 'Incyclix Bio', 'Incyte Biosciences International Sàrl', 'Incyte Biosciences Japan GK', 'Indapta Therapeutics, INC.', 'Indaptus Therapeutics, Inc', 'Indonesia University', 'Inhibrx Biosciences, Inc', 'Inhye Ahn', 'Inmune Bio, Inc.', 'Inna Chen, MD', 'Innate Pharma', 'InnoCare Pharma Inc.', 'Innolake Biopharm', 'Innovative Cellular Therapeutics Inc.', 'Inova Health Care Services', 'Inspirna, Inc.', \"Institut Cancerologie de l'Ouest\", 'Institut Guttmann', 'Institut Paoli-Calmettes', 'Institut de cancérologie Strasbourg Europe', 'Institut fuer Frauengesundheit', 'Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest', 'Institute of Automation, Chinese Academy of Sciences', 'Institute of Hematology and Blood Transfusion, Czech Republic', 'Institute of Mother and Child, Warsaw, Poland', 'Institute of Oncology Ljubljana', 'Instituto Nacional de Cancer, Brazil', 'Instituto Nacional de Cancerologia de Mexico', 'Instituto Valenciano de Infertilidad, IVI VALENCIA', 'Instituto de Investigación Biomédica de Salamanca', 'Instituto de Investigación Hospital Universitario La Paz', 'Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic', 'Instituto do Cancer do Estado de São Paulo', 'Integro Theranostics', 'Intensity Therapeutics, Inc.', 'Interius BioTherapeutics Inc.', 'International Cancer Research Group, United Arab Emirates', 'International Extranodal Lymphoma Study Group (IELSG)', 'IntraGel Therapeutics', 'Intuitive Surgical', 'InxMed (Shanghai) Co., Ltd.', 'Ioannis Mantzaris', 'Ionis Pharmaceuticals, Inc.', 'Iovance Biotherapeutics, Inc.', 'Ira Winer', 'Irene Ghobrial, MD', 'Irish Research Radiation Oncology Group', 'Israeli Medical Association', 'Istituto Oncologico Veneto IRCCS', 'Istituto Ortopedico Rizzoli', 'Italian Sarcoma Group', 'Ivan de Kouchkovsky, MD', 'Ivy Brain Tumor Center', 'Izidore Lossos, MD', 'J Ints Bio', 'JS InnoPharm, LLC', 'Jacob Laubach, MD', 'Jacob Soumerai, MD', 'Jacobio Pharmaceuticals Co., Ltd.', 'Jacqueline Garcia, MD', 'Jae Wook Lee', 'Jagiellonian University', 'Jakob Stenman', 'James Brugarolas', 'James Cleary, MD, PhD', 'James Felker', 'James Isaacs, MD', 'James Rubenstein', 'Janux Therapeutics', 'Japan Breast Cancer Research Group', 'Japanese Gynecologic Oncology Group', 'Jason J. Luke, MD', 'Javier Villaneuva-Meyer, MD', 'Jeanette Lundin', 'Jemincare', 'JenKem Technology Co., Ltd.', 'Jennifer Crombie, MD', 'Jennifer King', 'JiaRay Group', 'Jian Chen', 'Jian Guan', 'Jian Li', 'Jiang Feng', 'Jiang Long', 'Jiangsu Alphamab Biopharmaceuticals Co., Ltd', 'Jiangsu Aosaikang Pharmaceutical Co., Ltd.', 'Jiangsu Cancer Institute & Hospital', 'Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.', 'Jiangsu Famous Medical Technology Co., Ltd.', 'Jiangsu Hansoh Pharmaceutical Co., Ltd.', 'Jiangsu Healthy Life Innovation Medical Technology Co., Ltd', 'Jiangsu Province Nanjing Brain Hospital', 'Jiangsu Simcere Biologics Co., Ltd', 'Jiangsu Simcere Pharmaceutical Co., Ltd.', 'Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.', 'Jiangsu Yahong Meditech Co., Ltd aka Asieris', 'Jiangxi Provincial Cancer Hospital', 'Jianhui Tian', 'Jianjun Yang,MD', 'Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.', 'Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.', 'Jin Ying', 'Jing Jin, M.D.', 'Jing-yuan Fang, MD, Ph. D', 'Jinghui Wang', 'Jinhua Central Hospital', 'Jinling Hospital, China', 'Jinming Yu', 'Jiping Wang, MD, PhD', 'Jiuda Zhao', 'Joachim Aerts, MD PhD', 'Joachim Zdolsek', 'John Lister', 'John Reneau', 'John Rieth', 'John Sfakianos', 'John Yu', 'Johnpro Biotech, Inc.', \"Johns Hopkins All Children's Hospital\", 'Johnson & Johnson Enterprise Innovation Inc.', 'Jon Unosson', 'Jonathan Brammer', 'Jonathan Schoenfeld, MD, MPH', 'Jose Pablo Leone', 'Joseph J. Cullen, MD, FACS', 'Joseph Jurcic', 'Joseph Sparano', 'Joseph Tuscano', 'Joshua Palmer', 'Joshua Sasine, MD, PhD', 'Joshua Zeidner', 'Juan Du', 'Juan LI, MD', 'Juan P. Alderuccio, MD', 'Jubaan Ltd.', 'Jubilant DraxImage Inc.', 'Judit Pich Martínez', 'Judith Dixon-Hughes', 'Julie Gehl', 'Jun Huang', 'Jun-Lin Yi, MD', 'Juno Therapeutics, Inc., a Bristol-Myers Squibb Company', 'Juno Therapeutics, a Subsidiary of Celgene', 'Juventas Cell Therapy Ltd.', 'Jørgen Bjerggaard Jensen', 'K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc', 'K36 Therapeutics, Inc.', \"KK Women's and Children's Hospital\", 'KU Leuven', 'Kahr Medical', 'KaliVir Immunotherapeutics', 'Kamya Sankar', 'Kaohsiung Medical University Chung-Ho Memorial Hospital', 'Kara Romano, MD', 'Kara Yakhteh Tajhiz Azma Company', 'Karen Ballen, MD', 'Karen Carty', 'Karen Reckamp, MD, MS', 'Karen-Lise Garm Spindler', 'Kari Kendra', 'Kari Wisinski', 'Karolinska Institutet', 'Kartos Therapeutics, Inc.', 'Kathy Miller', 'Keimyung University Dongsan Medical Center', 'Keio University', 'Kenny Rodriguez-Wallberg', 'Keros Therapeutics, Inc.', 'Kerry Rogers', 'Keymed Biosciences Co.Ltd', 'Kibo Nam', 'Kim, Seok Jin', 'Kind Pharmaceuticals LLC', 'Kindai University', 'Kineta Inc.', 'King Abdullah Medical City', 'King Chulalongkorn Memorial Hospital', 'King Faisal Specialist Hospital & Research Center', 'King Saud University', \"King's College London\", 'Kintara Therapeutics, Inc.', 'Kiromic BioPharma Inc.', 'Kirsten Grønbæk', 'Klinikum Stuttgart', 'Klus Pharma Inc.', 'Kochi University', 'Konkuk University Medical Center', 'Koo Foundation Sun Yat-Sen Cancer Center', 'Korea Institute of Oriental Medicine', 'Korea University Guro Hospital', 'Kristen Ganjoo', 'Kristoffer Rohrberg', 'Krystal Biotech, Inc.', 'Kumquat Biosciences Inc.', 'Kura Oncology, Inc.', 'Kurt Weiss', 'Kuwait Cancer Control Center', 'Kyoto University Hospital', 'Kyowa Kirin China Pharmaceutical Co., Ltd.', 'Kyungpook National University Hospital', 'Kyushu University', 'L & L biopharma Co., Ltd., Shanghai China', 'L. Nicolas Gonzalez Castro, MD, PhD', 'LG Chem', 'LI XIN-XIANG', 'LLS PedAL Initiative, LLC', 'LaNova Medicines Limited', 'LaNova Medicines Zhejiang Co., Ltd.', 'Laboratorio Elea Phoenix S.A.', 'Laekna Limited', 'Lahey Clinic', 'Lai-ping Zhong', 'Lakshmi Nayak, MD', 'Laminar Pharmaceuticals', 'Lan Coffman', 'Lantern Pharma Inc.', 'Lantheus Medical Imaging', 'Lapo Alinari', 'Larysa Sanchez', 'Latin American Cooperative Oncology Group', 'Laura M. Spring, MD', 'Lazaros Lekakis', 'Lebanese University', 'Legend Biotech USA Inc', 'Lei Jiang', 'Lei Li', 'Lei Liu', 'Lei ZHAO', 'Leland Metheny', 'Li Zhang', 'Li Zhang, MD', 'Li Zhiming', 'Li-kun Chen', 'Light Chain Bioscience - Novimmune SA', 'Liling Zhang', 'Lindsay Ferguson, MD', 'Lisata Therapeutics, Inc.', 'Lithuanian University of Health Sciences', 'Liu Huang', 'Lixia Sheng', 'Lixte Biotechnology Holdings, Inc.', 'Loma Linda University', 'Loren Mell, MD', 'Loxo Oncology, Inc.', 'Lu Shun', 'Lu Wang, MD, PhD', 'Ludwig-Maximilians - University of Munich', 'Lumicell, Inc.', 'Luminary Therapeutics', 'Lutris Pharma Ltd.', 'Luye Pharma Group Ltd.', 'Lyvgen Biopharma Holdings Limited', 'M.R. Meijerink', 'MARILIA ALBANEZI BERTOLAZZI', 'MBQ Pharma', 'MEI Pharma, Inc.', 'MOMA Therapeutics', 'Maastricht University Medical Center', 'Mabscale, LLC', 'Mabwell (Shanghai) Bioscience Co., Ltd.', 'Malaghan Institute of Medical Research', 'Mamta Parikh', 'Mansoura University', 'MapKure, LLC', 'Mara Veenstra, MD', \"Marc Dall'Era, MD\", 'Marc de Perrot', 'Marcela V. Maus, M.D.,Ph.D.', 'March Biosciences Inc', 'Marco Lorenzo Bonu', 'Marco Oderda', 'Margaret Gatti-Mays', 'Margarita Louise Zuley', 'Maria Sklodowska-Curie National Research Institute of Oncology', 'Marina N Sharifi', 'Mark Stein', 'Mark Vincent', 'Marker Therapeutics, Inc.', 'Marlise Luskin, MD', 'Martha Mims', 'Martin Schrappe', 'Mary D Chamberlin', 'Marzieh Ebrahimi', 'Masahiro Tsuboi', 'Massachusetts Eye and Ear Infirmary', 'Matrix Biomed, Inc.', 'Mats Heyman', 'Maximilian Diehn', 'Maximilian Stahl, MD', 'Mayur Narkhede', 'Mclean Hospital', 'Med Discovery SA', 'MedPacto, Inc.', 'Meddoc', 'MediLink Therapeutics (Suzhou) Co., Ltd.', 'Medical University Innsbruck', 'Medical University of Gdansk', 'Medical University of Graz', 'Medical University of Silesia', 'Medicenna Therapeutics, Inc.', 'Medigen Biotechnology Corporation', 'Medolution Ltd.', 'Megan Daly, MD', 'Meghan Shea', 'Mehrdad Abedi, MD', 'Meir Medical Center', 'Melanie Hayden Gephart', 'Melanoma Institute Australia', 'Melanoma and Skin Cancer Trials Limited', 'Melbourne Health', 'Melissa Pugliano-Mauro', 'Memgen, Inc.', 'Meng Qiu', 'Menoufia University', 'Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany', 'Mercy Health System', 'Mersana Therapeutics', 'Merus N.V.', 'Meryx, Inc.', 'Michael B. Atkins, MD', 'Michael Bau Mortensen', 'Michael Burke', 'Michael Hopp', 'Michael K. Gibson', 'Michael McHale', 'Michael Topf', 'Michael Wagner, MD', 'Michelle S Ludwig', 'Microbiotica Ltd', 'MidLantic Urology', 'Mikkael Sekeres, MD', 'Miltenyi Biomedicine GmbH', 'Min Yan, MD', 'Minerva Biotechnologies Corporation', 'Ming-Yuan Chen', 'Mingzhi Zhang', 'Minia University', 'Minneamrita Therapeutics LLC', 'Minovia Therapeutics Ltd.', 'Miriam Elfström', 'Mirror Biologics, Inc.', 'Mitchell Cairo', 'MitoImmune Therapeutics', 'Mitsubishi Tanabe Pharma Corporation', 'ModeX Therapeutics, An OPKO Health Company', 'ModernaTX, Inc.', 'Modulation Therapeutics, Inc.', 'Molecular Partners AG', 'Molecular Targeting Technologies, Inc.', 'Molecure S.A.', 'Monash University', 'Monopar Therapeutics', 'Monte Rosa Therapeutics, Inc', 'Morten Ladekarl', 'Mridula George, MD', 'Muhammad Furqan', 'Multiple Myeloma Research Consortium', 'Multitude Therapeutics Inc.', 'Mural Oncology, Inc', 'Mustafa Khasraw, MBChB, MD, FRCP, FRACP', 'Myeloid Therapeutics', 'Mythic Therapeutics', 'N.N. Petrov National Medical Research Center of Oncology', 'NATCO Pharma Ltd.', 'NEC Bio B.V', 'NOBO Medicine', 'NX Development Corp', 'Nabil Adra', 'Nader Sadeghi', 'Nagoya City University', 'Nagoya University', 'Nammi Therapeutics Inc', 'Nancy Ann Oberheim Bush, MD', 'Nanjing Chia-tai Tianqing Pharmaceutical', \"Nanjing Children's Hospital\", 'Nanjing First Hospital, Nanjing Medical University', 'Nanjing IASO Biotechnology Co., Ltd.', 'Nanjing Leads Biolabs Co.,Ltd', 'Nanjing Legend Biotech Co.', 'Nanjing Medical University', 'Nanjing Sanhome Pharmaceutical, Co., Ltd.', 'Nanjing Yoko Biomedical Co., Ltd.', 'NanoEcho AB', 'NanoMab Technology (UK) Limited', 'NanoPharmaceuticals LLC', 'NanoRay Biotech Co., Ltd.', 'Nanobiotix', 'Nasser Hanna', 'Natalie Lockney', 'Nataliya Uboha', 'Nathan Denlinger', 'National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos', 'National Cancer Center Hospital East', 'National Cancer Center, China', 'National Cancer Center, Japan', 'National Cheng-Kung University Hospital', 'National Hepatology & Tropical Medicine Research Institute', 'National Hospital Organization Nagoya Medical Center', 'National Institute of Cancerología', 'National Institute of Neurological Disorders and Stroke (NINDS)', 'National Institute on Deafness and Other Communication Disorders (NIDCD)', 'National Research Center for Hematology, Russia', 'National University of Malaysia', 'NaviFUS Corporation', 'Navy General Hospital, Beijing', 'Nectin Therapeutics Ltd', 'NeoImmuneTech', 'Neogap Therapeutics AB', 'Neonc Technologies, Inc.', 'Nerissa T. Viola', 'Nerviano Medical Sciences', 'Nested Therapeutics, Inc', 'New Approaches to Neuroblastoma Therapy Consortium', 'Newave Pharmaceutical Inc', 'Newish Technology (Beijing) Co., Ltd.', 'NextCure, Inc.', 'NextPoint Therapeutics, Inc.', 'NiKang Therapeutics, Inc.', 'Nicholas Butowski', 'Nicholas DeVito, MD', 'Nicola Goekbuget', 'Niels Junker', 'Nihon Medi-Physics Co., Ltd.', 'Niigata University Medical & Dental Hospital', 'Nikolaj Frost MD', 'Ningbo No. 1 Hospital', 'Nir Peled', 'Noah Hahn, M.D.', 'Nordic Lymphoma Group', 'Nordic Society of Gynaecological Oncology - Clinical Trials Unit', 'Norman J. Lacayo', 'Norroy Bioscience Co., LTD', 'North American Consortium for Histiocytosis', 'North Eastern German Society of Gynaecological Oncology', 'North Estonia Medical Centre', 'North Florida Foundation for Research and Education', \"Northern Jiangsu People's Hospital\", 'Northside Hospital, Inc.', 'Norwegian University of Science and Technology', 'Nova Therapeutics LLC', 'NovaGo Therapeutics AG', 'NovaRock Biotherapeutics, Ltd', 'NovalGen Ltd.', 'Novatim Immune Therapeutics (Zhejiang) Co., Ltd.', 'Novelty Nobility, Inc.', 'Novelwise Pharmaceutical Corporation', 'NovoCure GmbH', 'NuCana plc', 'Numab Therapeutics AG', 'Nurix Therapeutics, Inc.', 'NuvOx LLC', 'Nuvalent Inc.', 'Nuvation Bio Inc.', 'Nuvectis Pharma, Inc.', 'Nykode Therapeutics ASA', 'OBI Pharma, Inc', 'ORIC Pharmaceuticals', 'OSE Immunotherapeutics', 'OX2 Therapeutics', 'Oana Danciu', 'Obsidian Therapeutics, Inc.', 'Ocellaris Pharma, Inc.', 'Odense University Hospital', 'Okayama University', 'Olema Pharmaceuticals, Inc.', 'Olivera Finn', 'Olivia Newton-John Cancer Research Institute', 'Omar Nadeem, MD', 'OnCusp Therapeutics, Inc.', 'OnKure, Inc.', 'OncoC4, Inc.', 'OncoNano Medicine, Inc.', 'OncoResponse, Inc.', 'OncoSil Medical Limited', 'OncoVerity, Inc.', 'Oncoinvent AS', 'Oncology Institute of Southern Switzerland', 'Oncology Institute of Vojvodina', 'Onconic Therapeutics Inc.', 'Oncorena AB', 'Oncotelic Inc.', 'Oncotherapeutics', 'Oncovir, Inc.', 'OneChain Immunotherapeutics', 'Ono Pharmaceutical Co. Ltd', 'Opna Bio LLC', 'Orano Med LLC', 'Orbus Therapeutics, Inc.', 'Orca Biosystems, Inc.', 'Oregon Health and Science University', 'Orexa BV', 'Orhan Kemal Oz', 'OriCell Therapeutics Co., Ltd.', 'Oryzon Genomics S.A.', 'Osaka University', 'Osel, Inc.', 'Ospedale Policlinico San Martino', 'Ospedale San Raffaele', 'Ossium Health, Inc.', 'Otsuka Beijing Research Institute', 'Otsuka Pharmaceutical Co., Ltd.', 'Owlstone Ltd', 'Oxford Vacmedix UK Ltd.', 'PMV Pharmaceuticals, Inc', 'POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company', 'Pacylex Pharmaceuticals', 'Panagiotis Konstantinopoulos, MD, PhD', 'Panbela Therapeutics, Inc.', 'Panolos Bioscience', 'Paolo Caimi, MD', 'Paolo Ghia', 'Parabilis Medicines, Inc.', 'Pathos AI, Inc.', 'Patrick C. Johnson, MD', 'Patrick Dillon, MD', 'Patrick Wen, MD', 'Paul Szabolcs', 'Pei-Rong Ding', 'Peking Union Medical College', 'Peking University First Hospital', 'Peking University Hospital of Stomatology', 'Pell Bio-Med Technology Co., Ltd.', 'Peng Liu', 'Peng Zhang', 'Pengyuan Liu', 'Pennington Biomedical Research Center', 'Pentixapharm AG', 'PeproMene Bio, Inc.', 'Peptomyc S.L.', 'PersonGen BioTherapeutics (Suzhou) Co., Ltd.', 'Perspective Therapeutics', 'Peter Busch Østergren', 'Peter H. Yang', 'Peter Siesjö', 'Phanes Therapeutics', 'PharmAbcine', 'PharmaEngine', 'Pharmbio Korea Co., Ltd.', 'Pheon Therapeutics', 'Phio Pharmaceuticals Inc.', 'Phoenix Molecular Designs', \"Phost'In Therapeutics\", 'Photolitec LLC', 'Pierre Fabre Medicament', 'Pingping Song', 'Plus Therapeutics', 'PlusVitech S.L.', 'Poitiers University Hospital', 'Polaris Group', 'Polly A. Niravath, MD', 'Population Health Research Institute', 'Poseida Therapeutics, Inc.', 'Post Graduate Institute of Medical Education and Research, Chandigarh', 'Prakash Pandalai', 'Pravin T.P Kaumaya', 'Precigen, Inc', 'Precision Biologics, Inc', 'Precision Biotech Taiwan Corp.', 'Prelude Therapeutics', 'Prestige Biopharma Limited', 'Princess Maxima Center for Pediatric Oncology', 'Prisma Health-Upstate', 'Privo Technologies', 'ProDa BioTech, LLC', 'Processa Pharmaceuticals', 'Prof. Dr. Christiane Matuschek', 'Prof. Dr. M. Dreyling (co-chairman)', 'Prof. Dr. med. Christian Gratzke', 'Prof. Janet Dunn', 'Prof. Johann Bauer', 'Prof. Wolfgang Janni', 'Professor Klaus Bønnelykke', 'ProfoundBio US Co.', 'Prokarium Ltd', 'Protara Therapeutics', 'Proton Collaborative Group', 'Proviva Therapeutics, Inc.', 'Psivac Ltd', 'PureTech', 'QBiotics Group Limited', 'QSAM Therapeutics, Inc.', 'Qian Chu', 'Qian Qin', 'Qianfoshan Hospital', 'Qilu Hospital of Shandong University', 'Qilu Pharmaceutical Co., Ltd.', 'Qingdao Central Hospital', 'Qinghai Red Cross Hospital', 'Qiu Lugui', 'Quanli Gao', 'QuantumLeap Healthcare Collaborative', 'Queen Mary Hospital, Hong Kong', 'Queensland Centre for Gynaecological Cancer', 'Queensland Health', 'Queensland Institute of Medical Research', 'QureBio Ltd.', 'Qurgen Inc.', 'Qurient Co., Ltd.', 'RDC Clinical Pty Ltd', 'RS Oncology LLC', 'RTOG Foundation, Inc.', 'Ractigen Therapeutics.', 'Radionetics Oncology', 'Rahem Fertility Center', 'Rahul Aggarwal', 'Rajiv Gandhi Cancer Institute & Research Center, India', 'Rakuten Medical, Inc.', 'Ralf Hofheinz', 'Rana McKay, MD', 'Rapa Therapeutics LLC', 'Rapamycin Holdings, Inc. dba Emtora Biosciences', 'RasCal Therapeutics, Inc.', 'Ravi Amaravadi, MD', 'RayzeBio, Inc.', 'Recursion Pharmaceuticals Inc.', 'RedCloud Bio', 'Reema A. Patel', 'Regina Elena Cancer Institute', 'Region Skane', 'Region Västerbotten', 'Region Örebro County', 'Regor Pharmaceuticals Inc.', 'Reid Merryman, MD', 'Reinier de Graaf Groep', 'Relay Therapeutics, Inc.', 'Remix Therapeutics', 'Renmin Hospital of Wuhan University', 'RenovoRx', 'Replimune Inc.', 'Reshma L. Mahtani, D.O.', 'Reveal Pharmaceuticals Inc.', 'Revolution Medicines, Inc.', 'Rgenta Therapeutics Inc', 'Rhizen Pharmaceuticals SA', 'Riboscience, LLC.', 'Rigel Pharmaceuticals', 'Rise Biopharmaceuticals, Inc.', 'Risen (Suzhou) Pharma Tech Co., Ltd.', 'Rita Assi', 'Robert Bok, MD, PhD', 'Robert Edwards', 'Robert Flavell, MD, PhD', 'Rocky Mountain Cancer Centers', 'Ronald Buckanovich', 'Rong Tao', 'Rongrong Zhou', 'Rottapharm Biotech', 'Russian Society of Colorectal Surgeons', 'Ruta Arays', \"Ruth O'Regan\", 'Ryan Carey', 'Ryan Gentzler, MD', 'Ryan Stephenson', 'Ryvu Therapeutics SA', 'Rznomics, Inc.', 'SBI ALApharma Canada, Inc.', 'SIRPant Immunotherapeutics, Inc.', 'SL VAXiGEN', 'SOFIE', 'STCube, Inc.', 'SUNHO（China）BioPharmaceutical CO., Ltd.', 'SURGE Therapeutics', 'Sabine Mueller, MD, PhD', 'Sacramento Pediatric Gastroenterology', 'Sahiwal medical college sahiwal', 'Sahlgrenska University Hospital', \"Saint John's Cancer Institute\", 'Saint Petersburg State University, Russia', 'Salubris Biotherapeutics Inc', 'Salzburger Landeskliniken', 'Samsung Bioepis Co., Ltd.', 'Samuel Achilefu', 'Sana Biotechnology', 'Sandoz', 'Sanjay Mohan', 'Sapience Therapeutics', 'Sarah K. Lynam MD', 'Sarah Sammons, MD', 'Sarcoma Alliance for Research through Collaboration', 'Sarcoma Oncology Research Center, LLC', 'Sarit Assouline', 'Sawa Ito, MD', 'Scancell Ltd', 'Schrödinger, Inc.', 'SciTech Development, Inc.', 'Sclnow Biotechnology Co., Ltd.', 'Scorpion Therapeutics, Inc.', 'Scott Antonia', 'Scott Steele', 'Scripps Health', 'Seagen, a wholly owned subsidiary of Pfizer', \"Seattle Children's Hospital\", 'Second Affiliated Hospital of Guangzhou Medical University', 'Second Affiliated Hospital of Soochow University', 'Second Affiliated Hospital of Wenzhou Medical University', \"Second Affiliated Hospital of Xi'an Jiaotong University\", 'Second Affiliated Hospital of Zunyi Medical University', 'Second Hospital of Shanxi Medical University', 'Second Xiangya Hospital of Central South University', 'Seema Bhat', 'Sensei Biotherapeutics, Inc.', 'Seoul National University Bundang Hospital', 'Sermonix Pharmaceuticals Inc.', 'Servicio de Salud Metropolitano Sur Oriente', 'Servier', 'Servier Affaires Médicales', 'Servier Bio-Innovation LLC', 'Sham Sunder Kakar', 'Shandong Boan Biotechnology Co., Ltd', 'Shandong New Time Pharmaceutical Co., LTD', 'Shandong Suncadia Medicine Co., Ltd.', 'Shandong University', \"Shanghai 6th People's Hospital\", 'Shanghai AbelZeta Ltd.', 'Shanghai Bovax Biotechnology Co., Ltd.', 'Shanghai Cancer Hospital, China', 'Shanghai Cell Therapy Group Co.,Ltd', 'Shanghai Changzheng Hospital', 'Shanghai Chest Hospital', \"Shanghai Children's Medical Center\", 'Shanghai East Hospital', 'Shanghai EpimAb Biotherapeutics Co., Ltd.', 'Shanghai Escugen Biotechnology Co., Ltd', 'Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.', 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.', 'Shanghai Gynecologic Oncology Group', 'Shanghai Hengrui Pharmaceutical Co., Ltd.', 'Shanghai Huaota Biopharmaceutical Co., Ltd.', 'Shanghai Institute Of Biological Products', 'Shanghai JMT-Bio Inc.', \"Shanghai Jiao Tong University Affiliated Sixth People's Hospital\", 'Shanghai Jiaolian Drug Research and Development Co., Ltd', 'Shanghai Juncell Therapeutics', 'Shanghai Kanda Biotechnology Co., Ltd.', 'Shanghai Kechow Pharma, Inc.', 'Shanghai Ming Ju Biotechnology Co., Ltd.', 'Shanghai Minimally Invasive Surgery Center', 'Shanghai Miracogen Inc.', \"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University\", 'Shanghai Pharmaceuticals Holding Co., Ltd', 'Shanghai Proton and Heavy Ion Center', 'Shanghai Pudong Hospital', 'Shanghai Runshi Pharmaceutical Technology Co., Ltd', 'Shanghai Simnova Biotechnology Co.,Ltd.', 'Shanghai Tong Ren Hospital', 'Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd', 'Shanghai Yizhong Pharmaceutical Co., Ltd.', 'Shanghai Zhongshan Hospital', 'Shanxi Bethune Hospital', 'Shanxi Province Cancer Hospital', 'Shaogang Wang', 'Shaw Cancer Center', 'Shayan Moosa, MD', 'Shen Lin', 'Sheng-Li Xue, MD', 'Shengjing Hospital', 'Shengke Pharmaceuticals (Jiangsu) Limited, China', 'Shenzhen Celconta Life Science Co., Ltd.', 'Shenzhen Geno-Immune Medical Institute', 'Shenzhen Hospital of Southern Medical University', 'Shenzhen Ionova Life Sciences Co., Ltd.', \"Shenzhen Second People's Hospital\", 'Shenzhen TargetRx, Inc.', 'Shenzhen University General Hospital', 'Shenzhen Yangli Pharmaceutical Technology Co., Ltd', 'Sheppard Pratt Health System', 'Sherief Abd-Elsalam', 'Sherrif Ibrahim', 'Shi Ming', 'Shijiazhuang Yiling Pharmaceutical Co. Ltd', 'Shinshu University', 'Shouyao Holdings (Beijing) Co. LTD', 'Shuhong Yi', 'Shuttle Pharmaceuticals, Inc.', 'Shyam S.D. Rao', 'Sichuan Cancer Hospital and Research Institute', 'Sichuan Enray Pharmaceutical Sciences Company', 'Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.', 'Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.', \"Sichuan Provincial People's Hospital\", 'SignPath Pharma, Inc.', 'SignalChem Lifesciences Corporation', 'SillaJen, Inc.', 'Simcha IL-18, Inc.', 'Sinocelltech Ltd.', 'Sinotau Pharmaceutical Group', 'Sir Mortimer B. Davis - Jewish General Hospital', 'Sir Run Run Shaw Hospital', 'Siriraj Hospital', 'Sixth Affiliated Hospital, Sun Yat-sen University', 'SkinJect, Inc.', 'Sol-Gel Technologies, Ltd.', 'Soligenix', 'Songqi Gao', 'Sonnet BioTherapeutics', 'Sonya Reid', 'Soroka University Medical Center', 'Sorrento Therapeutics, Inc.', 'Sotio Biotech Inc.', 'Spago Nanomedical AB', 'Spanish Oncology Genito-Urinary Group', 'SpectraCure AB', 'SpringWorks Therapeutics, Inc.', 'St George Hospital, Australia', \"St George's, University of London\", \"St Vincent's Hospital\", \"St Vincent's Hospital, Sydney\", 'St. Anna Kinderkrebsforschung', \"St. Joseph's Healthcare Hamilton\", \"St. Joseph's Hospital and Medical Center, Phoenix\", 'St. Louis University', 'St. Olavs Hospital', 'Stamford Pharmaceuticals, Inc.', 'Starton Therapeutics, Inc', 'State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia', 'State Key Laboratory of Respiratory Disease', 'State University of New York - Downstate Medical Center', 'State University of New York at Buffalo', 'Steba Biotech S.A.', 'Stefan Carlsson', 'Step Pharma, SAS', 'Stephan Grupp MD PhD', 'Stephen Bagley, MD, MSCE', 'Stephen Freedland', 'Stichting European Myeloma Network', 'Stichting Hemato-Oncologie voor Volwassenen Nederland', 'Stingray Therapeutics', 'Stony Brook University', 'Sumithira Vasu', 'Summit Therapeutics', 'Sung Yong Lee', 'Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.', 'Sunshine Lake Pharma Co., Ltd.', 'Suping ZHANG', 'Surgimab', 'Susan Chang', 'Susan Chi, MD', 'Sutro Biopharma, Inc.', 'Suzhou BlueHorse Therapeutics Co., Ltd.', 'Suzhou Genhouse Bio Co., Ltd.', 'Suzhou Immunofoco Biotechnology Co., Ltd', 'Suzhou Junjing BioSciences Co., Ltd.', 'Suzhou Maximum Bio-tech Co., Ltd.', 'Suzhou Municipal Hospital', 'Suzhou Puhe Pharmaceutical Technology Co., LTD', 'Suzhou Zanrong Pharma Limited', 'Sven Löffeler', 'Swiss GO Trial Group', 'Swiss Pediatric Oncology Group', 'SymBio Pharmaceuticals', 'SynDevRx, Inc.', 'Syncromune, Inc.', 'Synthekine', 'Syntrix Biosystems, Inc.', 'Syros Pharmaceuticals', 'SystImmune Inc.', 'TC Biopharm', 'TILT Biotherapeutics Ltd.', 'TJ Biopharma Co., Ltd.', 'TORL Biotherapeutics, LLC', 'TScan Therapeutics, Inc.', 'TVAX Biomedical', 'TYK Medicines, Inc', 'Taivex Therapeutics Corporation', \"Taixing People's Hospital\", 'Taizhou Hospital', 'Tampere University Hospital', 'Tang-Du Hospital', 'Tango Therapeutics, Inc.', 'Tanja Andrea Gruber', 'Tanta University', 'Taofeek Owonikoko', 'Tarapeutics Science Inc.', 'Targeted Therapy Technologies, LLC', 'Tasly Pharmaceutical Group Co., Ltd', 'Tata Memorial Centre', 'Tata Memorial Hospital', 'Tayu Huaxia Biotech Medical Group Co., Ltd.', 'Tcelltech Inc.', 'Technical University of Munich', 'Teclison Ltd.', 'Tel-Aviv Sourasky Medical Center', 'Teligene US', 'Telix Pharmaceuticals (Innovations) Pty Limited', 'Telix Pharmaceuticals (Innovations) Pty Ltd', 'TeneoOne Inc.', 'Terns, Inc.', 'Texas Tech University Health Sciences Center', 'The Affiliated Hospital of Qingdao University', 'The Affiliated Hospital of Xuzhou Medical University', 'The Affiliated Hospital of the Chinese Academy of Military Medical Sciences', 'The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School', \"The Affiliated People's Hospital of Ningbo University\", 'The Canadian College of Naturopathic Medicine', 'The Center for Clinical and Cosmetic Research', 'The Central and Eastern European Gynecologic Oncology Group', \"The Children's Hospital of Zhejiang University School of Medicine\", 'The Christie NHS Foundation Trust', 'The First Affiliated Hospital of Bengbu Medical University', 'The First Affiliated Hospital of Guangzhou Medical University', 'The First Affiliated Hospital of Nanchang University', 'The First Affiliated Hospital of Zhengzhou University', 'The First Hospital of Jilin University', \"The First People's Hospital of Lianyungang\", 'The Fourth Affiliated Hospital of Zhejiang University School of Medicine', 'The General Hospital of Western Theater Command', 'The Institute of Molecular and Translational Medicine, Czech Republic', 'The Second Affiliated Hospital of Shandong First Medical University', 'The Second Hospital of Nanjing Medical University', 'The Third Affiliated Hospital of Southern Medical University', 'The Third Affiliated hospital of Zhejiang Chinese Medical University', 'The University of Hong Kong', 'TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics', 'Theodor Bilharz Research Institute', 'Theodore S. Johnson', 'Theolytics Limited', 'TheraOp', 'Theragnostics Ltd', 'Theralase® Technologies Inc.', 'Therapex Co., Ltd', 'Theratechnologies', 'Theravectys S.A.', 'Theresa Jacob, PhD, MPH', 'Third Affiliated Hospital, Sun Yat-Sen University', 'Third Military Medical University', 'Thomas Ernst, PD Dr. med.', 'Thomas Helleday Foundation', 'Thomas Hope', 'Thomas Marron', 'Three Gorges Hospital of Chongqing University', 'Tian Xie', 'Tianhong Li', 'Tianjin Hemay Pharmaceutical Co., Ltd', 'Tianjin Medical University General Hospital', 'Tianjin Medical University Second Hospital', 'Timothy Voorhees', 'TiumBio Co., Ltd.', 'ToLymph Inc.', 'Tokyo Medical and Dental University', 'Tolmar Inc.', 'Tomsk National Research Medical Center of the Russian Academy of Sciences', 'Tong Chen, MD', 'Tongji Hospital', 'Tongji University', 'TopAlliance Biosciences', 'Toragen, Inc.', 'Toray Industries, Inc', 'Totus Medicines', 'Tr1X, Inc.', 'Trans Tasman Radiation Oncology Group', 'TransThera Sciences (Nanjing), Inc.', 'Transgene', 'Treadwell Therapeutics, Inc', 'Treeline Biosciences, Inc.', 'Trigone Pharma Ltd.', 'Trisha Wise-Draper', 'Tubulis GmbH', 'Turku University Hospital', 'Turning Point Therapeutics, Inc.', 'Tvardi Therapeutics, Incorporated', 'Tyler Seibert', 'Tyligand Bioscience (Shanghai) Limited', 'Tyra Biosciences, Inc', 'UTC Therapeutics Inc.', 'Udai Kammula', 'Ukrainian Society of Clinical Oncology', 'Uma Borate', 'Umeå University', 'Umoja Biopharma', 'United States Naval Medical Center, Portsmouth', 'Universidad de Colima', 'Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude', 'University Hopsital Schleswig Holstein Campus Lübeck', 'University Hospital Freiburg', 'University Hospital Southampton NHS Foundation Trust', 'University Hospital, Akershus', 'University Hospital, Angers', 'University Hospital, Antwerp', 'University Hospital, Brest', 'University Hospital, Caen', 'University Hospital, Clermont-Ferrand', 'University Hospital, Essen', 'University Hospital, Geneva', 'University Hospital, Linkoeping', 'University Hospital, Montpellier', 'University Hospitals Bristol and Weston NHS Foundation Trust', 'University Medical Centre Maribor', 'University of Aleppo', 'University of Campania Luigi Vanvitelli', 'University of Campinas, Brazil', 'University of Crete', 'University of Giessen', 'University of Guadalajara', 'University of Heidelberg Medical Center', 'University of Leeds', 'University of Leipzig', 'University of Liege', 'University of Malaya', 'University of Milano Bicocca', 'University of Missouri-Columbia', 'University of Rochester NCORP Research Base', 'University of Saskatchewan', 'University of Southampton', 'University of Thessaly', 'University of Turin, Italy', 'Universität Münster', 'Universität des Saarlandes', 'Université de Sherbrooke', 'Uppsala University', 'UroGen Pharma Ltd.', 'VA Ann Arbor Healthcare System', 'VA Greater Los Angeles Healthcare System', 'VBI Vaccines Inc.', 'VM Oncology, LLC', 'Vadim S Koshkin', 'Vaishalee Kenkre', 'Valent Technologies, LLC', 'Valerio Therapeutics', \"Vall d'Hebron Institute of Oncology\", 'Valo Therapeutics Oy', 'Vasgene Therapeutics, Inc', 'Vastra Gotaland Region', 'Vector Vitale LLC', 'Verastem, Inc.', 'Vergent Bioscience, Inc.', 'Verismo Therapeutics', 'Verity Pharmaceuticals Inc.', 'Veronica Morgan Jones', 'Veronika Bachanova', 'Vestre Viken Hospital Trust', 'Vincerx Pharma, Inc.', 'Vinmec Research Institute of Stem Cell and Gene Technology', 'Virogin Biotech Canada Ltd', 'Vironexis Biotherapeutics Inc.', 'Vittoria Biotherapeutics', 'Vivace Therapeutics, Inc', 'Volastra Therapeutics, Inc.', 'Vor Biopharma', 'Vyriad, Inc.', 'Wangxia LV', 'Wayshine Biopharm, Inc.', 'Wei Jiang', 'Weiguo Lv', 'Weijia Fang, MD', 'Weijun Fu', 'Wellmarker Bio', 'Wenxin Xu', 'Weprom', 'West Cancer Center', 'West China Second University Hospital', 'West German Study Group', 'West Virginia University', 'Western Sydney Local Health District', 'William Shomali', 'William Tyor', 'Williams Cancer Foundation', \"Women's College Hospital\", \"Women's Hospital School Of Medicine Zhejiang University\", 'Won Seog Kim', 'Wugen, Inc.', 'Wuhan University', 'Wuhan YZY Biopharma Co., Ltd.', 'XIANG YANQUN', 'Xenothera SAS', \"Xi'an Jiaotong University\", 'Xia Zhongjun', 'Xiang Lu', 'Xiangya Hospital of Central South University', 'Xianmin Song, MD', 'Xiaohua Wu', 'Xiaojun Chen', 'Xiaorong Dong', 'Xijing Hospital', 'Xin-Hua Xu', 'Xing Xie', 'Xinqiao Hospital of Chongqing', 'XuYan', 'Xuanwu Hospital, Beijing', 'Xuanzhu Biopharmaceutical Co., Ltd.', 'Xuekui Liu', 'Xuhua Duan', 'Xuzhou Medical University', 'Xynomic Pharmaceuticals, Inc.', 'Y-mAbs Therapeutics', 'YOUNGIL KOH', 'Yan Zhang, MD', 'Yana Najjar', 'Yang Li', 'Yang Zhang', 'Yanhong Deng', 'Yantai Yuhuangding Hospital', 'Yanyan Liu', 'Yazeed Sawalha', 'Ying Lin', 'Yizhuo Zhang', 'Yong Chen', 'Yong Zhang,MD', 'Yongchang Zhang', 'Yongpeng Wang', 'Yongsheng Wang', 'Yu Wang', 'Yuankai Shi', 'Yuanquan Yang', 'Yuhan Corporation', 'Yuhong Li', 'Yunnan Cancer Hospital', 'ZHOU FANGJIAN', 'Zai Lab (Hong Kong), Ltd.', 'Zai Lab (Shanghai) Co., Ltd.', 'ZePing Zhou', 'Zealand University Hospital', 'Zeng Jian', 'Zenith Epigenetics', 'Zhejiang ACEA Pharmaceutical Co. Ltd.', 'Zhejiang Doer Biologics Co., Ltd.', \"Zhejiang Provincial People's Hospital\", 'Zhejiang Teruisi Pharmaceutical Inc.', 'Zhen-Hai Lu', 'Zhengzhou University', 'Zhenzhen Liu', 'Zhifeng Tian,MD', 'Zhigang Li', 'Zhiyong Huang', 'Zhongda Hospital', 'Zhongnan Hospital', \"Zhongshan People's Hospital, Guangdong, China\", 'Zhou Chengzhi', 'Zhuhai Beihai Biotech Co., Ltd', 'Zhuhai Yufan Biotechnologies Co., Ltd', 'Zhujiang Hospital', 'Zin W Myint', 'Zumutor Biologics Inc.', 'Zunyi Medical College', 'Zymeworks BC Inc.', 'dr. Tom van der Hulle', 'enGene, Inc.', 'iOnctura', 'iTeos Therapeutics', 'invoX Pharma Limited', 'john eisenbrey', 'mAbxience Research S.L.', 'michal roll', 'photonamic GmbH & Co. KG', 'wang shusen', 'wang, jianxiang', 'xiaohua li', 'yair lotan', 'yangjianjun', 'yue junhan']\n"
     ]
    }
   ],
   "source": [
    "recruiting_df = df[df['overall_status'] == 'RECRUITING']\n",
    "\n",
    "# Step 1: Get list of lead sponsors in recruiting subset\n",
    "recruiting_sponsors = set(recruiting_df['lead_sponsor'].unique())\n",
    "\n",
    "# Step 2: Get list of top sponsors (>50 trials, already defined)\n",
    "top_sponsors_set = set(top_sponsors)\n",
    "\n",
    "# Step 3: Find intersection – sponsors who are in both\n",
    "common_sponsors = recruiting_sponsors.intersection(top_sponsors_set)\n",
    "\n",
    "# Step 4: See sponsors in recruiting that are *not* in top sponsors\n",
    "non_top_recruiting_sponsors = recruiting_sponsors.difference(top_sponsors_set)\n",
    "\n",
    "# Optional: Convert to sorted list for display\n",
    "print(\"✅ Sponsors in both Recruiting & Top Sponsors (>10 trials):\")\n",
    "print(sorted(common_sponsors))\n",
    "\n",
    "print(\"\\n❌ Sponsors in Recruiting but NOT in Top Sponsors:\")\n",
    "print(sorted(non_top_recruiting_sponsors))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "9cdd9525",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Number of lead sponsors in RECRUITING subset: 2230\n",
      "Number of lead sponsors with >10 trials: 409\n",
      "Number of common sponsors: 330\n"
     ]
    }
   ],
   "source": [
    "print(f\"\\nNumber of lead sponsors in RECRUITING subset: {len(recruiting_sponsors)}\")\n",
    "print(f\"Number of lead sponsors with >10 trials: {len(top_sponsors_set)}\")\n",
    "print(f\"Number of common sponsors: {len(common_sponsors)}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b1a3267d",
   "metadata": {},
   "source": [
    "Creating a sponsor success column"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "300af76e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Assuming completed_percent_dict is already defined\n",
    "\n",
    "# Create a new column based on sponsor's completed percentage\n",
    "df['sponsor_success'] = df['lead_sponsor'].apply(\n",
    "    lambda sponsor: completed_percent_dict.get(sponsor, 0.0)\n",
    ").astype(float)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "397f5a25",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'conditions', 'country', 'design_primary_purpose',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'organization_match', 'lead_sponsor',\n",
       "       'location_city', 'location_country', 'location_facility',\n",
       "       'location_state', 'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'stdage', 'study_type',\n",
       "       'affiliation_matches_org', 'total_study_duration_days',\n",
       "       'primary_outcome_duration_days', 'sponsor_success'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "760ad7f9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41761, 29)"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "bdbf3b42",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       26\n",
       "1       10\n",
       "2      500\n",
       "3      421\n",
       "4       51\n",
       "6        9\n",
       "8      381\n",
       "9       49\n",
       "11      11\n",
       "12      30\n",
       "13      75\n",
       "14     192\n",
       "16      37\n",
       "17     120\n",
       "19      17\n",
       "23      25\n",
       "24     303\n",
       "25      74\n",
       "26      34\n",
       "29      74\n",
       "30      40\n",
       "31      30\n",
       "32     706\n",
       "33      20\n",
       "35      94\n",
       "36      35\n",
       "37      34\n",
       "38      68\n",
       "39     569\n",
       "41      20\n",
       "42      54\n",
       "44     511\n",
       "46      22\n",
       "48      24\n",
       "50      27\n",
       "51      24\n",
       "52      20\n",
       "53     755\n",
       "54     200\n",
       "55      55\n",
       "57      83\n",
       "58     150\n",
       "59     224\n",
       "60      49\n",
       "61    1312\n",
       "62     170\n",
       "65      20\n",
       "67      30\n",
       "69      17\n",
       "70      52\n",
       "Name: enrollment, dtype: int64"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['enrollment'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "099e6386",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "secondary_outcomes               5881\n",
       "interventions_description        3735\n",
       "conditions                          0\n",
       "design_primary_purpose              0\n",
       "country                             0\n",
       "eligibility_criteria                0\n",
       "enrollment                          0\n",
       "interventions_name                  0\n",
       "organization_match                  0\n",
       "lead_sponsor                        0\n",
       "location_city                       0\n",
       "location_country                    0\n",
       "brief_summary                       0\n",
       "location_facility                   0\n",
       "location_state                      0\n",
       "minimum_age                         0\n",
       "maximum_age                         0\n",
       "overall_status                      0\n",
       "oversight_has_dmc                   0\n",
       "phase                               0\n",
       "organization_fullname               0\n",
       "primary_outcomes                    0\n",
       "sex                                 0\n",
       "stdage                              0\n",
       "study_type                          0\n",
       "affiliation_matches_org             0\n",
       "total_study_duration_days           0\n",
       "primary_outcome_duration_days       0\n",
       "sponsor_success                     0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "70aaf1fb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'conditions', 'country', 'design_primary_purpose',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'organization_match', 'lead_sponsor',\n",
       "       'location_city', 'location_country', 'location_facility',\n",
       "       'location_state', 'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'stdage', 'study_type',\n",
       "       'affiliation_matches_org', 'total_study_duration_days',\n",
       "       'primary_outcome_duration_days', 'sponsor_success'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "a6ebf868",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['secondary_outcomes', 'interventions_description'], axis=1, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "f78a9b7c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     55.600000\n",
       "1      0.000000\n",
       "2      0.000000\n",
       "3      0.000000\n",
       "4      0.000000\n",
       "6      0.000000\n",
       "8      0.000000\n",
       "9      0.000000\n",
       "11    30.841121\n",
       "12     0.000000\n",
       "13    61.764706\n",
       "14    26.470588\n",
       "16    34.131737\n",
       "17    67.500000\n",
       "19    37.500000\n",
       "23    54.104148\n",
       "24    54.104148\n",
       "25     0.000000\n",
       "26     0.000000\n",
       "29    65.950920\n",
       "30     0.000000\n",
       "31     0.000000\n",
       "32    40.512821\n",
       "33    53.658537\n",
       "35     0.000000\n",
       "36    58.333333\n",
       "37    92.753623\n",
       "38     0.000000\n",
       "39    35.877863\n",
       "41     0.000000\n",
       "42     0.000000\n",
       "44     0.000000\n",
       "46    45.390071\n",
       "48    59.375000\n",
       "50    25.000000\n",
       "51    63.924964\n",
       "52    55.371901\n",
       "53    51.960784\n",
       "54    37.500000\n",
       "55    39.855072\n",
       "57    68.556701\n",
       "58    54.104148\n",
       "59    43.558282\n",
       "60     0.000000\n",
       "61    50.000000\n",
       "62    67.567568\n",
       "65     0.000000\n",
       "67    66.666667\n",
       "69     3.703704\n",
       "70    63.924964\n",
       "Name: sponsor_success, dtype: float64"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['sponsor_success'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "id": "1036b2b1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'conditions', 'country', 'design_primary_purpose',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_name',\n",
       "       'organization_match', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname', 'overall_status',\n",
       "       'oversight_has_dmc', 'phase', 'primary_outcomes', 'sex', 'stdage',\n",
       "       'study_type', 'affiliation_matches_org', 'total_study_duration_days',\n",
       "       'primary_outcome_duration_days', 'sponsor_success'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "id": "0cd4aeac",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "brief_summary                     object\n",
       "conditions                        object\n",
       "country                           object\n",
       "design_primary_purpose            object\n",
       "eligibility_criteria              object\n",
       "enrollment                         int64\n",
       "interventions_name                object\n",
       "organization_match                  bool\n",
       "lead_sponsor                      object\n",
       "location_city                     object\n",
       "location_facility                 object\n",
       "location_state                    object\n",
       "maximum_age                       object\n",
       "minimum_age                       object\n",
       "organization_fullname             object\n",
       "overall_status                    object\n",
       "oversight_has_dmc                 object\n",
       "phase                             object\n",
       "primary_outcomes                  object\n",
       "sex                               object\n",
       "stdage                            object\n",
       "study_type                        object\n",
       "affiliation_matches_org             bool\n",
       "total_study_duration_days          int64\n",
       "primary_outcome_duration_days      int64\n",
       "sponsor_success                  float64\n",
       "dtype: object"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "d09cf969",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                Nivolumab 480mg and surgical resection\n",
       "1                                    Influenza Vaccines\n",
       "2     SHR-A2009 monotherapy, platinum-based dual-age...\n",
       "3                                    SIBP-02, Rituximab\n",
       "4     Venetoclax, Decitabine, Cedazuridine, Bone Mar...\n",
       "6                                  MAb 216, Vincristine\n",
       "8          Perifosine, Capecitabine, Perifosine Placebo\n",
       "9                             PRI-724, PRI-724, PRI-724\n",
       "11                                             DT388IL3\n",
       "12    Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...\n",
       "13                                           entinostat\n",
       "14    Sentinel lymph node procedure, Bone marrow asp...\n",
       "16    Bortezomib, Rituximab, Doxorubicin, Cyclophosp...\n",
       "17    Paxman Scalp Cooling System, Eribulin, Sacituz...\n",
       "19                                             Avelumab\n",
       "23                 Sacituzumab Govitecan, Pembrolizumab\n",
       "24                                   Erlotinib, Placebo\n",
       "25                                         TFX06 tablet\n",
       "26                              Er:YAG AFL-PDT, MAL-PDT\n",
       "29    Elotuzumab, Pomalidomide, Dexamethasone, Nivol...\n",
       "30                                               CT-322\n",
       "31                                         UCAR-T Cells\n",
       "32    Velcade, Melphalan, Prednisone, Daratumumab IV...\n",
       "33      Fludarabine, Busulfan, Rabbit ATG, Methotrexate\n",
       "35                                 FT-1101, Azacitidine\n",
       "36                                  Bevacizumab, TH-302\n",
       "37    carboplatin, cisplatin, gemcitabine hydrochloride\n",
       "38                        Pegzilarginase, Pembrolizumab\n",
       "39    Physician Intervention, Physician and Patient ...\n",
       "41                              Osimertinib Oral Tablet\n",
       "42                                       Ropidoxuridine\n",
       "44    Bortezomib, Melphalan, Prednisone, Thalidomide...\n",
       "46                                          C11-Choline\n",
       "48                       Avelumab, Best Supportive Care\n",
       "50                                             exercise\n",
       "51         Laboratory Biomarker Analysis, Pembrolizumab\n",
       "52                    Venetoclax, FLAG or CLAG Protocol\n",
       "53    cabazitaxel (XRP6258) (RPR116258), mitoxantron...\n",
       "54    Azacitidine, Donor lymphocytes, Tapering of im...\n",
       "55    Palbociclib, Letrozole, Fulvestrant, Optional ...\n",
       "57                             RO6874281, Pembrolizumab\n",
       "58                                Eflornithine, Placebo\n",
       "59    Lopinavir/ritonavir plus Emtricitabine/Tenofov...\n",
       "60                                                 A166\n",
       "61                                         Esomeprazole\n",
       "62    Doxorubicin, Bleomycin, Vinblastine, Dacarbazi...\n",
       "65    Memantine Tab. 10mg, Memantine Tab. 10mg + Don...\n",
       "67        Doxorubicine, DTIC, Lenalidomide, Vinblastine\n",
       "69                Rituximab, Lenalidomide, Methotrexate\n",
       "70                                          ixabepilone\n",
       "Name: interventions_name, dtype: object"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_name'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "id": "b0ed4a63",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                         United States\n",
       "1                                               Denmark\n",
       "2                                                 China\n",
       "3                                                 China\n",
       "4                                         United States\n",
       "6                                         United States\n",
       "8                                         United States\n",
       "9                                         United States\n",
       "11                                        United States\n",
       "12                                                China\n",
       "13                                        United States\n",
       "14                                          Switzerland\n",
       "16                                        United States\n",
       "17                                        United States\n",
       "19                                               Canada\n",
       "23                                        United States\n",
       "24                                        United States\n",
       "25                                                China\n",
       "26                                   Korea, Republic of\n",
       "29                                        United States\n",
       "30                                        United States\n",
       "31                                                China\n",
       "32    Croatia, Greece, United States, Argentina, Jap...\n",
       "33                                        United States\n",
       "35                                        United States\n",
       "36                                        United States\n",
       "37                                               Canada\n",
       "38                           Puerto Rico, United States\n",
       "39                                        United States\n",
       "41                                                China\n",
       "42                                        United States\n",
       "44                                                Italy\n",
       "46                                        United States\n",
       "48                                               Canada\n",
       "50                                               Canada\n",
       "51                                        United States\n",
       "52                                        United States\n",
       "53    Netherlands, United States, Argentina, Canada,...\n",
       "54                                               Sweden\n",
       "55                                        United States\n",
       "57    France, Spain, Belgium, United States, Russian...\n",
       "58                                        United States\n",
       "59                                               Uganda\n",
       "60                                        United States\n",
       "61    France, Finland, Greece, Netherlands, Spain, S...\n",
       "62       France, Croatia, Netherlands, Belgium, Denmark\n",
       "65                                   Korea, Republic of\n",
       "67                                              Germany\n",
       "69                                                China\n",
       "70                                        United States\n",
       "Name: country, dtype: object"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['country'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "551f8c71",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41761, 27)"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "135e8720",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "design_primary_purpose\n",
       "TREATMENT                   36853\n",
       "PREVENTION                   1593\n",
       "DIAGNOSTIC                   1099\n",
       "SUPPORTIVE_CARE               783\n",
       "OTHER                         549\n",
       "BASIC_SCIENCE                 506\n",
       "HEALTH_SERVICES_RESEARCH      101\n",
       "SCREENING                      76\n",
       "DEVICE_FEASIBILITY              9\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['design_primary_purpose'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "cba5f3ff",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[df['design_primary_purpose'] != '?']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "f0f86d75",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Cohort 1: Subjects must have histologically co...\n",
       "1     * Patients must be mentally capable of underst...\n",
       "2     1. Age 18 to 75 years old (inclusive), Female ...\n",
       "3     * 18-75 years old, male or female;\\n* Patients...\n",
       "4     * Age \\>= 18 years at the time of signing the ...\n",
       "6     3.1.1 Age Patients must be \\>= 18 years old at...\n",
       "8     1. In the opinion of the treating physician, t...\n",
       "9     1. Patients 18 years or older\\n2. Part I: Pati...\n",
       "11    * Diagnosis of 1 of the following:\\n\\n  * Hist...\n",
       "12    * Written informed consent provided.\\n* Unrese...\n",
       "13    * Histologically confirmed malignancy that is ...\n",
       "14    * Colon cancer at any stage diagnosed histolog...\n",
       "16    * Tissue diagnosis of a previously untreated, ...\n",
       "17    * Men and women with a diagnosis of metastatic...\n",
       "19    * Adults (males or females), aged 18 years or ...\n",
       "23    1. Female or male patients 18 years of age or ...\n",
       "24    1. Male or female patients with one of the fol...\n",
       "25    1. voluntary participation in clinical trials ...\n",
       "26    * patient's request for alternative treatment ...\n",
       "29    Inclusion Criteria:\\n\\n1. All subjects must ha...\n",
       "30    * Histologically proven advanced solid maligna...\n",
       "31    1. Male or female, aged 2-75 years;\\n2. A defi...\n",
       "32    * Participant must have documented multiple my...\n",
       "33    1. Age less than or equal to 75 years\\n2. The ...\n",
       "35    * Single agent (SA) Dose Escalation: Histologi...\n",
       "36    * At least 18 years of age\\n* Ability to under...\n",
       "37    * Histologically or cytologically confirmed ma...\n",
       "38    1. Patient is able and willing to provide writ...\n",
       "39    * Patients aged 50-75 years of age (in month 1...\n",
       "41    Participant must have histologically or cytolo...\n",
       "42    * Written informed consent form signed and dat...\n",
       "44    * Age \\> 65 year old and not a candidate for s...\n",
       "46    * Newly diagnosed or recurrent patients with l...\n",
       "48    * Histologically confirmed squamous cell carci...\n",
       "50    * newly diagnosed with stage I-IIIA breast can...\n",
       "51    * This trial will include subjects with stage ...\n",
       "52    * Patients have an established, pathologically...\n",
       "53    1. Histologically or cytologically confirmed a...\n",
       "54    Signed informed consent\\n\\n* Age ≥ 18 years\\n*...\n",
       "55    * Histologically confirmed metastatic ER+ ando...\n",
       "57    1. Histologically confirmed unresectable stage...\n",
       "58    1) Women with newly diagnosed or recurrent CIN...\n",
       "59    * Age 18 years or older\\n* HIV-1 infection\\n* ...\n",
       "60    Phase I\\n\\nPatients must meet the following cr...\n",
       "61    * Signs of a bleeding in the stomach\\n* One en...\n",
       "62    * Histologically confirmed CD30+ classical Hod...\n",
       "65    1. A healthy adult whose age is over 19 years ...\n",
       "67    * Hodgkin Lymphoma, intermediate or advanced s...\n",
       "69    1. Histologically confirmed Primary Central Ne...\n",
       "70    * Histologically confirmed endometrial adenoca...\n",
       "Name: eligibility_criteria, dtype: object"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['eligibility_criteria'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "id": "70d75769",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       26\n",
       "1       10\n",
       "2      500\n",
       "3      421\n",
       "4       51\n",
       "6        9\n",
       "8      381\n",
       "9       49\n",
       "11      11\n",
       "12      30\n",
       "13      75\n",
       "14     192\n",
       "16      37\n",
       "17     120\n",
       "19      17\n",
       "23      25\n",
       "24     303\n",
       "25      74\n",
       "26      34\n",
       "29      74\n",
       "30      40\n",
       "31      30\n",
       "32     706\n",
       "33      20\n",
       "35      94\n",
       "36      35\n",
       "37      34\n",
       "38      68\n",
       "39     569\n",
       "41      20\n",
       "42      54\n",
       "44     511\n",
       "46      22\n",
       "48      24\n",
       "50      27\n",
       "51      24\n",
       "52      20\n",
       "53     755\n",
       "54     200\n",
       "55      55\n",
       "57      83\n",
       "58     150\n",
       "59     224\n",
       "60      49\n",
       "61    1312\n",
       "62     170\n",
       "65      20\n",
       "67      30\n",
       "69      17\n",
       "70      52\n",
       "Name: enrollment, dtype: int64"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['enrollment'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "bada1db4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Sidney Kimmel Comprehensive Cancer Center at J...\n",
       "1                           Zealand University Hospital\n",
       "2          Suzhou Suncadia Biopharmaceuticals Co., Ltd.\n",
       "3             Shanghai Institute Of Biological Products\n",
       "4                                          Sanjay Mohan\n",
       "6                                      Steven E. Coutre\n",
       "8                                      AEterna Zentaris\n",
       "9                                Prism Pharma Co., Ltd.\n",
       "11      University of Texas Southwestern Medical Center\n",
       "12                 Beijing Tsinghua Chang Gung Hospital\n",
       "13    National Institutes of Health Clinical Center ...\n",
       "14              University Hospital, Basel, Switzerland\n",
       "16                                     Emory University\n",
       "17                         Dana-Farber Cancer Institute\n",
       "19                    Sunnybrook Health Sciences Centre\n",
       "23                          M.D. Anderson Cancer Center\n",
       "24                          M.D. Anderson Cancer Center\n",
       "25    Shenzhen Yangli Pharmaceutical Technology Co.,...\n",
       "26                                    Dong-A University\n",
       "29                                 Bristol-Myers Squibb\n",
       "30          Adnexus, A Bristol-Myers Squibb R&D Company\n",
       "31    920th Hospital of Joint Logistics Support Forc...\n",
       "32                  Janssen Research & Development, LLC\n",
       "33                   Dartmouth-Hitchcock Medical Center\n",
       "35                             Forma Therapeutics, Inc.\n",
       "36    The University of Texas Health Science Center ...\n",
       "37                           NCIC Clinical Trials Group\n",
       "38                               Aeglea Biotherapeutics\n",
       "39                              Northwestern University\n",
       "41                             Qingdao Central Hospital\n",
       "42                        Shuttle Pharmaceuticals, Inc.\n",
       "44                           Fondazione EMN Italy Onlus\n",
       "46               Wake Forest University Health Sciences\n",
       "48                   University Health Network, Toronto\n",
       "50                       University of British Columbia\n",
       "51                      National Cancer Institute (NCI)\n",
       "52           University of Michigan Rogel Cancer Center\n",
       "53                                               Sanofi\n",
       "54                       Karolinska University Hospital\n",
       "55             Washington University School of Medicine\n",
       "57                                    Hoffmann-La Roche\n",
       "58                          M.D. Anderson Cancer Center\n",
       "59              University of California, San Francisco\n",
       "60                                     Klus Pharma Inc.\n",
       "61                                          AstraZeneca\n",
       "62          The Lymphoma Academic Research Organisation\n",
       "65                        Chong Kun Dang Pharmaceutical\n",
       "67                                University of Cologne\n",
       "69    Second Affiliated Hospital, School of Medicine...\n",
       "70                      National Cancer Institute (NCI)\n",
       "Name: lead_sponsor, dtype: object"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['lead_sponsor'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "65974ec5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>location_country</th>\n",
       "      <th>country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Denmark</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>United States, United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Switzerland, Switzerland, Switzerland</td>\n",
       "      <td>Switzerland</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Canada</td>\n",
       "      <td>Canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>China, China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>United States, United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Canada, Canada, Canada, Canada</td>\n",
       "      <td>Canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Italy</td>\n",
       "      <td>Italy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Canada</td>\n",
       "      <td>Canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>Canada</td>\n",
       "      <td>Canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>United States, Argentina, Belgium, Brazil, Can...</td>\n",
       "      <td>Netherlands, United States, Argentina, Canada,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>Sweden</td>\n",
       "      <td>Sweden</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>United States, United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>France, Spain, Belgium, United States, Russian...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>Uganda</td>\n",
       "      <td>Uganda</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>Austria, Austria, Austria, Austria, Austria, A...</td>\n",
       "      <td>France, Finland, Greece, Netherlands, Spain, S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>Belgium, Belgium, Belgium, Belgium, Belgium, B...</td>\n",
       "      <td>France, Croatia, Netherlands, Belgium, Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>Germany</td>\n",
       "      <td>Germany</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>France, France, France, France, France, France...</td>\n",
       "      <td>France, Monaco</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>China, China, China, China, China, China, Chin...</td>\n",
       "      <td>Thailand, Hong Kong, China, Philippines, Indon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>United States</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>France, France, France, United Kingdom, United...</td>\n",
       "      <td>France, United Kingdom</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>France, Netherlands, Netherlands, Netherlands,...</td>\n",
       "      <td>France, Spain, Netherlands, United Kingdom</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>China</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     location_country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "6                                       United States   \n",
       "8   United States, United States, United States, U...   \n",
       "9   United States, United States, United States, U...   \n",
       "11                                      United States   \n",
       "12                                              China   \n",
       "13        United States, United States, United States   \n",
       "14              Switzerland, Switzerland, Switzerland   \n",
       "16                                      United States   \n",
       "17                       United States, United States   \n",
       "19                                             Canada   \n",
       "23                                      United States   \n",
       "24  United States, United States, United States, U...   \n",
       "25                                       China, China   \n",
       "26                                 Korea, Republic of   \n",
       "29  United States, United States, United States, U...   \n",
       "30        United States, United States, United States   \n",
       "31                                              China   \n",
       "32  United States, United States, United States, U...   \n",
       "33                                      United States   \n",
       "35  United States, United States, United States, U...   \n",
       "36                       United States, United States   \n",
       "37                     Canada, Canada, Canada, Canada   \n",
       "38  United States, United States, United States, U...   \n",
       "39                       United States, United States   \n",
       "41                                              China   \n",
       "42  United States, United States, United States, U...   \n",
       "44                                              Italy   \n",
       "46                                      United States   \n",
       "48                                             Canada   \n",
       "50                                             Canada   \n",
       "51  United States, United States, United States, U...   \n",
       "52                                      United States   \n",
       "53  United States, Argentina, Belgium, Brazil, Can...   \n",
       "54                                             Sweden   \n",
       "55                       United States, United States   \n",
       "57  United States, United States, United States, U...   \n",
       "58                                      United States   \n",
       "59                                             Uganda   \n",
       "60  United States, United States, United States, U...   \n",
       "61  Austria, Austria, Austria, Austria, Austria, A...   \n",
       "62  Belgium, Belgium, Belgium, Belgium, Belgium, B...   \n",
       "65                                 Korea, Republic of   \n",
       "67                                            Germany   \n",
       "69                                              China   \n",
       "70                                      United States   \n",
       "71                                              China   \n",
       "72                                      United States   \n",
       "73  France, France, France, France, France, France...   \n",
       "74  United States, United States, United States, U...   \n",
       "75  China, China, China, China, China, China, Chin...   \n",
       "78  United States, United States, United States, U...   \n",
       "81                                      United States   \n",
       "82  France, France, France, United Kingdom, United...   \n",
       "84  France, Netherlands, Netherlands, Netherlands,...   \n",
       "85                                              China   \n",
       "\n",
       "                                              country  \n",
       "0                                       United States  \n",
       "1                                             Denmark  \n",
       "2                                               China  \n",
       "3                                               China  \n",
       "4                                       United States  \n",
       "6                                       United States  \n",
       "8                                       United States  \n",
       "9                                       United States  \n",
       "11                                      United States  \n",
       "12                                              China  \n",
       "13                                      United States  \n",
       "14                                        Switzerland  \n",
       "16                                      United States  \n",
       "17                                      United States  \n",
       "19                                             Canada  \n",
       "23                                      United States  \n",
       "24                                      United States  \n",
       "25                                              China  \n",
       "26                                 Korea, Republic of  \n",
       "29                                      United States  \n",
       "30                                      United States  \n",
       "31                                              China  \n",
       "32  Croatia, Greece, United States, Argentina, Jap...  \n",
       "33                                      United States  \n",
       "35                                      United States  \n",
       "36                                      United States  \n",
       "37                                             Canada  \n",
       "38                         Puerto Rico, United States  \n",
       "39                                      United States  \n",
       "41                                              China  \n",
       "42                                      United States  \n",
       "44                                              Italy  \n",
       "46                                      United States  \n",
       "48                                             Canada  \n",
       "50                                             Canada  \n",
       "51                                      United States  \n",
       "52                                      United States  \n",
       "53  Netherlands, United States, Argentina, Canada,...  \n",
       "54                                             Sweden  \n",
       "55                                      United States  \n",
       "57  France, Spain, Belgium, United States, Russian...  \n",
       "58                                      United States  \n",
       "59                                             Uganda  \n",
       "60                                      United States  \n",
       "61  France, Finland, Greece, Netherlands, Spain, S...  \n",
       "62     France, Croatia, Netherlands, Belgium, Denmark  \n",
       "65                                 Korea, Republic of  \n",
       "67                                            Germany  \n",
       "69                                              China  \n",
       "70                                      United States  \n",
       "71                                              China  \n",
       "72                                      United States  \n",
       "73                                     France, Monaco  \n",
       "74                                      United States  \n",
       "75  Thailand, Hong Kong, China, Philippines, Indon...  \n",
       "78                                      United States  \n",
       "81                                      United States  \n",
       "82                             France, United Kingdom  \n",
       "84         France, Spain, Netherlands, United Kingdom  \n",
       "85                                              China  "
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['location_country','country']].head(60)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "id": "190e05d5",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['location_country'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "9513fd64",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Sidney Kimmel Comprehensive Cancer Center at J...\n",
       "1                           Zealand University Hospital\n",
       "2                Guangdong Provincial People's Hospital\n",
       "3     The First Affiliated Hospital of College of Me...\n",
       "4            Vanderbilt University/Ingram Cancer Center\n",
       "6                Stanford University School of Medicine\n",
       "8     AOI Pharmaceuticals Investigative Site, AOI Ph...\n",
       "9     Emory University / Winship Cancer Institute, U...\n",
       "11      University of Texas Southwestern Medical Center\n",
       "12                 Beijing Tsinghua Chang Gung Hospital\n",
       "13    National Naval Medical Center, Warren Grant Ma...\n",
       "14    Carsten T. Viehl, MD, Urban Laffer, MD, Markus...\n",
       "16            Emory University Winship Cancer Institute\n",
       "17    Brigham and Women's Hospital, Dana Farber Canc...\n",
       "19                    Sunnybrook Health Sciences Centre\n",
       "23                          M.D. Anderson Cancer Center\n",
       "24    Emory University Winship Cancer Institute, The...\n",
       "25    The 1st Affiliated Hospital of Henan Universit...\n",
       "26                                    Dong-A University\n",
       "29    Southern Cancer Center, Sansum Clinic - USOR, ...\n",
       "30    Indiana University Cancer Center, South Texas ...\n",
       "31    920th Hospital of Joint Logistics Support Forc...\n",
       "32    ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?...\n",
       "33                   Dartmouth-Hitchcock Medical Center\n",
       "35    Cedars Sinai, Florida Cancer Specialists, Moff...\n",
       "36    Dana-Farber Cancer Institute, University of Te...\n",
       "37    CancerCare Manitoba, London Regional Cancer Pr...\n",
       "38    University of Alabama, Mitchell Cancer Institu...\n",
       "39    Access Community Health Network, University of...\n",
       "41    Qingdao Central Hospital, Qingdao Cancer Hospital\n",
       "42    Lombardi Comprehensive Cancer Center, Miami Ca...\n",
       "44                          A.O.U. S. Giovanni Battista\n",
       "46               Wake Forest University Health Sciences\n",
       "48                      Princess Margaret Cancer Centre\n",
       "50    University of British Columbia Breast Cancer R...\n",
       "51    Stanford Cancer Institute Palo Alto, Yale Univ...\n",
       "52           University of Michigan Rogel Cancer Center\n",
       "53    sanofi-aventis US, sanofi-aventis Argentina, s...\n",
       "54    Department of Hematology, Karolinska Universit...\n",
       "55    Washington University School of Medicine, Univ...\n",
       "57    Yale University, University of Iowa, Beth Isra...\n",
       "58      University of Texas - MD Anderson Cancer Center\n",
       "59       Infectious Diseases Institute, Mulago Hospital\n",
       "60    Florida Cancer Specialists & Research Institut...\n",
       "61    Research Site, Research Site, Research Site, R...\n",
       "62    ZNA Middelheim, ZNA Stuivenberg, A.Z. Sint Jan...\n",
       "65                 Chonbuk National University Hospital\n",
       "67    1st Dept. of Medicine, Cologne University Hosp...\n",
       "69    Second Affiliated Hospital, School of Medicine...\n",
       "70                           Gynecologic Oncology Group\n",
       "Name: location_facility, dtype: object"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['location_facility'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "9baad9d0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                              Maryland\n",
       "1                                               Zealand\n",
       "2                                             Guangdong\n",
       "3                                                     ?\n",
       "4                                             Tennessee\n",
       "6                                            California\n",
       "8     Arizona, California, California, California, C...\n",
       "9     Georgia, Massachusetts, New Mexico, North Caro...\n",
       "11                                                Texas\n",
       "12                                              Beijing\n",
       "13                         Maryland, Maryland, Maryland\n",
       "14                                              ?, ?, ?\n",
       "16                                              Georgia\n",
       "17                         Massachusetts, Massachusetts\n",
       "19                                              Ontario\n",
       "23                                                Texas\n",
       "24                   Georgia, Illinois, New York, Texas\n",
       "25                                      Henan, Shanghai\n",
       "26                                               Seo-gu\n",
       "29    Alabama, California, Colorado, Colorado, Flori...\n",
       "30                                Indiana, Texas, Texas\n",
       "31                                               Yunnan\n",
       "32    California, California, California, California...\n",
       "33                                        New Hampshire\n",
       "35    California, Florida, Florida, Illinois, Maryla...\n",
       "36                                 Massachusetts, Texas\n",
       "37                  Manitoba, Ontario, Ontario, Ontario\n",
       "38    Alabama, Colorado, Colorado, Florida, Florida,...\n",
       "39                                   Illinois, Illinois\n",
       "41                                             Shandong\n",
       "42    District of Columbia, Florida, New Jersey, Nor...\n",
       "44                                                    ?\n",
       "46                                       North Carolina\n",
       "48                                              Ontario\n",
       "50                                     British Columbia\n",
       "51    California, Connecticut, Florida, Maryland, Ne...\n",
       "52                                             Michigan\n",
       "53    New Jersey, ?, ?, ?, Quebec, ?, ?, ?, ?, ?, ?,...\n",
       "54                                                    ?\n",
       "55                                   Missouri, Nebraska\n",
       "57    Connecticut, Iowa, Massachusetts, Massachusett...\n",
       "58                                                Texas\n",
       "59                                                    ?\n",
       "60    Florida, Massachusetts, Michigan, New York, Ok...\n",
       "61    ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?...\n",
       "62    ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?...\n",
       "65                                                    ?\n",
       "67                                                  NRW\n",
       "69                                             Zhejiang\n",
       "70                                         Pennsylvania\n",
       "Name: location_state, dtype: object"
      ]
     },
     "execution_count": 108,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['location_state'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "id": "8c435210",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['location_state'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "fd099a71",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "brief_summary                     object\n",
       "conditions                        object\n",
       "country                           object\n",
       "design_primary_purpose            object\n",
       "eligibility_criteria              object\n",
       "enrollment                         int64\n",
       "interventions_name                object\n",
       "organization_match                  bool\n",
       "lead_sponsor                      object\n",
       "location_city                     object\n",
       "location_facility                 object\n",
       "maximum_age                       object\n",
       "minimum_age                       object\n",
       "organization_fullname             object\n",
       "overall_status                    object\n",
       "oversight_has_dmc                 object\n",
       "phase                             object\n",
       "primary_outcomes                  object\n",
       "sex                               object\n",
       "stdage                            object\n",
       "study_type                        object\n",
       "affiliation_matches_org             bool\n",
       "total_study_duration_days          int64\n",
       "primary_outcome_duration_days      int64\n",
       "sponsor_success                  float64\n",
       "dtype: object"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "93b2bd76",
   "metadata": {},
   "source": [
    "Fixing the maximum_age and minimum_age"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "id": "2a82b931",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0             ?\n",
       "1             ?\n",
       "2      75 Years\n",
       "3      75 Years\n",
       "4             ?\n",
       "6             ?\n",
       "8             ?\n",
       "9             ?\n",
       "11            ?\n",
       "12     70 Years\n",
       "13            ?\n",
       "14            ?\n",
       "16            ?\n",
       "17            ?\n",
       "19            ?\n",
       "23            ?\n",
       "24            ?\n",
       "25            ?\n",
       "26     78 Years\n",
       "29            ?\n",
       "30            ?\n",
       "31     75 Years\n",
       "32            ?\n",
       "33     75 Years\n",
       "35            ?\n",
       "36            ?\n",
       "37    120 Years\n",
       "38            ?\n",
       "39     75 Years\n",
       "41     80 Years\n",
       "42            ?\n",
       "44    100 Years\n",
       "46            ?\n",
       "48            ?\n",
       "50            ?\n",
       "51            ?\n",
       "52            ?\n",
       "53            ?\n",
       "54            ?\n",
       "55            ?\n",
       "57            ?\n",
       "58            ?\n",
       "59            ?\n",
       "60            ?\n",
       "61            ?\n",
       "62     60 Years\n",
       "65            ?\n",
       "67     75 Years\n",
       "69     75 Years\n",
       "70            ?\n",
       "Name: maximum_age, dtype: object"
      ]
     },
     "execution_count": 111,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['maximum_age'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "7f4e0b39",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Step 1: Replace '?' with NaN\n",
    "df['maximum_age'] = df['maximum_age'].replace('?', np.nan)\n",
    "\n",
    "# Step 2: Remove 'Years' and strip spaces\n",
    "df['maximum_age'] = df['maximum_age'].str.replace('Years', '').str.strip()\n",
    "\n",
    "# Step 3: Convert to numeric (float or integer)\n",
    "df['maximum_age'] = pd.to_numeric(df['maximum_age'], errors='coerce') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "id": "f8bb5258",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.float64(2.0)"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['maximum_age'].min()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "id": "68ef8e54",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>organization_match</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>location_city</th>\n",
       "      <th>...</th>\n",
       "      <th>oversight_has_dmc</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_type</th>\n",
       "      <th>affiliation_matches_org</th>\n",
       "      <th>total_study_duration_days</th>\n",
       "      <th>primary_outcome_duration_days</th>\n",
       "      <th>sponsor_success</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>11994</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy use diff...</td>\n",
       "      <td>Brain Tumors, Central Nervous System Tumors, N...</td>\n",
       "      <td>Canada, Australia, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>* Histologically proven malignant brain or spi...</td>\n",
       "      <td>94</td>\n",
       "      <td>filgrastim, carboplatin, cisplatin, cyclophosp...</td>\n",
       "      <td>False</td>\n",
       "      <td>Children's Oncology Group</td>\n",
       "      <td>Duarte, Los Angeles, Los Angeles, Los Angeles,...</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>Feasibility; Maximal tolerated dose of thiotep...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>False</td>\n",
       "      <td>4962</td>\n",
       "      <td>3562</td>\n",
       "      <td>87.341772</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40871</th>\n",
       "      <td>In pediatric patients (newborns and infants we...</td>\n",
       "      <td>Bleeding, Cardiac Defect, Surgery--Complicatio...</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>* newborns and infants with weight lower than ...</td>\n",
       "      <td>40</td>\n",
       "      <td>Fibrinogen Concentrate Human, Prothrombin Comp...</td>\n",
       "      <td>True</td>\n",
       "      <td>IRCCS Policlinico S. Donato</td>\n",
       "      <td>San Donato Milanese</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>Transfusion of Fresh Frozen Plasma (FFP)</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>True</td>\n",
       "      <td>489</td>\n",
       "      <td>459</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41454</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy work in ...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>Australia, Canada, New Zealand, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>* Histologically confirmed infantile, congenit...</td>\n",
       "      <td>7</td>\n",
       "      <td>dactinomycin, cyclophosphamide, etoposide, ifo...</td>\n",
       "      <td>False</td>\n",
       "      <td>Children's Oncology Group</td>\n",
       "      <td>Phoenix, Little Rock, Downey, Loma Linda, Long...</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>Failure-free Survival (FFS) in \"Chemotherapy P...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>False</td>\n",
       "      <td>1216</td>\n",
       "      <td>1216</td>\n",
       "      <td>87.341772</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47245</th>\n",
       "      <td>The proposed study is a pilot randomized contr...</td>\n",
       "      <td>Bronchiolitis, Viral</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>1. Less than or equal to 24 months\\n2. First e...</td>\n",
       "      <td>3</td>\n",
       "      <td>Placebos, Dexamethasone Oral</td>\n",
       "      <td>False</td>\n",
       "      <td>Allison Williams</td>\n",
       "      <td>Pittsburgh</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Hospital Length of Stay</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>True</td>\n",
       "      <td>1062</td>\n",
       "      <td>1062</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54167</th>\n",
       "      <td>This was a randomized, double-blind, multicent...</td>\n",
       "      <td>Respiratory Syncytial Virus Lower Respiratory ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>1. Subject was a Japanese male or female infan...</td>\n",
       "      <td>15</td>\n",
       "      <td>ALX-0171 1.5 mg/kg, Placebo</td>\n",
       "      <td>False</td>\n",
       "      <td>Ablynx, a Sanofi company</td>\n",
       "      <td>Aoi-ku, Asahikawa, Fuchu-shi, Fukuyama-shi, Fu...</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>Safety and Tolerability of Inhaled ALX-0171 1....</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>False</td>\n",
       "      <td>237</td>\n",
       "      <td>237</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55309</th>\n",
       "      <td>The purpose of the study is to evaluate the ef...</td>\n",
       "      <td>Post-Operative Pain, Acute Pain</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>1. Is male or female \\&lt;2 years of age at the t...</td>\n",
       "      <td>28</td>\n",
       "      <td>Oxymorphone HCl, Placebo</td>\n",
       "      <td>False</td>\n",
       "      <td>Endo Pharmaceuticals</td>\n",
       "      <td>Durham, Dallas, Houston</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>Cumulative Total Amount of Morphine Rescue Med...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>True</td>\n",
       "      <td>1614</td>\n",
       "      <td>1538</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>6 rows × 25 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           brief_summary  \\\n",
       "11994  RATIONALE: Drugs used in chemotherapy use diff...   \n",
       "40871  In pediatric patients (newborns and infants we...   \n",
       "41454  RATIONALE: Drugs used in chemotherapy work in ...   \n",
       "47245  The proposed study is a pilot randomized contr...   \n",
       "54167  This was a randomized, double-blind, multicent...   \n",
       "55309  The purpose of the study is to evaluate the ef...   \n",
       "\n",
       "                                              conditions  \\\n",
       "11994  Brain Tumors, Central Nervous System Tumors, N...   \n",
       "40871  Bleeding, Cardiac Defect, Surgery--Complicatio...   \n",
       "41454                                            Sarcoma   \n",
       "47245                               Bronchiolitis, Viral   \n",
       "54167  Respiratory Syncytial Virus Lower Respiratory ...   \n",
       "55309                    Post-Operative Pain, Acute Pain   \n",
       "\n",
       "                                             country design_primary_purpose  \\\n",
       "11994               Canada, Australia, United States              TREATMENT   \n",
       "40871                                          Italy              TREATMENT   \n",
       "41454  Australia, Canada, New Zealand, United States              TREATMENT   \n",
       "47245                                  United States              TREATMENT   \n",
       "54167                                          Japan              TREATMENT   \n",
       "55309                                  United States              TREATMENT   \n",
       "\n",
       "                                    eligibility_criteria  enrollment  \\\n",
       "11994  * Histologically proven malignant brain or spi...          94   \n",
       "40871  * newborns and infants with weight lower than ...          40   \n",
       "41454  * Histologically confirmed infantile, congenit...           7   \n",
       "47245  1. Less than or equal to 24 months\\n2. First e...           3   \n",
       "54167  1. Subject was a Japanese male or female infan...          15   \n",
       "55309  1. Is male or female \\<2 years of age at the t...          28   \n",
       "\n",
       "                                      interventions_name  organization_match  \\\n",
       "11994  filgrastim, carboplatin, cisplatin, cyclophosp...               False   \n",
       "40871  Fibrinogen Concentrate Human, Prothrombin Comp...                True   \n",
       "41454  dactinomycin, cyclophosphamide, etoposide, ifo...               False   \n",
       "47245                       Placebos, Dexamethasone Oral               False   \n",
       "54167                        ALX-0171 1.5 mg/kg, Placebo               False   \n",
       "55309                           Oxymorphone HCl, Placebo               False   \n",
       "\n",
       "                      lead_sponsor  \\\n",
       "11994    Children's Oncology Group   \n",
       "40871  IRCCS Policlinico S. Donato   \n",
       "41454    Children's Oncology Group   \n",
       "47245             Allison Williams   \n",
       "54167     Ablynx, a Sanofi company   \n",
       "55309         Endo Pharmaceuticals   \n",
       "\n",
       "                                           location_city  ...  \\\n",
       "11994  Duarte, Los Angeles, Los Angeles, Los Angeles,...  ...   \n",
       "40871                                San Donato Milanese  ...   \n",
       "41454  Phoenix, Little Rock, Downey, Loma Linda, Long...  ...   \n",
       "47245                                         Pittsburgh  ...   \n",
       "54167  Aoi-ku, Asahikawa, Fuchu-shi, Fukuyama-shi, Fu...  ...   \n",
       "55309                            Durham, Dallas, Houston  ...   \n",
       "\n",
       "      oversight_has_dmc   phase  \\\n",
       "11994              True  PHASE1   \n",
       "40871              True  PHASE2   \n",
       "41454              True  PHASE2   \n",
       "47245              True  PHASE4   \n",
       "54167              True  PHASE2   \n",
       "55309              True  PHASE3   \n",
       "\n",
       "                                        primary_outcomes  sex stdage  \\\n",
       "11994  Feasibility; Maximal tolerated dose of thiotep...  ALL  CHILD   \n",
       "40871           Transfusion of Fresh Frozen Plasma (FFP)  ALL  CHILD   \n",
       "41454  Failure-free Survival (FFS) in \"Chemotherapy P...  ALL  CHILD   \n",
       "47245                            Hospital Length of Stay  ALL  CHILD   \n",
       "54167  Safety and Tolerability of Inhaled ALX-0171 1....  ALL  CHILD   \n",
       "55309  Cumulative Total Amount of Morphine Rescue Med...  ALL  CHILD   \n",
       "\n",
       "           study_type affiliation_matches_org total_study_duration_days  \\\n",
       "11994  INTERVENTIONAL                   False                      4962   \n",
       "40871  INTERVENTIONAL                    True                       489   \n",
       "41454  INTERVENTIONAL                   False                      1216   \n",
       "47245  INTERVENTIONAL                    True                      1062   \n",
       "54167  INTERVENTIONAL                   False                       237   \n",
       "55309  INTERVENTIONAL                    True                      1614   \n",
       "\n",
       "      primary_outcome_duration_days sponsor_success  \n",
       "11994                          3562       87.341772  \n",
       "40871                           459        0.000000  \n",
       "41454                          1216       87.341772  \n",
       "47245                          1062        0.000000  \n",
       "54167                           237        0.000000  \n",
       "55309                          1538        0.000000  \n",
       "\n",
       "[6 rows x 25 columns]"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['maximum_age'] == df['maximum_age'].min()]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "id": "5735a474",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11994          ?\n",
       "40871      1 Day\n",
       "41454          ?\n",
       "47245      1 Day\n",
       "54167    28 Days\n",
       "55309    0 Years\n",
       "Name: minimum_age, dtype: object"
      ]
     },
     "execution_count": 117,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Step 1: Get the minimum value of 'maximum_age'\n",
    "min_max_age = df['maximum_age'].min()\n",
    "\n",
    "# Step 2: Filter rows where 'maximum_age' equals the min value, then check their 'minimum_age'\n",
    "df[df['maximum_age'] == min_max_age]['minimum_age']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "id": "6ed70d52",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.float64(69.0118449142621)"
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['maximum_age'].mean()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "id": "c5d1322c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>overall_status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>11994</th>\n",
       "      <td>?</td>\n",
       "      <td>COMPLETED</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40871</th>\n",
       "      <td>1 Day</td>\n",
       "      <td>TERMINATED</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41454</th>\n",
       "      <td>?</td>\n",
       "      <td>TERMINATED</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47245</th>\n",
       "      <td>1 Day</td>\n",
       "      <td>TERMINATED</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54167</th>\n",
       "      <td>28 Days</td>\n",
       "      <td>TERMINATED</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55309</th>\n",
       "      <td>0 Years</td>\n",
       "      <td>TERMINATED</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      minimum_age overall_status\n",
       "11994           ?      COMPLETED\n",
       "40871       1 Day     TERMINATED\n",
       "41454           ?     TERMINATED\n",
       "47245       1 Day     TERMINATED\n",
       "54167     28 Days     TERMINATED\n",
       "55309     0 Years     TERMINATED"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Step 1: Get the minimum value of 'maximum_age'\n",
    "min_max_age = df['maximum_age'].min()\n",
    "\n",
    "# Step 2: Filter rows where 'maximum_age' equals the min value and display overall_status\n",
    "df[df['maximum_age'] == min_max_age][['minimum_age', 'overall_status']]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "id": "c68a6877",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.int64(27048)"
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['maximum_age'].isna().sum()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "id": "b8ccf299",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# Step 1: Replace '?' with NaN\n",
    "df['minimum_age'] = df['minimum_age'].replace('?', np.nan)\n",
    "\n",
    "# Step 2: Remove 'Years' and strip spaces\n",
    "df['minimum_age'] = df['minimum_age'].str.replace('Years', '').str.strip()\n",
    "\n",
    "# Step 3: Convert to numeric (float or integer)\n",
    "df['minimum_age'] = pd.to_numeric(df['minimum_age'], errors='coerce') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "id": "bf0b2592",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.float64(0.0)"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['minimum_age'].min()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "id": "e15ce560",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1044"
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['minimum_age'].isna() & df['maximum_age'].isna()].shape[0]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "fd34140c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41569, 25)"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "66c2aa6c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Series([], Name: count, dtype: int64)"
      ]
     },
     "execution_count": 129,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['minimum_age'].isna() & df['maximum_age'].isna()]['overall_status'].value_counts()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "id": "e6dbfad0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "stdage\n",
       "ADULT, OLDER_ADULT           34886\n",
       "CHILD, ADULT, OLDER_ADULT     2323\n",
       "ADULT                         1637\n",
       "CHILD, ADULT                  1587\n",
       "CHILD                          767\n",
       "OLDER_ADULT                    369\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 127,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['stdage'].value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ebc4b997",
   "metadata": {},
   "source": [
    "Filling in the Minimum and Maximum Age values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2208aa3f",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'ADULT, OLDER_ADULT'), 'minimum_age'] = 18\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'ADULT, OLDER_ADULT'), 'maximum_age'] = 75\n",
    "\n",
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'CHILD, ADULT, OLDER_ADULT'), 'minimum_age'] = 0\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'CHILD, ADULT, OLDER_ADULT'), 'maximum_age'] = 75\n",
    "\n",
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'ADULT'), 'minimum_age'] = 18\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'ADULT'), 'maximum_age'] = 60\n",
    "\n",
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'CHILD, ADULT'), 'minimum_age'] = 0\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'CHILD, ADULT'), 'maximum_age'] = 60\n",
    "\n",
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'CHILD'), 'minimum_age'] = 0\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'CHILD'), 'maximum_age'] = 18\n",
    "\n",
    "df.loc[(df['minimum_age'].isna()) & (df['stdage'] == 'OLDER_ADULT'), 'minimum_age'] = 60\n",
    "df.loc[(df['maximum_age'].isna()) & (df['stdage'] == 'OLDER_ADULT'), 'maximum_age'] = 75"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "id": "1e91b9ef",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "brief_summary                     object\n",
       "conditions                        object\n",
       "country                           object\n",
       "design_primary_purpose            object\n",
       "eligibility_criteria              object\n",
       "enrollment                         int64\n",
       "interventions_name                object\n",
       "organization_match                  bool\n",
       "lead_sponsor                      object\n",
       "location_city                     object\n",
       "location_facility                 object\n",
       "maximum_age                      float64\n",
       "minimum_age                      float64\n",
       "organization_fullname             object\n",
       "overall_status                    object\n",
       "oversight_has_dmc                 object\n",
       "phase                             object\n",
       "primary_outcomes                  object\n",
       "sex                               object\n",
       "stdage                            object\n",
       "study_type                        object\n",
       "affiliation_matches_org             bool\n",
       "total_study_duration_days          int64\n",
       "primary_outcome_duration_days      int64\n",
       "sponsor_success                  float64\n",
       "dtype: object"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "12a0f974",
   "metadata": {},
   "source": [
    "Checking for oversight_has_dmc "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "id": "41e86efe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "oversight_has_dmc\n",
       "True     19554\n",
       "False    15897\n",
       "?         6118\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['oversight_has_dmc'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "id": "48f245c4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41569, 25)"
      ]
     },
     "execution_count": 134,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "a199caa3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_status\n",
       "COMPLETED     2966\n",
       "TERMINATED    1640\n",
       "RECRUITING    1512\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['oversight_has_dmc'] == '?']['overall_status'].value_counts()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "id": "46cde060",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "oversight_has_dmc                                   DMC_No_%  DMC_Yes_%\n",
      "organization_fullname                                                  \n",
      "\"Regina Elena\" National Cancer Institute               100.0        0.0\n",
      "1# Banshan East Rd. Zhejiang cancer hospital, J...     100.0        0.0\n",
      "101 Therapeutics                                       100.0        0.0\n",
      "1200 Pharma, LLC                                         0.0      100.0\n",
      "1Digestive Disease Center and Department of Int...       0.0      100.0\n",
      "...                                                      ...        ...\n",
      "the Second Affiliated Hospital, College of Medi...      50.0       50.0\n",
      "the second hospital of Changzhou city, Nanjing ...       0.0      100.0\n",
      "vTv Therapeutics                                         0.0      100.0\n",
      "Ångstrom Pharmaceuticals                               100.0        0.0\n",
      "Örebro University, Sweden                                0.0      100.0\n",
      "\n",
      "[9589 rows x 2 columns]\n"
     ]
    }
   ],
   "source": [
    "# Step 1: Filter only rows where oversight_has_dmc is 'Yes' or 'No'\n",
    "valid_dmc_df = df[df['oversight_has_dmc'].isin(['True', 'False'])]\n",
    "\n",
    "# Step 2: Group by organization_fullname and oversight_has_dmc, then count\n",
    "counts = valid_dmc_df.groupby(['organization_fullname', 'oversight_has_dmc']).size().unstack(fill_value=0)\n",
    "\n",
    "# Step 3: Calculate percentages\n",
    "percentages = counts.div(counts.sum(axis=1), axis=0) * 100\n",
    "\n",
    "# Optional: Rename columns for clarity\n",
    "percentages = percentages.rename(columns={'True': 'DMC_Yes_%', 'False': 'DMC_No_%'})\n",
    "\n",
    "# Display the resulting DataFrame\n",
    "print(percentages)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "id": "64742310",
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyError",
     "evalue": "'DMC_True_%'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mKeyError\u001b[39m                                  Traceback (most recent call last)",
      "\u001b[32m/tmp/ipykernel_9954/3066934156.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m()\u001b[39m\n\u001b[32m      7\u001b[39m \u001b[38;5;66;03m# Rename columns for clarity (optional)\u001b[39;00m\n\u001b[32m      8\u001b[39m study_type_percentages = study_type_percentages.rename(columns={\u001b[38;5;28;01mTrue\u001b[39;00m: \u001b[33m'DMC_True_%'\u001b[39m, \u001b[38;5;28;01mFalse\u001b[39;00m: \u001b[33m'DMC_False_%'\u001b[39m})\n\u001b[32m      9\u001b[39m \n\u001b[32m     10\u001b[39m \u001b[38;5;66;03m# Sort by highest DMC_True_% (optional)\u001b[39;00m\n\u001b[32m---> \u001b[39m\u001b[32m11\u001b[39m study_type_percentages = study_type_percentages.sort_values(by=\u001b[33m'DMC_True_%'\u001b[39m, ascending=\u001b[38;5;28;01mFalse\u001b[39;00m)\n\u001b[32m     12\u001b[39m \n\u001b[32m     13\u001b[39m \u001b[38;5;66;03m# Show the result\u001b[39;00m\n\u001b[32m     14\u001b[39m print(study_type_percentages)\n",
      "\u001b[32m~/Desktop/Office/Python/Projects/clinical-trials-analysis/venv/lib/python3.12/site-packages/pandas/core/frame.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m(self, by, axis, ascending, inplace, kind, na_position, ignore_index, key)\u001b[39m\n\u001b[32m   7192\u001b[39m             )\n\u001b[32m   7193\u001b[39m         \u001b[38;5;28;01melif\u001b[39;00m len(by):\n\u001b[32m   7194\u001b[39m             \u001b[38;5;66;03m# len(by) == 1\u001b[39;00m\n\u001b[32m   7195\u001b[39m \n\u001b[32m-> \u001b[39m\u001b[32m7196\u001b[39m             k = self._get_label_or_level_values(by[\u001b[32m0\u001b[39m], axis=axis)\n\u001b[32m   7197\u001b[39m \n\u001b[32m   7198\u001b[39m             \u001b[38;5;66;03m# need to rewrap column in Series to apply key function\u001b[39;00m\n\u001b[32m   7199\u001b[39m             \u001b[38;5;28;01mif\u001b[39;00m key \u001b[38;5;28;01mis\u001b[39;00m \u001b[38;5;28;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n",
      "\u001b[32m~/Desktop/Office/Python/Projects/clinical-trials-analysis/venv/lib/python3.12/site-packages/pandas/core/generic.py\u001b[39m in \u001b[36m?\u001b[39m\u001b[34m(self, key, axis)\u001b[39m\n\u001b[32m   1907\u001b[39m             values = self.xs(key, axis=other_axes[\u001b[32m0\u001b[39m])._values\n\u001b[32m   1908\u001b[39m         \u001b[38;5;28;01melif\u001b[39;00m self._is_level_reference(key, axis=axis):\n\u001b[32m   1909\u001b[39m             values = self.axes[axis].get_level_values(key)._values\n\u001b[32m   1910\u001b[39m         \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m-> \u001b[39m\u001b[32m1911\u001b[39m             \u001b[38;5;28;01mraise\u001b[39;00m KeyError(key)\n\u001b[32m   1912\u001b[39m \n\u001b[32m   1913\u001b[39m         \u001b[38;5;66;03m# Check for duplicates\u001b[39;00m\n\u001b[32m   1914\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m values.ndim > \u001b[32m1\u001b[39m:\n",
      "\u001b[31mKeyError\u001b[39m: 'DMC_True_%'"
     ]
    }
   ],
   "source": [
    "# Count True/False values of oversight_has_dmc grouped by study_type\n",
    "study_type_counts = df.groupby('study_type')['oversight_has_dmc'].value_counts().unstack(fill_value=0)\n",
    "\n",
    "# Convert counts to percentages\n",
    "study_type_percentages = study_type_counts.div(study_type_counts.sum(axis=1), axis=0) * 100\n",
    "\n",
    "# Rename columns for clarity (optional)\n",
    "study_type_percentages = study_type_percentages.rename(columns={True: 'DMC_True_%', False: 'DMC_False_%'})\n",
    "\n",
    "# Sort by highest DMC_True_% (optional)\n",
    "study_type_percentages = study_type_percentages.sort_values(by='DMC_True_%', ascending=False)\n",
    "\n",
    "# Show the result\n",
    "print(study_type_percentages)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "425afd86",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
